final_programme_asia2024

06-12-2024
09:00 - 10:00 Type: Special session Hall 406

Title: Opening session and Keynote lecture
09:00 - 09:10 Welcome address by the ESMO President, Prof. Andrés Cervantes
A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES
09:10 - 09:15 Scientific Co-Chairs: Programme and key highlights of the meeting
H. Van Laarhoven1, G. Long 2, 1Academic Medical Center, University of Amsterdam, Amsterdam,

NL, 2University of Sydney, Sydney, AU
09:15 - 09:35 Token of Appreciation Endorsing society representatives
09:35 - 10:00 Keynote lecture: Obesity: Impact on cancer prevalence, management and outcomes -
Actions to improve on prevention
E. Narayan, World Health Organization Western Pacific Regional Office, Manila, PH
10:15 - 11:45 Type: Educational session Hall 405

Title: Incorporating immunotherapy in gastrointestinal (GI) cancer
Chair: Raghav Sundar, US; Sara Lonardi, IT
10:15 - 10:35 Combat against pancreato-biliary tract cancer using immunotherapy

D.-Y. Oh, Seoul National University Hospital, Seoul, KR
10:35 - 10:55 Optimal care with immunotherapy in esophageal and gastric cancer
R. Sundar, Yale School of Medicine, New Haven, US
10:55 - 11:15 Immunotherapy for colorectal cancer: The winners and the losers thus far?
T. Price, The Queen Elizabeth Hospital - Emergency Department, Woodville, AU
11:15 - 11:35 Future development of immunotherapy in GI cancers

F. Wang, Sun Yat-sen University Cancer Center, Guangzhou, CN
11:35 - 11:45 Q&A and discussion
10:15 - 11:30 Type: Proffered Paper session Hall 404

Title: Proffered Paper session: Breast cancer
Chair: Evandro de Azambuja, BE; Yeon Hee Park, KR
10:15 - 10:25 1O - A prognostic value of BCT gene score in ER+HER2- breast cancer patients with 21-gene
recurrence score
S.G. Ahn, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR
Last update: 21-11-2024 08:38:22am Final Programme

10:25 - 10:35 36O - 18F-fluoroestradiol (18F-FES) PET/CT guided first-line treatment for HR+/HER2-
metastatic breast cancer patients: experience from real-world
B. Wang, Fudan University Shanghai Cancer Center, Shanghai, CN
10:35 - 10:47 Invited discussant 1O and 36O

L. Del Mastro, IRCCS Ospedale Policlinico San Martino, Genova, IT
10:47 - 10:57 27O - Assessment of Overall Survival Benefit from Neoadjuvant Chemotherapy in Elderly
HER-2 Negative Breast Cancer Patients: A Population-Based Study
W. Lv, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CN
10:57 - 11:07 2O - Analysis of Asian and non-Asian patients (pts) from the NATALEE trial of ribociclib
(RIB) + a nonsteroidal aromatase inhibitor (NSAI) in pts with HR+/HER2− early breast
cancer (EBC)
B. Xu, Chinese Academy of Medical Sciences (CAMS), and Peking Union Medical College (PUMC),
Beijing, CN
11:07 - 11:19 Invited Discussant 27O and 2O

H. Iwata, Nagoya City University Graduate School of Medical Sciences, Nagoya, JP

Title: New frontiers in the treatment of gynaecolagical malignancies
Chair: Kosei Hasegawa, JP; Ilaria Colombo, CH
10:15 - 10:40 Treatments of recurrent ovarian cancer: What we have and what is coming
K. Hasegawa, Saitama Medical University International Medical Center, Saitama, JP
10:40 - 11:05 How to treat endometrial cancer according to molecular subtypes with and after
immunotherapy
D.S. Tan, NUHS - National University Health System, Singapore, SG
11:05 - 11:30 Embedding immunotherapy in the treatment of cervical cancer

R. Kristeleit, Guy's and St Thomas' NHS Foundation Trust, London, GB

Title: Proffered Paper session: Developmental and precision medicine
Chair: Ruth Plummer, GB; Herbert Ho Fung Loong, HK
10:15 - 10:25 57O - A phase 1/2 multicenter, first-in-human study of DB-1311/BNT324 (a novel B7H3
ADC) in patients with advanced solid tumors
A. Lisberg, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US

10:25 - 10:35 58O - Clinical efficacy, safety, and PK/PD from the first in human study of BM201, a TLR7/8
agonist
R. Li, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, CN

A. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG
10:57 - 11:07 478O - Updated Results of Oral PD-L1 Inhibitor ABSK043 in Advanced Solid Tumor Patients
(pts) from a Phase 1 Study
S. Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN
11:07 - 11:17 59O - A first-in-human, phase I study of BPI-371153, a novel small-molecule PD-L1
inhibitor, in advanced solid tumors or recurrent/refractory (r/r) lymphoma
J. Yang, Chinese Academy of Medical Sciences and Peking Union Medical College - National
Cancer Center, Cancer Hospital, Beijing, CN

S. Symeonides, University of Edinburgh, Edinburgh, GB

Title: Proffered Paper session: Thoracic malignancies
Chair: Lizza Hendriks, NL; Hiroaki Akamatsu, JP
10:15 - 10:25 LBA8 - Phase II trial of atezolizumab plus carboplatin and paclitaxel in patients with
metastatic or recurrent thymic carcinoma: Marble study
T. Mimori, Juntendo University Graduate School of Medicine, Bunkyo-ku, JP
10:25 - 10:35 625O - Efficacy and safety of Lucitanib (AL3810) in second or subsequent-line treatment of
advanced recurrent or metastatic thymic carcinoma: a randomized, double-blind, placebo-
controlled multicenter phase II trial
W. Fang, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai,
CN
10:35 - 10:47 Invited Discussant LBA8 and 625O

J. Remon Masip, Institut Gustave Roussy, Villejuif, Cedex, FR
10:52 - 11:02 LBA5 - Zongertinib in patients with HER2-mutant NSCLC: Updated analysis of Beamion
LUNG-1
N. Yamamoto, National Cancer Center Hospital, Tokyo, JP

11:02 - 11:12 LBA6 - PACIFIC-5: A phase 3 study of consolidation durvalumab (D) in patients (pts) with
unresectable stage III NSCLC and no progression after concurrent or sequential
chemoradiotherapy (cCRT or sCRT)
Y.-L. Wu, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences),
Southern Medical University and Guangdong Provincial Key Laboratory of Translational Medicine
in Lung Cancer, Guangzhou, CN
11:12 - 11:22 LBA7 - Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with
previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): a pooled
analysis of TROPION-Lung01 and TROPION-Lung05
M.-J. Ahn, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR
11:22 - 11:37 Invited Discussant LBA5, LBA6 and LBA7

S. Popat, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

Title: Cell and gene therapy for solid tumours: Coming to a bedside near
you soon?
Chair: Han Chong Toh, SG; John Haanen, NL
10:15 - 10:35 Virotherapy for cancer: Coming into the clinic

K.-W. Peng, Mayo Clinic - Rochester, Rochester, US
10:35 - 10:55 What to look forward to in the future of CAR T cell therapy
C. Qi, Peking University Cancer Hospital & Institute, Beijing, CN
10:55 - 11:15 TIL therapy: 2024 landmark approval year and clinical potential in solid tumours
J. Haanen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam,
NL
11:15 - 11:45 Interactive discussion: Cell and gene therapy for solid tumours – What’s hot, what’s hype
and what’s not.
10:15 - 11:45 Type: Educational session Room 324

Title: Bispecific antibodies
Chair: Won Seog Kim, KR; Michelle Poon, SG
10:15 - 10:40 Bispecific antibodies in diffuse large B cell lymphoma (DLBCL)

W.S. Kim, Samsung Medical Center (SMC), Seoul, KR
10:40 - 11:05 Bispecific antibodies in frontline treatment

M. Poon, National Healthcare Group - Tan Tock Seng Hospital, Singapore, SG

11:05 - 11:30 Bispecific antibodies in multiple myeloma
Y. Chen, SGH - Singapore General Hospital, Singapore, SG
10:30 - 11:15 Type: Meet the expert Discussion hub (exhibition

Title: Management of oligometastatic renal cell area)
carcinoma (OM-RCC)
Chair: Darren Poon, HK; Marniza Saad, MY
10:30 - 11:15 Expert

R. Iacovelli, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT
12:00 - 13:30 Type: Industry Satellite Symposium Hall 405

Title: Amgen - Transforming lung cancer treatment with precision medicine
Chair: Tony S.K. Mok, HK
12:00 - 12:10 Advancing therapeutic strategies in precision medicine

T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK
12:10 - 12:25 Driving improved outcomes in NSCLC: KRASG12C inhibitors

T. Yoshida, NCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP
12:25 - 12:45 Innovative approaches in SCLC: DLL3 T-cell engager therapy

M.-J. Ahn, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul,
KR
12:45 - 13:05 Optimizing care in DLL3 T-cell engager therapy

C.L. Chiang, Taipei Veterans General Hospital, Taipei City, TW
13:05 - 13:25 Panel discussion and Q&A
13:25 - 13:30 Summary and close


Title: Roche - Patient-centricity in action: Innovating for today and the
future in lung and liver cancers
Chair: Han Chong Toh, SG
12:00 - 12:05 Welcome and introduction

H.C. Toh, NCCS - National Cancer Centre Singapore, Singapore, SG

12:05 - 12:20 Plenary: Unlocking real-world insights and transforming patient care in unresectable HCC
with immunotherapies
D. Pinato, Imperial College London - Hammersmith Hospital, London, GB
12:20 - 12:35 Case study discussion: Redefining unresectable HCC towards a cancer-free, drug-free
future
H. Sun, Zhongshan Hospital of Fudan University, Shanghai, CN
12:35 - 12:55 Plenary: Improving patient convenience and healthcare efficiencies with subcutaneous
atezolizumab
K. Korphaisarn, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, TH
12:55 - 13:25 Panel discussion: Shaping care for lung and liver cancer patients now and beyond
13:25 - 13:30 Closing remarks

H.C. Toh, NCCS - National Cancer Centre Singapore, Singapore, SG

Title: Merck Healthcare KGaA - Informing choices: Applying clinical trial and
real-world data to bladder cancer care
Chair: Ravindran Kanesvaran, SG

R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG
12:05 - 12:25 Right treatment for the right patient: Individualizing first-line therapy in la/mUC
E. Grande, MD Anderson Cancer Center Madrid, Madrid, ES
12:25 - 12:45 Improving quality of survival with first-line maintenance therapy in la/mUC
S. Hussain, University of Sheffield Medical School, Sheffield, GB
12:45 - 13:05 Optimizing outcomes in la/mUC: What can we learn from real-world evidence?
B. Tran, Peter MacCallum Cancer Centre, Melbourne, AU


Title: Astellas - Precision medicine in action: Biomarker-directed strategies
for advanced gastric cancer
Chair: Su Pin Choo, SG
12:00 - 12:10 Welcome and opening remarks: Gastric cancer in Asia

S.P. Choo, NCCS - National Cancer Centre Singapore, Singapore, SG
12:10 - 12:30 Precision medicine in gastric cancer: Targeted therapy approaches

S.Y. Rha, Yonsei University, Seoul, KR
12:30 - 12:50 Targeting CLDN in gastric cancer: A promising approach for treatment
K. Shitara, National Cancer Center Hospital East, Kashiwa, JP
12:50 - 13:10 Solutions and future directions for biomarker testing in gastric cancer
K. Matkowskyj, University of Wisconsin - School of Medicine and Public Health, Madison, US
13:10 - 13:25 Panel discussion: Challenges in the management of advanced gastric cancer

S.P. Choo, NCCS - National Cancer Centre Singapore, Singapore, SG

Title: GSK - Evolving treatment landscape for patients with endometrial
cancer
Chair: David SP Tan, SG; Kosei Hasegawa, JP
12:00 - 12:05 Introduction

12:05 - 12:35 Molecular subclassification and biomarker strategies in endometrial cancer

R. Kristeleit, Guy's and St Thomas' NHS Foundation Trust, London, GB
12:35 - 12:55 Recent advances and changing therapeutic landscape: Identifying the right patient
12:55 - 13:15 Future directions: Emerging trends and unanswered questions

12:00 - 12:30 Type: Young Oncologists session Discussion hub (exhibition
Title: Meet your mentor session 1 - How to build a area)
successful career in oncology (medical oncology, radiation oncology,
translational research)
Chair: Elizabeth Connolly, AU; Hongcheng Zhu, CN
12:00 - 12:30 Mentors
F. Mornex1, Y.H. Park2, E. De Azambuja3, 1Université Claude Bernard Lyon1, Lyon, FR, 2Samsung
Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, 3Institute Jules
Bordet, Anderlecht, BE

Title: Management of EGFRm NSCLC
Chair: Pei Li Stephanie Saw, SG; Myung-Ju Ahn, KR
13:45 - 14:05 Perioperative treatment in early stage EGFRm NSCLC

P.L.S. Saw, NCCS - National Cancer Centre Singapore, Singapore, SG
14:05 - 14:25 Unresectable EGFRm stage III NSCLC

J. Remon Masip, Institut Gustave Roussy, Villejuif, Cedex, FR
14:25 - 14:45 Should we intensify treatment and how to choose from different options in EGFRm SCLC?
X. Le, The University of Texas M. D. Anderson Cancer Center, Houston, US
14:45 - 15:05 Treatment options after failure of first-line EGFR TKI

M.-J. Ahn, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul,
KR

Title: Proffered Paper session: Gynaecological cancers
Chair: Ilaria Colombo, CH; Clare Scott, AU
13:45 - 13:55 372O - Balstilimab (bal) alone or with zalifrelimab (zal) treatment for cervical cancer: an
open-label, non-comparative, randomised, phase 2 trial
J. An, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer
Center, Cancer Hospital, Beijing, CN
13:55 - 14:05 373O - First-line iparomlimab and tuvonralimab (QL1706) + chemotherapy (chemo) ±
bevacizumab (BEV) for recurrent or metastatic cervical cancer (r/mCC): Updated results of
the phase II DUBHE-C-204 study
D. Wang, Liaoning Cancer Hospital & Institute, Shenyang, CN


14:27 - 14:37 374O - The burden and trends of gynecological cancers in Asia from 1980 to 2021: A
systematic analysis for the Global Burden of Disease Study 2021
R. Miao, Anhui Medical University, Hefei, CN
14:37 - 14:47 375O - DIsease burden and treatment pattern of Recurrent or advanced Endometrial
Cancer in Korea: a naTIONwide database (DIRECTION) study
H.-W. Cho, Korea University Guro Hospital, Seoul, KR

J.-Y. Lee, Yonsei University, Seoul, KR
13:45 - 15:15 Type: Multidisciplinary Tumour Board Hall 401

Title: Treatment de-escalation for early breast cancer (eBC)
Chair: Hiroji Iwata, JP; Lucia Del Mastro, IT
13:45 - 13:50 Presentation of case/condition

O. Pitiyarachchi, Prince of Wales Hospital - Nelune Comprehensive Cancer Centre, Randwick, AU
13:50 - 14:10 De-escalating axillary surgery after neoadjuvant systemic therapy for stage I-III breast
cnacer
J. De Boniface, Karolinska University Hospital, Stockholm, SE
14:10 - 14:30 Who are the patients that do not require radiation therapy?
B. Chua, Prince of Wales Hospital - Nelune Comprehensive Cancer Centre, Randwick, AU
14:30 - 14:50 Adjuvant systemic therapy: Who needs less treatment?

H. Iwata, Nagoya City University Graduate School of Medical Sciences, Nagoya, JP

Title: Integrating supportive and palliative care into oncology practice
Chair: Gudrun Kreye, AT; Grace Yang, SG
13:45 - 14:10 Palliative and supportive care: Is there a difference?

G. Kreye, Universitätsklinikum Krems, Krems an der Donau, AT
14:10 - 14:35 Integrating palliative and supportive care in practice

R. Lo, CUHK - Chinese University of Hong Kong, Sha Tin, HK

14:35 - 15:00 The role of the oncologist in palliative care
S. Kaasa, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO

Title: Neoadjuvant treatment in melanoma
Chair: Alexander van Akkooi, AU; Ana Maria Arance, ES
13:45 - 14:10 Neoadjuvant treatment: Which is the optimal regimen?

M. Lucas, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam,
NL
14:10 - 14:35 Who needs lymph node dissection after neoadjuvant treatment?
A. Van Akkooi, Melanoma Institute Australia, Wollstonecraft, AU
14:35 - 15:00 Neaodjuvant in acral and mucosal melanoma

L. Si, Peking University Cancer Hospital and Institute, Beijing, CN

Title: Mantle cell lymphoma (MCL): Where are we going?
Chair: Won Seog Kim, KR; Jason Chan Yong Sheng, SG
13:45 - 14:10 What can be the optimal frontline treatment?

C. Buske, Ulm Medical University, Ulm, DE
14:10 - 14:35 How can we manage the R/R MCL?

J.C.Y. Sheng, NCCS - National Cancer Centre Singapore, Singapore, SG
14:35 - 15:00 Management of MCL from Asian perspective

Y.H. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG

13:45 - 14:45 Type: Special session Discussion hub (exhibition
Title: ESMO Women for Oncology Forum - Bridging the area)
gap: Insights on salary disparities, female authorship, and leadership
representation in oncology
Chair: Janice Wing-Hang Tsang, HK; Jyoti Bajpai, IN
13:45 - 14:25 Panellists
S. Peters1, Y.H. Park2, J. Tolentino3, 1CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne,
CH, 2Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR,
3The Medical City, Pasig City, PH

Title: Proffered Paper session: Gastrointestinal tumours
Chair: Su Pin Choo, SG; Angela Lamarca, ES
13:45 - 13:55 LBA1 - Multicenter phase 2 trial of lenvatinib in patients with advanced hepatocellular
carcinoma after progression on first-line atezolizumab plus bevacizumab (KCSG HB23-04)
C. Yoo, Asan Medical Center - University of Ulsan, Seoul, KR
13:55 - 14:05 126O - Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as
first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): CheckMate
9DW Asian subgroup analysis
T. Yau, Queen Mary Hospital, Pok Fu Lam, HK
14:05 - 14:15 127O - Five-year overall survival (OS) and OS by baseline liver function from the Phase 3
HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular
carcinoma (uHCC)
M. Kudo, Kindai University Faculty of Medicine, Osaka, JP
14:15 - 14:30 Invited Discussant LBA1, 126O and 127O

J.O. Park, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul,
KR
14:38 - 14:48 133O - Safety of 30 min infusion of durvalumab (D) in combination with gemcitabine (G)-
based chemotherapy in first-line treatment (tx) of advanced biliary tract cancer (aBTC):
TOURMALINE early results
D.-Y. Oh, Seoul National University Hospital; Cancer Research Institute, Seoul National University
College of Medicine, Seoul, KR
14:48 - 14:58 134O - Asia Subgroup Overall Survival and Long-Term Follow-up Results of the Phase 2b
HERIZON-BTC-01 Study: Zanidatamab in Previously Treated Human Epidermal Growth
Factor Receptor 2 (HER2)-Amplified Biliary Tract Cancer (BTC)
J.W. Kim, Seoul National University Bundang Hospital, Seongnam, KR

L. Rimassa, IRCCS Humanitas Research Hospital, Rozzano, IT

Title: Takeda Pharmaceuticals - Navigating later-line treatment decisions
in mCRC: Using the latest data to guide treatment selection
Chair: Timothy Price, AU

15:37 - 16:07 Reshaping later-line management of mCRC: Latest developments, practical implications
C. Eng, Vanderbilt Ingram Cancer Center, Nashville, US
16:07 - 16:27 Panel discussion
T. Price1, C. Eng 2, S.P. Choo3, 1The Queen Elizabeth Hospital - Emergency Department,
Woodville, AU, 2Vanderbilt Ingram Cancer Center, Nashville, US, 3NCCS - National Cancer Centre
Singapore, Singapore, SG


Title: AbbVie - The emerging role of c-Met protein directed antibody-drug
conjugates (ADCs)
Chair: Shobhit Baijal, GB

S. Baijal, Heartlands Hospital - University Hospitals Birmingham NHS Foundation Trust,
Birmingham, GB
15:32 - 15:35 c-Met as a therapeutic target in solid tumors

Birmingham, GB
15:35 - 15:50 Targeting c-Met in advanced non-small cell lung cancer (NSCLC) with antibody-drug
conjugates (ADCs)
R. Soo, NCIS - National University Cancer Institute Singapore, Singapore, SG
15:50 - 16:05 Emerging evidence on targeting c-Met in gastrointestinal cancers

Birmingham, GB

16:05 - 16:20 Integrating biomarker testing and patient selection into clinical practice
T. Lim, SGH - Singapore General Hospital, Singapore, SG

Title: AstraZeneca - Pathway to advancing care: Evolving treatment
strategies for HR-positive mBC
Chair: Rebecca Dent, SG
15:30 - 15:35 The current HR-positive mBC treatment paradigm

R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG
15:35 - 15:50 Exploring biomarker-driven approaches in HR-positive mBC

H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
15:50 - 16:00 Navigating new frontiers post-ET with ADCs

S. Dawood, Mediclinic City Hospital, Dubai, AE
16:00 - 16:30 Advancing patient care: Optimising treatment strategies
R. Dent1, H. Rugo2, S. Dawood3, 1NCCS - National Cancer Centre Singapore, Singapore, SG,
2UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, 3Mediclinic City
Hospital, Dubai, AE

Title: Pfizer - Cyclin' through innovation: Next Generation CDKs in HR+ MBC
Chair: Soo Chin Lee, SG

S.C. Lee, Cancer Science Institute (CSI) - National University of Singapore (NUS), Singapore, SG
15:35 - 15:45 Challenges in frontline treatment of HR+ MBC

15:45 - 16:00 Mechanisms of resistance to CDK4/6 inhibition in HR+ MBC

Y. Naito, National Cancer Center Hospital East, Kashiwa, JP
16:00 - 16:20 Innovation in CDK inhibition in HR+ MBC

A. Giordano, Dana Farber Cancer Institute, Boston, US
16:20 - 16:30 Q&A

Title: MSD - Through the lens of Asia: Advancing standard of care with
immunotherapy
Chair: Hwai Loong Kong, SG

H.L. Kong, Icon Cancer Centre - Mount Elizabeth Medical Clinic, Singapore, SG
15:35 - 15:45 Managing gastric cancer patients in the immuno-oncology era

S.Y. Rha, Yonsei University, Seoul, KR
15:45 - 15:55 Tackling the burden of cervical cancer in Asia and embracing breakthrough therapies for
locally advanced disease
B.-G. Kim, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul,
KR
15:55 - 16:25 Expert panel dialogue with Q&A


Title: Meet your mentor session 2 - How to get involved area)
or set up clinical trial research
15:30 - 16:00 Mentors
N. Harbeck1, K. Chua2, F. Pietrantonio3, J.W.-H. Tsang 4, 1Ludwig Maximilians University -

Grosshadern, Munich, DE, 2NCCS - National Cancer Centre Singapore, Singapore, SG,
3
Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, 4HKBOG - Hong Kong Breast
Oncology Group, Hong Kong, HK

Title: Session in collaboration with endorsing societies - Prevention, early
diagnosis and interception programmes across the globe
Chair: Eileen Poon, SG; Suzette Delaloge, FR
16:45 - 17:00 The novel concept of tumour-informed personalised Interception

S. Delaloge, Institut Gustave Roussy, Villejuif, Cedex, FR
17:00 - 17:15 Prevention and screening programmes for prevalent tumours in Japan
K. Kono, Fukushima University, Fukushima, JP
17:15 - 17:30 Prevention and screening activities in prevalent tumours in Singapore

E. Poon, NCCS - National Cancer Centre Singapore, Singapore, SG

17:30 - 17:45 The challenges of implementing national prevention and screening activities in Asia
Pacific: Malaysia
R.S. Ahmad Bustamam, Ministry of Health Malaysia, Kuala Lumpur, MY
17:45 - 18:00 The challenges of implementing national prevention and screening activities in Asia:
Kazakhstan
D. Kaidarova, Kazakh Research Institute of Oncology and Radiology-KazIOR, Almaty, KZ

Title: Session in collaboration with endorsing societies - Managing patients
with rare cancers in Asia: Perspectives and challenges
Chair: Jean-Yves Blay, FR; Zefei Jiang, CN
16:45 - 17:00 The EURACAN paradigm: Challenges and solutions

J.-Y. Blay, Centre Léon Bérard, Lyon, FR
17:00 - 17:15 State of the art management of patients with nasopharyngeal cancer
H. Mai, Sun Yat-Sen University Cancer Center, Guangzhou, CN
17:15 - 17:30 State of the art management of patients with rare genitourinary tumours
C. Charoentum, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University,
Chiang Mai, Thailand, Chiang Mai, TH
17:30 - 17:45 The challenges of setting up rare cancer networks in Asia Pacific
H.T. Soe, Defense Services Medical Academy, Yangon, MM
17:45 - 18:00 Current challenges facing the clinical treatment for human T-lymphotropic virus 1 (HTLV-
1) in the Middle East
M. Payandeh, Behestandarou-Amgen, Tehran, IR

Title: Session in collaboration with endorsing societies -
Environmental/infection-related cancers and early integration of
breakthroughs in their clinical management
Chair: Lizza Hendriks, NL; Asif Masood, PK
16:45 - 17:00 The European directives: Asbestos, air pollution and tobacco policies
L. Hendriks, Maastricht University Medical Center (MUMC), Maastricht, NL

17:00 - 17:15 Integrating breakthroughs in the management of patients with advanced non-small cell
lung cancer
A. Masood, Shifa International Hospital, Islamabad, PK
17:15 - 17:30 Integrating breakthroughs in the management of patients with mesothelioma

O. Tuychiyev, Andijan Regional Branch of the Republican Specialized Scientific and Practical
Medical Center of Oncology and Radiology, Andijan, UZ
17:30 - 17:45 Integrating breakthroughs in the management of patients with hepatocellular cancer
T. Atmakusuma, RSUPN Dr. Cipto Mangunkusumo, Central Jakarta, ID
17:45 - 18:00 Multidisciplinary tumour boards in clinical practice: National perspectives

M. Sumon, Kurmitola General Hospital, Dhaka, BD
16:45 - 18:10 Type: Young Oncologists session Hall 407

Title: Young Oncologists clinical cases discussion
Chair: Elizabeth Connolly, AU; Hongcheng Zhu, CN; Matteo Lambertini, IT
16:45 - 16:47 Introduction to the session
E. Connolly1, H. Zhu2, M. Lambertini3, 1Chris O'Brien Lifehouse, Sydney, AU, 2Fudan University
Shanghai Cancer Center, Shanghai, CN, 3IRCCS AOU San Martino - IST-Istituto Nazionale per la
Ricerca sul Cancro, Genova, IT
16:47 - 16:52 YO34 - A recalcitrant case of chronic diarrhea in a young female and a near miss in
diagnosis – a case report
A. Raheem, Apollo Hospitals, Visakhapatnam, IN
16:52 - 16:57 YO33 - Muco-cutaneous adverse drug reaction associated with oral Temozolomide in a case
of GBM : when rare become common.
A. Mannan, Labaid Cancer Hospital & Super Specialty Centre, Dhaka, BD
16:57 - 17:07 Invited Discussant YO34 and YO33

E. Connolly, Chris O'Brien Lifehouse, Sydney, AU
17:12 - 17:17 YO27 - Negative Predicting Value of Longitudinal Undetectable MRD in Maintenance
Immunotherapy for Advanced Lung Cancer Patients: A Case Report
H. Zheng, Beijing Chest Hospital, Capital Medical University, Beijing, CN
17:17 - 17:22 YO28 - TKI for Metastatic Non Small Cell Lung Cancer in Pregnancy.
S.M. Yacob, National Cancer Institute,Malaysia, PUTRAJAYA, MY

17:22 - 17:27 YO29 - Multiple primary cancers (MPC) of breast and lung with primary EGFR T790M
mutation Responded to Aumolertinib: A case report
S. Kong, Xijing Hospital of Air Force Military Medical University, Xi'an, CN
17:27 - 17:39 Invited Discussant YO27, YO28 and YO29

H. Zhu, Fudan University Shanghai Cancer Center, Shanghai, CN
17:44 - 17:49 YO1 - Trastuzumab deruxtecan and Stereotactic radiosurgery (SRS) in HER2-positive
(HER2+) breast cancer with brain metastases (BM)
T. Meng, Daping Hospital Army Medical University, Chongqing, CN
17:49 - 17:54 YO2 - Taking Control With The Knife: Managing Brain Metastasis With Gamma Knife In
Metastatic Breast Cancer in Pregnancy
T. Keh Yee, University Malaya, Kuala Lumpur, MY
17:54 - 18:04 Invited Discussant YO1 and YO2

M. Lambertini, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova,
IT
18:09 - 18:10 Close
E. Connolly1, H. Zhu2, M. Lambertini3, 1Chris O'Brien Lifehouse, Sydney, AU, 2Fudan University
Shanghai Cancer Center, Shanghai, CN, 3IRCCS AOU San Martino - IST-Istituto Nazionale per la
Ricerca sul Cancro, Genova, IT
16:45 - 18:30 Type: Special session Room 324

Title: Radiation oncology session 1
Chair: Francoise Mornex, FR; Kevin Chua, SG
16:45 - 17:05 SABR for primary kidney cancer

M. Ali, Peter MacCallum Cancer Centre, Melbourne, AU
17:05 - 17:10 Q&A
17:10 - 17:30 SBRT-IO combinations: State of the art in 2024

D. Antoni, ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR
17:30 - 17:35 Q&A
17:35 - 17:55 Artificial intelligence: Implementation in radiation oncology

J.S. Kim, Yonsei Cancer Center Yonsei University, Seoul, KR

17:55 - 18:00 Q&A
18:00 - 18:20 Oligometastatic disease: A clinical case

F. Lim, NCCS - National Cancer Centre Singapore, Singapore, SG
18:20 - 18:25 Q&A
18:25 - 18:30 General discussion and conclusions

Title: How to optimize the use of radiation therapy for area)
breast cancer oligo-metastasis or oligo-progression?
Chair: Kevin Punie, BE; Heekyung Ahn, KR
16:45 - 17:30 Expert

I. Meattini, University of Florence, Florence, IT
16:45 - 18:20 Type: Mini Oral session Hall 406

Title: Mixed session - Proffered Paper and Mini Oral: Developmental and
precision medicine
Chair: David Thomas, AU; Sun Min Lim, KR; Tira Tan, SG
16:45 - 16:55 60O - A phase 1a study of DNP002, a monoclonal antibody that binds to tumor-associated
CEACAM family proteins, in patients with advanced solid tumors: Interim results from
dose escalation study
W. Choi, National Cancer Center, Goyang, KR
16:55 - 17:05 61O - Updated results of a phase II trial evaluating an Anti-EpCAM x Anti-CD3 bispecific
antibody, M701, for the treatment of malignant ascites
R. Liu, Chinese PLA General Hospital (301 Military Hospital), Beijing, CN

T. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG
17:22 - 17:27 479MO - Erlotinib plus Bevacizumab in Patients with metastatic solid tumors with EGFR
amplification: Results from the KOSMOS-II (KOrean Precision Medicine Networking Group
Study of MOlecular profiling guided therapy based on genomic alterations in advanced
Solid tumors, KCSG AL 22-09)
J.W. Lee, Korea University Anam Hospital, Seoul, KR
17:27 - 17:32 480MO - Prevalence and characteristics of TP53 Y220C Mutations in Patients with solid
malignancies
Y. Mekhail, MFM - Menoufia University - Faculty of Medicine, Shebeen El-Kom, EG

17:32 - 17:37 481MO - Next-Generation Sequencing (NGS) Of Paired Tumor Tissue And Blood Samples
From Patients With Advanced Solid Cancers – A Complementary Approach
N. Rohatgi, Fortis Memorial Research Institute,, Gurugram, IN
17:37 - 17:49 Invited Discussant 479MO, 480MO and 481MO

S.M. Lim, Yonsei Cancer Center Yonsei University, Seoul, KR
17:54 - 17:59 482MO - Clinical Usefulness of Next-Generation Sequencing for metastatic or unresectable
Gastric Cancer in Molecular Profiling-Guided Therapy Era
S. Choi, Seoul National University Hospital, Seoul, KR
17:59 - 18:04 483MO - RNA-based multiplex polymerase chain reaction and sequencing to detect fusion
genes in melanoma
T. Hida, Sapporo Medical University School of Medicine, Sapporo, JP
18:04 - 18:14 Invited Discussant 482MO and 483MO

D. Thomas, Garvan Institute of Medical Research, Darlinghurst, AU

07-12-2024
Title: Emerging diagnostics and systemic treatments for patients with
metastatic breast cancer (mBC)
Chair: Evandro de Azambuja, BE; Yeon Hee Park, KR
09:00 - 09:20 Changing treatment landscape for HER2+ mBC

J.W.-H. Tsang, HKBOG - Hong Kong Breast Oncology Group, Hong Kong, HK
09:20 - 09:40 Current treatment options for patients with metastatic triple-negative breast cancer
(TNBC)
09:40 - 10:00 New treatment paradigms for HR+ / HER2- mBC

E. De Azambuja, Institute Jules Bordet, Anderlecht, BE
10:00 - 10:20 Liquid biopsy in patients with mBC: Ready for standard practice?
Y. Naito, National Cancer Center Hospital East, Kashiwa, JP

Title: Mini Oral session: Gastrointestinal tumours
Chair: Sylvie Lorenzen, DE; Izuma Nakayama, JP
09:00 - 09:05 128MO - Final overall survival for the phase 3, KEYNOTE-811 study of pembrolizumab plus
trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ
adenocarcinoma
S.Y. Rha, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR
09:05 - 09:10 129MO - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously
treated HER2-positive (HER2+) advanced gastric or gastroesophageal junction
adenocarcinoma (GEJA): DESTINY-Gastric06 (DG-06) final analysis
Z. Peng, Peking University Cancer Hospital & Institute, Beijing, CN

S. Lorenzen, Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE
09:25 - 09:30 130MO - EDGE-Gastric Arm A1: Phase 2 study of domvanalimab (D), zimberelimab (Z), and
FOLFOX in first-line (1L) advanced gastroesophageal (GE) cancer
S.Y. Rha, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR

09:30 - 09:35 131MO - Tislelizumab (TIS) Plus Chemotherapy (Chemo) vs Placebo (PBO) Plus Chemo as
First-Line (1L) Treatment of Advanced Gastric or Gastroesophageal Junction
Adenocarcinoma (GC/GEJC): Patient Reported Outcomes (PRO) in the Asian Subgroup of
the RATIONALE-305 Study
K. Kato, National Cancer Center Hospital, Tokyo, JP

I. Nakayama, National Cancer Center Hospital East, Kashiwa, JP
09:50 - 09:55 132MO - Anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients
(pts) with advanced pancreatic ductal adenocarcinoma (PDAC): updated results from a
phase 1 study
J. Zhang, Fudan University Shanghai Cancer Center, Shanghai, CN
09:55 - 10:00 138MO - Baseline characteristics and molecular testing of patients with IDH1-mutated
cholangiocarcinoma: initial results from the phase 3b ProvIDHe study
L. Rimassa, IRCCS Humanitas Research Hospital, Rozzano, IT
10:15 - 10:20 73MO - Sotorasib (soto), panitumumab (pani), and FOLFIRI in first-line (1L) KRAS G12C–
mutated metastatic colorectal cancer (mCRC): regional analysis of safety and efficacy from
CodeBreaK 101
T. Masuishi, Aichi Cancer Center Hospital, Nagoya, JP
10:20 - 10:25 74MO - mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody in Locally Advanced MSS
CRC (BASKETⅡ): A Prospective, Single-Arm, Open-Label, Phase II Study
J. Huang, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN

Title: Proffered Paper session: Head and neck cancers
Chair: Christophe Le Tourneau, FR; Brigette Ma, HK
09:00 - 09:10 402O - Preliminary Results of Phase II Study to Evaluate Safety and Efficacy of
Combination Pucotenlimab with Epidermal Growth Factor Receptor-ADC (EGFR-ADC)
MRG003 in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)
D. Ruan, Sun Yat-sen University Cancer Center, Guangzhou, CN

09:10 - 09:20 403O - Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L)
treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from
the RATIONALE-309 study
W.F. Fang, Sun Yat-Sen University Cancer Center, Guangzhou, CN

D.W.-T. Lim, NCCS - National Cancer Centre Singapore, Singapore, SG
09:42 - 09:52 404O - A Phase 3 Prospective Randomised Trial Of Two- Weekly TPF(Taxane/Platinum/5FU)
vs Three Weekly TPF As Induction Chemotherapy In Locally Advanced Squamous Cell
Carcinoma Of Head And Neck- A Preliminary Analysis
A. Gupta, Kidwai Memorial Institute of Oncology, bengaluru, IN
09:52 - 10:02 405O - Accuracy of Plasma Epstein-Barr virus (EBV) DNA for Disease Surveillance in
Endemic Nasopharyngeal Carcinoma (NPC):Analysis of a Real-world Database (RWD)
M.L.K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG

C. Le Tourneau, Institut Curie, Paris, FR

Title: Optimising immune checkpoint inhibitors (ICI) treatment in
advanced melanoma
Chair: Richard Quek, SG; Lu Si, CN
09:00 - 09:25 Efficacy of low-dose ICI

A. Patel, Army Hospital Research And Referral, New Delhi, IN
09:25 - 09:50 Optimal treatment duration: When is it safe to stop?

A. Van Der Veldt, Erasmus MC - University Medical Center, Rotterdam, NL
09:50 - 10:15 Novel ICI combinations

A.M. Arance, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

Title: Proffered Paper session: Genitourinary tumours
Chair: Roberto Iacovelli, IT; Marniza Saad, MY
09:00 - 09:10 LBA2 - Belzutifan Versus Everolimus for Previously Treated Advanced Clear Cell Renal Cell
Carcinoma (ccRCC): Updated Follow-Up of the East Asian Subgroup of the Randomized
Phase 3 LITESPARK-005 Trial
J.-L. Lee, Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR
09:10 - 09:20 268O - Determinants of neoadjuvant immune checkpoint inhibitor plus tyrosine kinase
inhibitor therapy response in renal cell carcinoma
L. Gu, Chinese PLA General Hospital (301 Military Hospital), Beijing, CN
09:20 - 09:32 Invited Discussant LBA2 and 268O

W.C. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG
09:37 - 09:47 269O - Enfortumab Vedotin Plus Pembrolizumab (EV+P) Vs Chemotherapy (Chemo) in
Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Pan-
Asian Subgroup Analysis From EV-302/KEYNOTE-A39
E. Kikuchi, St. Marianna University School of Medicine, Kanagawa, JP
09:47 - 09:57 270O - Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone in Asian patients
with previously untreated unresectable or metastatic urothelial carcinoma (u/mUC) from
CheckMate 901
Y. Tomita, Niigata University Medical and Dental Hospital, Niigata, JP
09:57 - 10:07 271O - Interim analysis (IA) of SPADE: a prospective, real-world study of avelumab first-line
maintenance (1LM) treatment in patients (pts) with locally advanced or metastatic
urothelial carcinoma (la/mUC) in the Asia-Pacific (APAC) region
J. Jo, Ewha Womans University Mokdong Hospital, Seoul, KR
10:07 - 10:17 LBA9 - TROPiCS-04, a randomized phase 3 study of sacituzumab govitecan (SG) vs
chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): Overall survival
(OS) and safety analysis.
P. Grivas, University of Washington, Fred Hutchinson Cancer Center, Seattle, US
10:17 - 10:32 Invited Discussant 269O, 270O, 271O and LBA9

T. Friedlander, UCSF - University of California San Francisco, San Francisco, US

Title: Intracranial germ cell tumors in East Asia and Europe
Chair: Giuseppe Minniti, IT; Wan-Yee Teo, SG
09:00 - 09:20 Management of germinomas in Europe (GCTIII)

D. Frappaz, IHOPe - Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, FR
09:20 - 09:40 Molecular pathology and clinical management of germinomas in Japan

H. Takami, The University of Tokyo Hospital, Bunkyo-ku, JP
09:40 - 10:00 Treatment of CNS germ cell tumour: Asian perspective

J.-Y. Kim, National Cancer Center - Korea (NCCK), Gyeonggi-do, KR
10:00 - 10:20 Spatial transcriptomics and scRNAseq of TME in germinomas

H.-K. Ng, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK

Title: Diversity and inclusion in supportive and palliative care
Chair: Raymond Lo, HK; Jayne Wood, GB
09:00 - 09:20 The Patient Dignity Inventory (PDI) in oncology and palliative care
D. Natarajan, Shatin Hospital, Sha Tin, HK
09:20 - 09:40 Palliative for adolescents and young adults

E. Poon, NCCS - National Cancer Centre Singapore, Singapore, SG
09:40 - 10:00 Prisoner health: Addressing the health needs of patients in prison
J. Wood, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

Title: Setting up a cellular therapies service area)
Chair: Ruth Plummer, GB
09:00 - 09:45 Expert

Y.H. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG

Title: ESMO 2024 Highlights session 2
11:00 - 11:10 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer:
Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-
3047/KEYNOTE-A18 study
11:10 - 11:20 Invited Discussant – Asian perspectives

W.Y. Chay, NCCS - National Cancer Centre Singapore, Singapore, SG
11:20 - 11:30 Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the
HypoG-01 phase III Unicancer trial
S. Rivera, Institut Gustave Roussy, Villejuif, FR

F. Lim, NCCS - National Cancer Centre Singapore, Singapore, SG
11:40 - 11:50 Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant

pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from
the phase III KEYNOTE-522 study


Title: ESMO 2024 Highlights session 1
11:00 - 11:10 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus
osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early
analysis from the phase III MARIPOSA study
B.C. Cho, Yonsei University, Seoul, KR

B.-C. Liao, NTUH - National Taiwan University Hospital, Taipei City, TW
11:20 - 11:30 A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by
radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer
(NIAGARA)
T. Powles, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

S.J. Rajappa, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, IN

11:40 - 11:50 POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (C-P)
in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma
of the anal canal (SCAC) not previously treated with systemic chemotherapy
S. Rao, The Royal Marsden Hospital - Chelsea, London, GB

K. Korphaisarn, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, TH
12:00 - 12:10 Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab
(pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study
M. Kudo, Kindai University - Faculty of Medicine, Osaka, JP

D. Tai, NCCS - National Cancer Centre Singapore, Singapore, SG

Title: AstraZeneca- Advancing horizons: Emerging strategies for lung cancer
care
Chair: Solange Peters, CH
12:45 - 12:49 Advancing horizons: Emerging strategies for enhanced lung cancer care
S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH
12:49 - 12:59 Optimising diagnostic work-up and patient management through multidisciplinary
decision making
12:59 - 13:09 Novel treatment approaches for LS-SCLC

13:09 - 13:27 Redefining treatment strategies for unresectable NSCLC

13:37 - 13:47 Navigating emerging treatment options in 1L EGFRm metastatic NSCLC

13:47 - 14:05 Emerging data for post-progression treatment of metastatic NSCLC

14:05 - 14:15 Panel discussion and conclusions

Title: Novartis - Expanding evidence for CDK4/6 inhibitors in HR+/HER2-
breast cancer: From clinical trials to clinical practice
Chair: Yoon-Sim Yap, SG

Y.-S. Yap, NCCS - National Cancer Centre Singapore, Singapore, SG
12:50 - 13:00 Unmet need for patients with HR+/HER2- early breast cancer
13:00 - 13:35 Patient selection and clinical outcomes of CDK4/6 inhibitors in HR+/HER2- early breast
cancer
D. Juric, MGH - Massachusetts General Hospital, Boston, US
13:35 - 13:40 Clinical guidance on use of CDK4/6 inhibitors in HR+/HER2- ABC

13:40 - 14:05 Applying CDK4/6 inhibitor data to patient management in HR+/HER2- ABC
S. Wang, Sun Yat-sen University Cancer Center, Guangzhou, CN
14:05 - 14:15 Key takeaways and live Q&A


Title: MSD - Immunotherapy for early-stage cancers: Bridging knowledge
gaps and optimizing treatment strategies
Chair: Ravindran Kanesvaran, SG; Rina Hui, HK
12:45 - 12:50 Welcome, objectives and introductions
R. Hui1, R. Kanesvaran2, 1The University of Hong Kong - Queen Mary Hospital, Hong Kong, HK,
2NCCS - National Cancer Centre Singapore, Singapore, SG
12:50 - 13:10 Opportunities and challenges: Immuno-oncology in early-stage TNBC

13:10 - 13:30 Incorporating immunotherapy into the early-stage NSCLC treatment paradigm
J. Donington, The University of Chicago, Chicago, US
13:30 - 13:50 Systemic treatments in early-stage renal cell carcinoma: Then and now
13:50 - 14:10 Panel discussion with audience Q&A
14:10 - 14:15 Key takeaways and closing remarks

R. Hui, The University of Hong Kong - Queen Mary Hospital, Hong Kong, HK

Title: Daiichi Sankyo - Empowering cancer therapy with ADC advancements
Chair: Do-Youn Oh, KR
12:45 - 12:55 Breaking boundaries: Emerging ADC technology in cancer therapy

12:55 - 13:15 Breast cancer breakthroughs: Shaping the future of treatment

T. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG
13:15 - 13:35 Lung cancer leap: The expanding horizon of ADCs in advanced NSCLC
J.-H. Lee, National Taiwan University Hospital, Taipei City, TW
13:35 - 13:55 Pan-tumor potential: The progress and future of ADCs in multiple cancer types

Title: Johnson and Johnson International (Singapore) Pte Ltd, - Pioneering
advances in EGFRm NSCLC therapy: Navigating the future of patient care
Chair: Ross Soo, SG

12:50 - 13:00 Overview of unmet needs in EGFRm advanced NSCLC in Asia

13:00 - 13:25 Treatment advances in common EGFRm advanced NSCLC

A. Spira, Virginia Cancer Specialist, Fairfax, US
13:25 - 13:45 The evolving treatment landscape for advanced NSCLC with EGFR exon20insertion
mutations
R. Soo1, T.S.K. Mok2, A. Spira3, 1NCIS - National University Cancer Institute Singapore, Singapore,
SG, 2Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK, 3Virginia Cancer
Specialist, Fairfax, US
14:05 - 14:10 Close


12:45 - 13:45 Type: ESMO Colloquium Room 324
Title: ESMO Colloquium supported by AbbVie - Hot topics in ovarian cancer:
Platinum resistance and emerging therapies
Chair: Ilaria Colombo, CH; Clare Scott, AU

I. Colombo, EOC - Ospedale Regionale di Bellinzona e Valli, San Giovanni, Bellinzona, CH
12:50 - 13:02 Insights from the biology of cancer of the ovaries, fallopian tube and peritoneum: The
promise of biomarkers
13:02 - 13:14 A clinical case of a patient with platinum-resistant ovarian cancer: Resistance pathways
and state-of-the-art treatment options
A. Mukhopadhyay, CNCI - Chittaranja National Cancer Institute, Kolkata, IN
13:14 - 13:26 The promise of antibody drug conjugates (ADCs) in ovarian cancer: Mechanisms of action
and emerging therapeutics
C. Scott, Walter and Eliza Hall Institute WEHI, Parkville, AU
13:26 - 13:38 A clinical case of a patient on anti-folate receptor ADC: Efficacy and safety data from
registrational trials
13:38 - 13:45 Q&A, discussion and concluding remarks


Title: Meet your mentor session 3 - How to build a area)
successful career: Transforming Asian experience to global impact
12:45 - 13:15 Mentors
L. Si1, X. Le2, E. Poon3, T.W.-W. Chen4, 1Peking University Cancer Hospital and Institute, Beijing,
CN, 2The University of Texas M. D. Anderson Cancer Center, Houston, US, 3NCCS - National
Cancer Centre Singapore, Singapore, SG, 4NTU - National Taiwan University - College of
Medicine, Taipei City, TW

Title: Challenges in the management of advanced prostate cancer
Chair: Dominik Berthold, CH; Elena Castro, ES
14:30 - 14:35 Presentation of the case: T3N1M0 (M1 oligometastatic on PSMA-PET)

D. Berthold, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

14:35 - 14:50 The impact of imaging on staging and treatment
R. Eapen, Peter MacCallum Cancer Centre, Melbourne, AU
14:50 - 15:05 Role of local therapy in oligometastatic disease

D. Poon, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK
15:05 - 15:10 Progression of the case to metastatic disease

D. Berthold, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH
15:10 - 15:25 Systemic therapy options

15:25 - 15:40 Targeted therapies with a focus on PARP inhibitors and genetic testing
E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES

Title: Mini Oral session: Head and neck cancers
Chair: Victor Lee, HK; Nandini Menon, IN
14:30 - 14:35 406MO - Unique molecular features of Epstein Barr virus-specific cytotoxic T lymphocyte
(EBV-CTL) as biomarkers for advanced nasopharyngeal cancer (NPC) patients who received
chemotherapy and EBV-CTL.
T. Shuen, NCCS - National Cancer Centre Singapore, Singapore, SG
14:35 - 14:40 407MO - Capecitabine combined with PD-1 antibody as maintenance therapy after first-
line treatment of recurrent or metastatic nasopharyngeal carcinoma: A propensity score
matching study
Y. Li, Sun Yat-sen University Cancer Center, Guangzhou, CN
14:40 - 14:45 LBA3 - First-line HLX07 vs. Placebo Combined with Serplulimab and Chemotherapy for
Nasopharyngeal Cancer: a Randomised, Double-blind, Multicentre Phase 2 study
L. Zhang, Sun Yat-Sen University Cancer Center, Guangzhou, CN
14:45 - 14:57 Invited Discussant 406MO, 407MO and LBA3

V. Lee, The University of Hong Kong - Li Ka Shing Faculty of Medicine, Hong Kong, HK
15:02 - 15:07 408MO - Determining the optimal timing of adjuvant chemotherapy initiation after
concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma
H. Chen, Sun Yat-sen University Cancer Center, Guangzhou, CN

15:07 - 15:12 409MO - Induction chemo-immunotherapy with camrelizumab plus modified TPF (nab-
paclitaxel, cisplatin, and S1) in locally advanced nasopharyngeal carcinoma: A phase II,
single-arm study
S. Wu, The First Affiliated Hospital of Xiamen University, Xiamen, CN

E. Hui, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK
15:27 - 15:32 410MO - Pattern and treatment outcomes of second primary cancer (SPC) of the upper
aerodigestive tract (UADT) in head and neck squamous cell carcinoma (HNSCC) survivors: A
multi-center retrospective cohort study with long-term follow-up
J. Yung, Queen Elizabeth Hospital, Kowloon, HK
15:32 - 15:37 411MO - Petosemtamab (MCLA-158) monotherapy in previously treated (2L+)

recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 trial
C. Le Tourneau, Institut Curie, INSERM U900 Research Unit, Paris-Saclay University, Paris, FR
15:37 - 15:42 412MO - A Real-World Phase IV Superiority Study Among Recurrent or Advanced Head and
Neck Cancer Patients Prescribed with Low-Dose Nivolumab and Triple Metronomic
Chemotherapy versus Paclitaxel Carboplatin Regimen
A. Khadela, L. M. College of Pharmacy, Ahmedabad, IN
15:42 - 15:47 413MO - Impacts of time-of-day of nivolumab infusion on treatment efficacy for patients
with head and neck squamous cell carcinoma
T. Tsunoki, Aichi Cancer Center Hospital, Nagoya, JP
15:47 - 16:02 Invited Discussant 410MO, 411MO, 412MO and 413MO

N. Menon, Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN

Title: Prevention and treatment of vulvar cancer
Chair: David SP Tan, SG; Rebecca Kristeleit, GB
14:30 - 14:35 Presentation of case - Vulvar cancer: How the multidisciplinary management makes a
difference
14:35 - 14:50 Is vulvar cancer a preventable disease?

N. Bhatla, AIIMS - All India Institute of Medical Sciences, New Delhi, IN

14:50 - 15:05 The challenges of surgery and how to deal with it
T. Baert, UZ Leuven, Leuven, BE
15:05 - 15:20 Locoregional recurrence: What are the options?

Y.H. Leong, Singapore Society of Oncology, Singapore, SG
15:20 - 15:35 Metastatic disease: Can we do better?


Title: Mini Oral session: Breast cancer
Chair: Hiroji Iwata, JP; Heekyung Ahn, KR; Yeon Hee Park, KR
14:30 - 14:35 37MO - HER2-low Heterogeneity and Its Impact on Benefit from Trastuzumab Deruxtecan
in Metastatic Breast Cancer
Y. Zou, Sun Yat-sen University Cancer Center, Guangzhou, CN
14:35 - 14:40 38MO - Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with
pre-treated inoperable/metastatic hormone receptor-positive, HER2-negative (HR+/HER2–)
breast cancer (BC): Results from TROPION-Breast01 China cohort
S. Wang, Cancer Center of Sun Yat-sen University, Guangzhou, CN

H. Ahn, Gachon University Gil Hospital, Incheon, KR
14:55 - 15:00 3MO - Efficacy of neoadjuvant pembrolizuamb in early triple-negative breast cancer
according to germline BRCA-1/2 mutation
J.H. Kim, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR
15:00 - 15:05 28MO - Dynamic evolution of vascular features based on magnetic resonance imaging to
predict pathological response and survival outcomes in breast cancer patients undergoing
neoadjuvant chemotherapy
Q. Wu, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, CN

Y.H. Park, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul,
KR

Title: Recent advances in SCLC
Chair: Hiroaki Akamatsu, JP; Noemi Reguart, ES
14:30 - 14:50 Challenges in limited disease SCLC

H. Akamatsu, Wakayama Medical University, Wakayama, JP
14:50 - 15:10 Challenges in extensive disease SCLC

N. Reguart, Hospital Clinic y Provincial de Barcelona, Barcelona, ES
15:10 - 15:30 Biomarkers in SCLC and biomarker driven trials

T.M. Kim, Seoul National University - College of Medicine - Yeongeon Medical Campus, Seoul, KR
15:30 - 15:50 Novel drugs and future strategies in SCLC

L. Hendriks, Maastricht University Medical Center (MUMC), Maastricht, NL

Title: Optimal treatment of soft tissue sarcomas (STS)
Chair: Silvia Stacchiotti, IT; Tom Wei-Wu Chen, TW
14:30 - 14:45 Staging and prognostication

A. Gronchi, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
14:45 - 15:00 Neoadjuvant and adjuvant chemotherapy: When and how?

V. Yang, NCCS - National Cancer Centre Singapore, Singapore, SG
15:00 - 15:15 Oligometastatic disease in STS: How to treat and when surgery is an option
C. Roland, MD Anderson Cancer Center, Houston, US
15:15 - 15:30 Metastatic soft tissue sarcoma: Standard and new options
T.W.-W. Chen, NTU - National Taiwan University - College of Medicine, Taipei City, TW

Title: Preventive oncology: Some current perspectives
Chair: Jean-Yves Blay, FR; Hemant Malhotra, IN
14:30 - 14:55 Virus induced cancers and their prevention

H. Malhotra, MGMCH - Mahatma Gandhi Medical College & Hospital, Jaipur, IN
14:55 - 15:20 Molecular techniques in the early detection of cancer: Are we ready for that?
M.-H. Tan, Lucence, Palo Alto, US

15:20 - 15:45 Molecular characterisation of cancer: The emerging role of ai in histo-pathology
J.M. Coindre, Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR

Title: Controversies in localised rectal cancer treatment area)
Chair: Sara Lonardi, IT
14:45 - 15:30 Expert

C. Karapetis, Flinders Centre for Innovation in Cancer, Bedford Park, AU

Title: Personalising gastrointestinal (GI) oncology: From old to new target
inhibition
Chair: Kohei Shitara, JP; Angela Lamarca, ES
16:15 - 16:35 HER2 inhibition: Agnostic approach or disease-specific strategy?

F. Pietrantonio, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
16:35 - 16:55 Targeted options in patients with RAS or BRAF mutant tumours: Not only a colorectal
cancer matter
D. Modest, Charité - Universitaetsmedizin Berlin, Berlin, DE
16:55 - 17:15 Other emerging targeted agents in different GI cancers: Are they ready for primetime?
K. Shitara, National Cancer Center Hospital East, Kashiwa, JP
17:15 - 17:35 Rare targets and comprehensive genome profiling

A. Lamarca, Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES

Title: Latest advances/controversies in drug development
Chair: Tira Tan, SG; Sun Min Lim, KR
16:15 - 16:35 ESMO Frameworks for biology-informed and primary tumour-agnostic drug development
in the era of molecular niches
G. Curigliano, IEO - Istituto Europeo di Oncologia, Milan, IT
16:35 - 16:55 How can collaborative drug matching programmes make the most of genomic profiling for
patient benefit?
D. Thomas, Garvan Institute of Medical Research, Darlinghurst, AU

16:55 - 17:15 Advancing ADCs: Managing toxicities and harnessing combination treatments
E. Calvo, CIOCC - Centro Integral Oncológico Clara Campal, Hospital Universitario HM
Sanchinarro, Madrid, ES
17:15 - 17:35 Artificial intelligence (AI): Shaping the future of drug development
U. Banerji, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB

Title: Mini oral session: Supportive and palliative care
Chair: Stein Kaasa, NO; Gudrun Kreye, AT; Deepa Natarajan, HK
16:15 - 16:20 526MO - The Mitigation Impact of Self-Management Strategy for Health on Anxiety and
Depression in Patients with Fear of Recurrence
H. Kim, Graduate School, Hallym University, Chuncheon, KR
16:20 - 16:25 463MO - Active treatment in final weeks of life. Importance of palliative care in advanced
non-small-cell lung cancer
L. Posado-Domínguez, University Hospital of Salamanca, Salamanca, ES
16:25 - 16:30 464MO - Comprehensive Geriatric Assessment, Patterns of Care, and Outcome of Palliative
Chemotherapy in Elderly Patients with Advanced Solid Tumors: A Prospective
Observational Study from India
M. Khanna, AIIMS - All India Institute of Medical Science - Rishikesh, Rishikesh, IN

S. Kaasa, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO
16:47 - 16:52 527MO - Sexual health care in cancer patients: An evaluation of knowledge, attitudes, and
practices among Filipino medical oncologists
L.F. Revillas, St Lukes Medical Center, Quezon City, PH
16:52 - 16:57 528MO - Cognitive Phenotypes and its Association with Role Functioning Outcomes in
Adolescents and Young Adults (AYAs) with Cancer
P. Xiao, The Chinese University of Hong Kong, Sha Tin, HK
16:57 - 17:02 465MO - Tele-Palliative Care Services Implementation to Improve Palliative Care Services
in Remote Islands of Riau Province, Indonesia
N. Nasution, University of Indonesia - Faculty of Medicine, Central Jakarta, ID

D. Natarajan, Shatin Hospital, Sha Tin, HK

17:19 - 17:24 LBA4 - A randomized controlled trial to relieve distress of chemotherapy-induced

peripheral neuropathy by magnetic field: SMILE study
E. Kubo, National Cancer Center Hospital East, Kashiwa, JP
17:24 - 17:29 466MO - Effectiveness of Yoga on pain and spiritual well-being in patients with advanced
cancer: a single-arm interventional study in India
T. Shinde, Tata Memorial Hospital - Parel, Mumbai, IN
17:29 - 17:34 529MO - Cell-free concentrated ascites reinfusion therapy (CART) followed by
chemotherapy for the patients with cancerous ascites: a case control study from a single
institution in Japan
M. Hosoda, Tokyo Women's Medical University, Adachi Medical Center, Adachi-ku, JP
17:34 - 17:46 Invited Discussant LBA4, 466MO and 529MO

G. Kreye, Universitätsklinikum Krems, Krems an der Donau, AT

Title: Session in collaboration with AACR - Walkthroughs in clinical trials in
the era of molecular oncology
Chair: Nadia Harbeck, DE; Benjamin Haibe-Kains, CA
16:15 - 16:35 Platform, umbrella, basket and adaptive designs: What is new?
C. Yap, ICR - The Institute of Cancer Research - North Site, Sutton, GB
16:35 - 16:55 The applications of artificial intelligence (AI) in the clinical trial lifecycle
B. Haibe-Kains, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA
16:55 - 17:15 Which endpoints? Clinical endpoints and surrogacies

N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE
17:15 - 17:35 Novel statistical concepts for the clinician scientist-Bayesian and beyond
S.H. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG

Title: Mini Oral session: Thoracic malignancies
Chair: Noemi Reguart, ES; Yang Xia, CN; Pei Li Stephanie Saw, SG; Xiuning Le, US
16:15 - 16:20 626MO - Tarlatamab in previously treated small cell lung cancer (SCLC): Subgroup analysis
of patients from the Asia region in the phase 2 DeLLphi-301 study
H. Akamatsu, Wakayama Medical University, Wakayama, JP
16:20 - 16:25 627MO - POD1UM-304: Phase 3 Study of Retifanlimab Plus Platinum-Based Chemotherapy
(Chemo) as First-Line (1L) Therapy For Nonsquamous or Squamous Metastatic Non–Small
Cell Lung Cancer (mNSCLC)
S. Lu, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CN

Y. Xia, The Second Affiliated Hospital of Zhejiang University School of Medicine - East Gate 1,
Hangzhou, CN
16:40 - 16:45 614MO - A Phase Ⅱ Study of Becotatug (JMT101) in Combination with Osimertinib (Osi) in
Patients (pts) with classical EGFR-mutated Non-small Cell Lung Cancer (NSCLC) (BOOSTER
Study)
L. Zhang, Sun Yat-sen University Cancer Center, Guangzhou, CN
16:45 - 16:50 630MO - First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for
EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian
cohort
J.C.-H. Yang, National Taiwan University Hospital and Graduate Institute of Oncology, National
Taiwan University, Taipei, TW

17:05 - 17:10 628MO - Comparing Subcutaneous vs Intravenous Amivantamab with Lazertinib in EGFR-
Mutated Advanced NSCLC: Analysis of Asian Patients From PALOMA-3
S.-H. Lee, Sungkyunkwan University School of Medicine, Seoul, KR
17:10 - 17:15 629MO - ALESIA 7-year update: alectinib vs crizotinib in Asian patients (pts) with
treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC)
T. Baisamut, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, TH

X. Le, The University of Texas M. D. Anderson Cancer Center, Houston, US

Title: Cancer in low- or middle-income countries (LMICs): Challenges to
prevention and providing equitable care
Chair: Jean-Yves Blay, FR; Hemant Malhotra, IN
16:15 - 16:35 Air pollution and cancer: Fact or fiction?

N. Prasongsook, Phramongkutklao Hospital, Bangkok, TH
16:35 - 16:55 Early detection and screening for lung cancer in the Asia Pacific region
H.H.F. Loong, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK
16:55 - 17:15 Utility of the ESMO Magnitude of Clinical Benefit Scale (MCBS) in high-income countries
(HIC) and LMIC, and access to drugs
A. Mathew, MOSC Medical College, Kolenchery, IN
17:15 - 17:35 Challenges of equitable drug access: The WHO Essential Diagnostics List (EDL) for all or
high-end molecules for few?
D. Trapani, Università degli Studi di Milano, Milan, IT

Title: How to approach anaplastic thyroid cancer in the area)
era of precision medicine
Chair: Mei-Kim Ang, SG; Bhumsuk Keam, KR; Jean-Pascal Machiels, BE
16:15 - 17:00 Expert

N. Kiyota, Kobe University Hospital, Kobe, JP
17:50 - 18:45 Type: Poster Display session Exhibition area

Title: Poster Display session
17:50 - 17:50 Breast cancer, early stage
17:50 - 17:50 4P - Long-term outcomes of sentinel lymph node biopsy alone versus complete axillary
lymph node dissection following neoadjuvant treatment in breast cancer
H. Chen, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene
Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN

17:50 - 17:50 6P - Impact of Immediate Breast Reconstruction after mastectomy on Vertebral Alignment
K.-T. Hwang, Seoul National University College of Medicine, Seoul Metropolitan Government
Seoul National University Boramae Medical Center, Seoul, KR
17:50 - 17:50 7P - The efficacy of neoadjuvant endocrine therapy during the waiting period for surgery
in premenopausal hormone receptor positive breast cancer
Y. Maeda, Teikyo University School of Medicine, Tokyo, JP
17:50 - 17:50 8P - Real-world outcomes of anthracycline-containing versus anthracycline-sparing

chemotherapy in early HER2 breast cancer: Western Australia experience
H.H. Lee, Fiona Stanley Hospital, Perth, AU
17:50 - 17:50 9P - Impact of Neoadjuvant Systemic Therapies on Axillary Response in Early-Stage Triple-
Negative Breast Cancer
Y. Kook, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR
17:50 - 17:50 10P - Predictive Value of Serum Thymidine Kinase 1 during Neoadjuvant Chemotherapy in
HER2-negative Breast Cancer
X. Zhao, Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University &
Yunnan Cancer Center, Kunming, CN
17:50 - 17:50 11P - Prognostic implications of HER2 change after neoadjuvant chemotherapy in HER2-
positive breast cancer patients.
A. Sato, Teikyo University School of Medicine, Tokyo, JP
17:50 - 17:50 12P - A Nomogram Predicting the Long-term Survival Outcome of Neoadjuvant Therapy
for Patients with Metaplastic Breast Carcinoma: A Real World Study
C. Zhou, the first affiliated hospital,Xi'an Jiaotong University School of Medicine, Xi'an, CN
17:50 - 17:50 13P - Efficacy of topical plantago, marigold and honey hydrogel on prevalence of
radiation‐induced dermatitis in breast cancer patients: A randomised, double-blind,
parallel-group trial
S.A. Javadinia, Sabzevar University of Medical Sciences, Sabzevar, IR
17:50 - 17:50 14P - Enhancing quality of life and reducing inflammation in postmenopausal breast
cancer survivors receiving aromatase inhibitors through supplementation with fish oil and
evening primrose oil: a pilot randomized placebo-controlled trial
V. Vucic, Institute for Medical Research, National Institute of Republic of Serbia, University of
Belgrade, Belgrade, RS
17:50 - 17:50 15P - HER2-Positive Breast Cancer in a low-middle income country (LMIC): Lack of
Pathology Capability and The Urgent Need for targeted treatment
T.H. Hoang, K Hospital - Vietnam National Cancer Hospital - BASE 3, Hanoi, VN

17:50 - 17:50 16P - Prognostic Significance of HER2-Low Early-Stage Breast Cancer at King Chulalongkorn
Memorial Hospital: A Single Center, Retrospective study
P. Angsulajit, King Chulalongkorn Memorial Hospital - Thai Red Cross Society, Bangkok, TH
17:50 - 17:50 17P - To use or not to use adjuvant trastuzumab emtansine in early breast cancer in
resource constrained settings. Can residual cancer burden (RCB) help us to stratify risk of
residual disease?
V. Simha, Sri Shankara Cancer Hospital and Research Centre - SSCF, BENGALURU, IN
17:50 - 17:50 18P - A Comparative Real World Non Inferiority Study on Radiation-Induced Acute
Esophagitis in the Era of Hypofractionated Radiotherapy for Ca Breast.
S.S. Gopireddy, HCG HealthCare Global Enterprises Ltd, Bangalore, IN
17:50 - 17:50 19P - Molecular subtyping and prediction of risk of recurrence for early stage receptor
positive breast cancer for using NanoString nCounter – First Study from India
V. Ramshankar, Cancer Institute (WIA), Chennai, IN
17:50 - 17:50 20P - Exploring the impact of neoadjuvant therapy on suicide risk among breast cancer
patients: A comprehensive retrospective study and mendelian randomization analysis
Y. Yu, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN
17:50 - 17:50 22P - Usefulness of neutrophil-to-lymphocyte ratios to predict pathologic response and
prognosis in patients with operable breast cancer receiving neoadjuvant chemotherapy
with Abraxane
N. Yugo, Yokkaichi Municipal Hospital, Yokkaichi, JP
17:50 - 17:50 23P - Clinicopathological features of HR+/HER2 low breast cancer in a real-world setting in
China
Z. Min, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, CN
17:50 - 17:50 24TiP - A Phase 3, Randomized Study of Adjuvant Sacituzumab Tirumotecan (sac-TMT) Plus
Pembrolizumab Vs Treatment of Physician’s Choice (TPC) in Patients With TNBC Who
Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response
(pCR) at Surgery
R. Dent, National Cancer Centre Singapore and Duke-National University of Singapore (NUS)
Medical School, Singapore, SG
17:50 - 17:50 25TiP - Short-term Pre-OPerative Durvalumab in early small triple negative breast cancer
patients (POP-Durva)
J. Dixon Douglas, Gustave Roussy, Villejuif, FR
17:50 - 17:50 26TiP - Tislelizumab combined with nab-paclitaxel, adriamycin and cyclophosphamide
chemotherapy in neoadjuvant treatment in triple-negative breast cancer: A prospective,
single-arm, open-label phase II study
G. Zhang, Army Specialty Medical Center of PLA, Chongqing, CN

17:50 - 17:50 Breast cancer, locally advanced
17:50 - 17:50 29P - Intratumor heterogeneity and its variation during neoadjuvant therapy is associated
with treatment response and long-term prognosis in locally advanced breast cancer
M. Zhu, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, CN
17:50 - 17:50 30P - Pan-Immune Inflammation Value (PIV) - A Predictive Marker of Response to Neo-
Adjuvant Chemotherapy (NACT) in Locally Advanced Breast Cancer (LABC).
G. Shenoy, Kidwai Memorial Institute of Oncology, Bangalore, IN
17:50 - 17:50 31P - Clinical Profile, Treatment Outcomes and Long-Term Survival of Young Breast Cancer
Patients in India: A 10-Year Follow-Up Study from a Tertiary Cancer Institute
R. Gullapalli, Basavatarakam Indoamerican Cancer Hospital and Research Institute, Hyderabad,
IN
17:50 - 17:50 32P - Can PETCT help axillary de escalation in LABC post NAC?
M. Andrews, Medical College Hospital - Yenepoya University, Mangalore, IN
17:50 - 17:50 33P - Does the choice of radiation technique and nodal irradiation influence the incidental
dose to Internal Mammary Nodes?
R. Nair, AIIMS - All India Institute of Medical Sciences, Jodhpur, Jodhpur, IN
17:50 - 17:50 34P - MicroRNAs as therapeutic and prognostic markers for resistance to therapy in
HER2/neu positive breast cancers
P. D V M, Sri Shankara Cancer Hospital and Research Centre, Bangalore, IN
17:50 - 17:50 35P - Association Between Deprivation Index and Breast Cancer Survival Rates in county
level units.
H. Park, Pusan National University Hospital, Busan, KR
17:50 - 17:50 Breast cancer, metastatic
17:50 - 17:50 39P - Estradiol suppression in premenopausal patients with hormone receptor–positive
advanced breast cancer: MONALEESA-7 post hoc analysis
J. Lin, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene
Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN
17:50 - 17:50 40P - Real-world safety and effectiveness of ribociclib in Korean patients with HR+/HER2-
locally advanced or metastatic breast cancer
J.H. Kim, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR
17:50 - 17:50 41P - Impact of HER2-low and HER2-zero Status on Metastatic Hormonal Receptor-Positive
Breast Cancer Patients Treated with First-Line Aromatase Inhibitors, with or without
CDK4/6 Inhibitors: A Multicenter Retrospective Analysis
T. Susiriwatananont, King Chulalongkorn Memorial Hospital - Thai Red Cross Society, Bangkok,
TH

17:50 - 17:50 42P - Safety, tolerability, pharmacokinetics, and antitumor activity of FDA022-BB05 in
patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-
human, phase 1/1b study
X. Wang, Beijing Shijitan Hospital, Beijing, CN
17:50 - 17:50 43P - Efficacy and Safety of Paclitaxel Liposomes in Combination with Anti-HER-2 Targeted
Drugs as First-Line Rescue Therapy for HER-2-Positive Locally Advanced or Metastatic
Breast Cancer: A Retrospective, Real-World Study Based on the Cancer Database of China
National Cancer Center（NCC）
J. Yue, Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing,
CN
17:50 - 17:50 44P - Genomic mutational profile of breast cancer patients from India through
comprehensive next-generation sequencing analysis of circulating tumor DNA
N. Rohatgi, Fortis Flt. Lt. Rajan Dhall Hospital, Vasant Kunj, New Delhi, IN
17:50 - 17:50 46P - Real-world Treatment Patterns and Survival Outcomes in Patients (pts) With HER2+
Unresectable (u) or Metastatic Breast Cancer (mBC): HER2 REAL Asia Cohort
S.C. Lee, National University of Singapore (NUS), Singapore, SG
17:50 - 17:50 47P - The Role of Radiation Therapy for Patients with Ophthalmic Metastases from Breast
Cancer: A Systematic Review
C. Budiputri, UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID
17:50 - 17:50 48P - Clinical characteristics of patients (pts) with HER2+ unresectable (u) or metastatic
(m) breast cancer (BC): HER2 REAL Asia cohort
S.C. Lee, National University of Singapore (NUS), Singapore, SG
17:50 - 17:50 49P - Ethnicity assessment of ribociclib pharmacokinetics in advanced breast cancer
patients
Y.-S. Lu, NTUH - National Taiwan University Hospital, Taipei City, TW
17:50 - 17:50 50P - Establishment and validation of a predictive model for the risk and prognosis of
bone metastasis in breast cancer -- research based on provincial hospital data in China
L. Miao, Liaoning Cancer Hospital & Institute, Shenyang, CN
17:50 - 17:50 51P - Taxane-based chemotherapy versus endocrine therapy plus CDK4/6 inhibitor as first
line treatment in hormone receptor-positive HER2-negative metastatic breast cancer that
progressed on adjuvant endocrine therapy
Y. Yuan, The Fifth Medical Center of Chinese PLA General Hospital/No.307 Chinese PLA Hospital -
South Campus, Beijing, CN
17:50 - 17:50 52P - Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated
HER2-low metastatic breast cancer with distinct IHC statuses: Evidence from a Chinese
population
S. Wu, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, CN

17:50 - 17:50 53P - Real-World Treatment Patterns for HER2+ and HR+/HER2- Advanced Breast Cancer in
County Areas of China
Y. Ji, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, CN
17:50 - 17:50 55P - A Retrospective Study to Investigate the Prevalence and Describe the Treatment
Outcomes of HER2-low Unresectable and/or Metastatic Breast Cancer in Taiwan — the
RetroBC-HER2L-TW Study
C.-Y. Hsu, Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital,
Taipei, Taiwan, Taipei, TW
17:50 - 17:50 56P - Palbociclib versus ribociclib in first-line therapy of patients with metastatic breast
cancer: direct comparison in real-world practice.
E. Tsareva, Moscow State Budgetary Healthcare Institution "Moscow City Hospital named S.S.
Yudina, Moscow Healthcare Department", Moscow, RU
17:50 - 17:50 Developmental therapeutics
17:50 - 17:50 62P - Patient satisfaction and preference for atezolizumab subcutaneous (atezo SC) by
body mass index (BMI) or race (Asian vs non-Asian) from IMscin001 and IMscin002
B. Chewaskulyong, Chiang Mai Hospital, Mueang Chiang Mai District, TH
17:50 - 17:50 63P - A Randomised, Double-blind, Phase I Study to Compare the Pharmacokinetics,
Safety, Tolerability, and Immunogenicity of HLX15 and Daratumumab in Healthy Male
Participants
Y.-W. Su, Sir Run Run Hospital, Nanjing Medical University, Nanjing, CN
17:50 - 17:50 64P - FGF19 Promotes Hepatocellular Carcinoma Evasion of Immune Response by
Stabilizing PD-L1
J. Zhou, Sun Yat-Sen University Cancer Center, Guangzhou, CN
17:50 - 17:50 65P - The Role of Desmocollin-3 Glycoprotein in EMT-Driven Melanomagenesis:

Implications for Progression and Patient Outcome
S. Imani, Zhejiang Shuren University, Hangzhou, CN
17:50 - 17:50 66P - Comprehensive Analysis of Hippo Pathway Dysregulation in Uveal Melanoma:
Towards Prognostic Biomarkers and Therapeutic Targets
N. Kumar, AIIMS - All India Institute of Medical Sciences, New Delhi, IN
17:50 - 17:50 67P - Bioplatin, a Novel Oral Platinum-Based Compound: Potential for Cancer Prevention
and Treatment in SCID Mice Using Xenograft Models of Prostate cancer
Y. Bendale, Rasayani Biologics, Pune, IN
17:50 - 17:50 68P - Patient-reported outcomes (PROs) in Chinese patients with mantle cell lymphoma
(MCL) after covalent Bruton’s tyrosine kinase inhibitor (cBTKi) treatment: post-hoc analysis
from a phase 2 study
Y. Liu, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN

17:50 - 17:50 69P - Enhanced Efficacy of Resveratrol-Loaded Porous Silicon Nanocarriers in Targeting
Nucleolin for Breast Cancer Therapy
S. Shaw, Amity University, Noida, IN
17:50 - 17:50 70P - Hypofractionated radiotherapy in Combination With PD-1 Inhibitors, GM-CSF and
Thymosin α1 in Advanced Relapsed Metastatic Solid Tumors: An Interim Analysis of a
Single-Arm Phase II Multicenter Prospective Clinical Study
J. Yu, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and
Jiangsu Institute of Cancer Research, Nanjing, CN
17:50 - 17:50 71P - Efficacy of Low-Dose Nivolumab in Advanced Carcinomas

A. Tiwari, IMS & SUM Hospital SOA University, Bhubaneswar, IN
17:50 - 17:50 72TiP - Next-generation T-cell Receptor T Cell Therapy (SCG142) Against Human Papilloma
Virus (HPV) for Patients with Recurrent or Metastatic HPV16/52-Positive Carcinomas
H. Lv, The Affiliated Hospital of Qingdao University, Qingdao, CN
17:50 - 17:50 Gastrointestinal tumours, colorectal
17:50 - 17:50 75P - Anlotinib plus Sintilimab as First-line Treatment for Patients with Advanced
Colorectal Cancer (APICAL-CRC): an Open-Label, Single-arm, Phase II study
Z. Wang, Shanghai Changzheng Hospital, Shanghai, CN
17:50 - 17:50 76P - Impact of Quality of Life Factors on Survival in Colorectal Cancer Patients: A
Retrospective Cohort Study
D.S. Park, Graduate School, Hallym University, Chuncheon, KR
17:50 - 17:50 77P - Efficacy and safety of iparomlimab and tuvonralimab (QL1706) in untreated
metastatic colorectal cancer (mCRC)
J. Li, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, CN
17:50 - 17:50 78P - Design and Optimization of Colorectal Cancer Neoantigens mRNA Vaccines with a
naturel TLR-Stimulating Adjuvant
S. Imani, Zhejiang Shuren University, Hangzhou, CN
17:50 - 17:50 79P - The role of regorafenib for metastatic colorectal cancer in the new era of later-line
treatment: results of the OSERO study
T. Matsumoto, Kobe City Medical Center General Hospital, Kobe, JP
17:50 - 17:50 80P - Split-Course Hypofraction Radiotherapy Combined with Chemotherapy and
Tislelizumab as Preoperative treatment for Locally Advanced Rectal Cancer: Interim
Analysis of A Prospective, Single-Arm Phase II Trial
B. Xu, Fujian Medical University Union Hospital, Fuzhou, CN

17:50 - 17:50 81P - Stereotactic body radiation therapy followed by fruquintinib in combination with
immunotherapy as third- and later-line treatment in metastatic colorectal cancer
Y. Wang, Ningbo No.2 Hospital, Ningbo, CN
17:50 - 17:50 82P - Results from FRONT study: A multicenter, randomized, open-label clinical trial of
fruquintinib as maintenance therapy after 1L treatment in metastatic colorectal cancer
(mCRC)
X. Xu, Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN
17:50 - 17:50 83P - Efficacy and safety of cetuximab plus raltitrexed as first-line maintenance therapy in
patients with RAS wild-type metastatic colorectal cancer (mCRC) : an interim analysis of a
multi-center phase II trial
X. Li, Jiangsu Cancer Hospital, Nanjing, CN
17:50 - 17:50 84P - A multi-centre analysis of metastatic colorectal cancer diagnosed under the age of
35; a molecularly distinct group?
C. Williams, WEHI - Walter and Eliza Hall Institute of Medical Research, Parkville, AU
17:50 - 17:50 85P - ZNF334 Contributes to 5-Fluorouracil Sensitivity in Colorectal Cancer by

Ubiquitination Modification of CDK1-cylin B1
R. Sun, Chongqing Jiulongpo People's Hospital, Chongqing, CN
17:50 - 17:50 86P - Impact of renal impairment on chemotherapy-induced neutropenia in patients who
are treated with trifluridine/thymidine phosphorylase inhibitor + bevacizumab for
metastatic colorectal cancer
M. Shibutani, Osaka Metropolitan University, Osaka, JP
17:50 - 17:50 87P - Primary colorectal signet ring cell carcinoma and the risk of multiple primary
gastrointestinal malignancies
B. Hamed, 1Faculty of Medicine, Al-Azhar University, Boys Branch, Egypt, cairo, EG
17:50 - 17:50 88P - Machine learning models to predict the chemotherapy induced hepatotoxicity in
patients with colorectal cancer with liver metastasis
J.H. Kim, Korea University Anam Hospital, Seoul, KR
17:50 - 17:50 89P - Spatial analysis using MultiOmyx hyperplex assay reveals high prevalence of mature
tertiary lymphoid structure (TLS) and PDL1 expression in the MSI-high colorectal
carcinoma (CRC)
Q. Au, NeoGenomics Laboratories, Aliso Viejo, US
17:50 - 17:50 90P - Intensity-modulated radiation therapy can reduce acute toxicities in long-course
neoadjuvant radiation therapy combined with S-1 for locally advanced rectal cancer.
S. Tatsuno, Kindai University - Faculty of Medicine, Osaka, JP

17:50 - 17:50 91P - Clinicopathological and Molecular Features of Claudin-18 Isoform 2 in Pathological
Stage I–III Colorectal Cancer
S. Takamizawa, NCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP
17:50 - 17:50 92P - Clinical and mutational landscape of geriatric colorectal carcinoma: A real-world data
analysis from the GENIE database
Y. Mekhail, MFM - Menoufia University - Faculty of Medicine, Shebeen El-Kom, EG
17:50 - 17:50 93P - FOLFIRI plus bevacizumab versus FOLFIRI plus ramucirumab as second-line
chemotherapy for metastatic colorectal cancer in the real-world
T. Shimura, Nagoya City University Graduate School of Medical Sciences, Nagoya, JP
17:50 - 17:50 94P - Enhanced Recovery After Surgery (ERAS) Protocols in Vietnamese Colon Cancer.
T. Nguyen, Hue University of Medicine and Pharmacy, Hue City, VN
17:50 - 17:50 95P - ADAR1 of T cells rather than epitheliums contributes the bulk expression and
induces immune exhaustion in colorectal cancer
R. Zhang, Sun Yat-sen University Cancer Center, Guangzhou, CN
17:50 - 17:50 96P - Liposomal irinotecan + 5-FU/LV + bevacizumab for second-line treatment of
metastatic colorectal cancer (IRIS): a prospective, multi-center, single-arm clinical study
X. Hu, The Fourth Hospital of Hebei Medical University, Shijiazhuang, CN
17:50 - 17:50 97P - Study on monitoring ripretinib and its metabolites plasma concentration in Chinese
patients with gastrointestinal stromal tumors
H. Xu, Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University,
Nanjing, CN
17:50 - 17:50 98P - Real-world evidence on Total Neoadjuvant Therapy (TNT) vs. Neoadjuvant
Concurrent chemoradiation (NA CCRT) for locally advanced rectal cancer (LARC) from a
Tertiary Asian Cancer Centre.
M. Wang, NUHS - National University Health System, Singapore, SG
17:50 - 17:50 99P - Analysis of Prognostic Factors on Trifluridine-Tipiracil Plus Bevacizumab Treatment
in Metastatic Colorectal Cancer: A Retrospective Real-World Analysis
M. Onishi, NCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP
17:50 - 17:50 100P - Treatment outcomes in rectal cancer with radiological positive circumferential
resection margin treated with short course radiation therapy
S. Mahajan, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN
17:50 - 17:50 101P - A1Check: External validation of an intraoperative machine learning model
predicting colorectal anastomotic leakage
S. Ben Hmido, Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL

17:50 - 17:50 102P - Impact of Primary Tumor Sidedness on Survival Outcomes in Early-Onset and Late-
Onset Colorectal Cancer
M. Al Habsi, Sultan Qaboos University Hospital, Muscat, OM
17:50 - 17:50 103P - Characteristics of colon cancer in the comprehensive cancer center and overall
survival of young versus old patients: single institute experience from 2015 -2021.
H. Alghanmi, KAMC - King Abdullah Medical City Specialist Hospital, Makkah, SA
17:50 - 17:50 104P - Clinical observation and immune effects of high-intensity focused ultrasound
(HIFU) in the treatment of liver metastasis in colorectal cancer
S. Wang, The Affiliated Hospital of Qingdao University, Qingdao, CN
17:50 - 17:50 105P - TAS-102 (trifluridine/tipiracil) plus Bevacizumab versus TAS-102 alone as Salvage
Treatment Options for Metastatic Colorectal Cancer in Routine Clinical Practice
J.E. Shin, St. Vincent’s Hospital, College of Medicine, Catholic University of Korea, Seoul, Republic
of Korea, Suwon, KR
17:50 - 17:50 106P - A Study on the Effect of Prognostic Nutritional Index on the Safety and Survival of
Patients With Metastatic Colorectal Cancer Receiving Three Lines of Regorafenib and
Above
Z. Wang, Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, CN
17:50 - 17:50 107P - Anlotinib plus chemotherapy as first-line (1L) treatment in gastrointestinal cancer
patients with unresectable liver metastases
J. Wu, Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN
17:50 - 17:50 108P - Assessment of Quality of Life in Locally Advanced Carcinoma Rectum undergoing
Total Neoadjuvant Therapy: An Eastern Indian Subcontinent Prospective Study
A. Mahajan, AIIMS - All India Institute of Medical Sciences - Bhubaneswar, Bhubaneswar, IN
17:50 - 17:50 110P - Longitudinal measurements of the neutrophil-lymphocyte ratio during treatment
for locally advanced rectal cancer and associations with smoking, ethnicity and
pathological response
N. Huang, Macarthur Cancer Therapy Centre, Campbelltown, AU
17:50 - 17:50 111P - Real world experience with Trifluridine–Tipiracil and Bevacizumab combination
with an alternate schedule in Refractory Metastatic Colorectal Cancer
P. S N, Manipal Comprehensive Cancer Center Manipal Hospital, Bangalore, IN
17:50 - 17:50 112P - “Comparative Treatment between Pembrolizumab and Chemotherapy on Patients
diagnosed with Mismatch Repair Deficient Colorectal Cancer: A Systematic Review and
Meta-Analysis”
A. Kurniawan, UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID

17:50 - 17:50 113P - Associating Factors of Capecitabine-Induced Hand-Foot Syndrome in Patients with
Colorectal Cancer; What and How Impactful?
A. Sirichavaroj, Phramongkutklao Hospital, Bangkok, TH
17:50 - 17:50 114P - Impact of Elevated CEA Level on the Clinicopathological Features of Colorectal
Cancer Patients
A. Almezaine, Tanta University, TANTA, EG
17:50 - 17:50 115P - Optimal first-line chemotherapy for the elderly with metastatic colorectal cancer,
based on the real-world data
N. Sugimura, Nagoya City University Graduate School of Medical Sciences, Nagoya, JP
17:50 - 17:50 116P - Ripretinib Used for Preoperative Treatment of Metastatic Gastrointestinal Stromal
Tumor After Failure of Imatinib Therapy
L. Yang, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, CN
17:50 - 17:50 117TiP - Safety and Efficacy of Reduced-port Laparoscopic Surgery for Patients with Colon
and Upper Rectal Cancer: A multicenter, prosopective, randomized phase III study
Z. Liu, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN
17:50 - 17:50 118TiP - Neoadjuvant CAPOX plus SCT510 (bevacizumab biosimilar) and finotonlimab in
high-risk resectable colorectal liver metastases (CRLM): a multicenter, phase II study
W. Qiu, The Affiliated Hospital of Qingdao University, Qingdao, CN
17:50 - 17:50 119TiP - A randomized, controlled, multicenter phase 3 study of IBI310 (anti-CTLA-4
antibody) plus sintilimab (anti-PD-1 antibody) as neoadjuvant treatment for resectable
microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colon cancer: Trial
in Progress
R.-H. Xu, Sun Yat-sen University Cancer Center, Guangzhou, CN
17:50 - 17:50 120TiP - Neoadjuvant short-course radiotherapy combined with chemotherapy and
cadonilimab for patients with locally advanced rectal cancer: A prospective, single-arm
phase II trial
J. Rao, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN
17:50 - 17:50 121TiP - Comparison of Postoperative Anal Function Between Parks and Bacon Techniques
in Lower Rectal Cancer: A multicenter, prospective, randomized control study
Z. Liu, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN
17:50 - 17:50 122TiP - Watch and wait in patients with DNA mismatch repair-deficient or microsatellite
instability-high distal rectal cancer accessed pathological complete response after PD-1
monoclonal antibody therapy (BASKET)
F. He, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN

17:50 - 17:50 123TiP - Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy
Response in Locally Advanced Rectal Cancer
Y. Zhao, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN
17:50 - 17:50 124TiP - Safety and efficacy of PD-1 monoclonal antibody with or without mFOLFOX6
neoadjuvant therapy in patients with local advanced deficient mismatch
repair/microsatellite instability-high synchronous multiple primary colorectal cancer
Y. Zhao, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN
17:50 - 17:50 125TiP - Prophylactic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Locally
Advanced Colorectal Cancer: A Single-centre, open-label, randomized controlled trial
S. Xu, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN
17:50 - 17:50 Gastrointestinal tumours, non-colorectal
17:50 - 17:50 135P - Three-year survival, safety and extended long-term survivor (eLTS) analysis from
the Phase 3 TOPAZ-1 study of durvalumab (D) plus chemotherapy in advanced biliary tract
cancer (aBTC)
D.-Y. Oh, Seoul National University Hospital; Cancer Research Institute, Seoul National University
College of Medicine, Seoul, KR
17:50 - 17:50 136P - Tislelizumab combined with donafenib and GEMOX as first-line treatment for
advanced biliary tract cancer: a single-center, single-arm, phase 2 study
Y. Zhao, Fudan University Shanghai Cancer Center, Shanghai, CN
17:50 - 17:50 137P - A single-arm, multicenter, phase II study of hepatic arterial infusion chemotherapy
(HAIC) combined with donafenib and sintilimab as first-line treatment for unresectable
intrahepatic cholangiocarcinoma (CHANCE 2203)
G. Teng, Zhongda Hospital Affiliated to Southeast University, Nanjing, CN
17:50 - 17:50 139P - KEYNOTE-966: 3-Year Follow-Up for Pembrolizumab (pembro) + Gemcitabine and
Cisplatin (gem/cis) vs Placebo (pbo) + gem/cis for Patients (pts) With Advanced Biliary
Tract Cancer (BTC)
M. Ueno, Kanagawa Medical Center, Yokohama, JP
17:50 - 17:50 140P - Tinengotinib (TT-00420) in Combination with Atezolizumab (atezo) in Chinese
Patients (pts) with Biliary Tract Carcinoma (BTC): Efficacy and Safety Results from a Phase
Ib/II Study
P. Zhang, Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN
17:50 - 17:50 141P - Predictive MINT Pathological Risk Score for Adjuvant Chemotherapy in Resected
Cholangiocarcinoma: A Propensity Score Matched Multicenter Study in Thailand
K. Jeerapradit, Mahidol University - Faculty of Medicine - Ramathibodi Hospital, Bangkok, TH

17:50 - 17:50 142P - Lenvatinib Demonstrates Enhanced Efficacy in IDH1-Mutated Cholangiocarcinoma
with Hypervascular Features on Abdominal CT
W.-C. Wu, Taipei Veterans General Hospital, Taipei City, TW
17:50 - 17:50 143P - Claudin-18.2 Is a Poor Prognostic Indicator for Intrahepatic Cholangiocarcinoma
Y.H. Kuo, National Sun Yat-sen University, Kaohsiung City, TW
17:50 - 17:50 144P - The role of adjuvant chemo(radio)therapy in the management of Esophageal
keratinizing squamous cell carcinoma
M. Elkarany, Alexandria Faculty of Medicine, Alexandria, EG
17:50 - 17:50 145P - Efficacy and Safety in the KEYNOTE-966 Study of Pembrolizumab (pembro) +
Gemcitabine and Cisplatin (gem/cis) for Advanced Biliary Tract Cancer (BTC): Impact of
Hepatitis B Virus (HBV) Infection
T. Yau, The University of Hong Kong, Hong Kong, HK
17:50 - 17:50 146P - A retrospective study of the efficacy of gemcitabine combined with capecitabine
versus capecitabine alone for biliary tract cancer after curative resection
J. Ma, West China Hospital, Sichuan University, Chengdu, CN
17:50 - 17:50 147P - Baseline characteristics and molecular testing of Australian patients with IDH1
mutated cholangiocarcinoma: initial results from the phase 3b ProvIDHe study
17:50 - 17:50 148P - Real-world data of Advanced Gallbladder Cancers in Eastern India: A single
institutional analysis of 100 patients.
K. Ygl, AIIMS - All India Institute of Medical Sciences - Bhubaneswar, Bhubaneswar, IN
17:50 - 17:50 149P - Positivity rates of FGFR2 fusion gene or rearrangement and genetic profiling in
Asian Cholangiocarcinoma
Y. Maruki, National Cancer Center - Tsukiji Campus, Chuo-ku, JP
17:50 - 17:50 150P - The Prognostic Nutritional Index is linked to textbook outcomes and the status of
lymphocyte infiltration in patients with perihilar cholangiocarcinoma
Q.-Q. Liu, Sun Yat-Sen University, Guangzhou, CN
17:50 - 17:50 151P - A new prognostic index for patients with advanced biliary tract cancer treated with
cisplatin, gemcitabine and durvalumab.
M. Persano, AOU di Cagliari - Ospedale Civile, Cagliari, IT
17:50 - 17:50 152P - Spatial analyses revealed CXCL5 and SLC6A14 as the markers of microvascular
invasion in intrahepatic cholangiocarcinoma
G. Fan, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN

17:50 - 17:50 153P - Preliminary activity of Camrelizumab plus gemcitabine and oxaliplatin in the
transformation of unresectable gallbladder cancer：a single arm, phase II, prospective
clinical study.
R. Zhang, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, CN
17:50 - 17:50 154P - Biliary tract cancer: Trends, Incidence, and Survival in Chiang Mai University
Hospital-Based Cancer Registry Study in Thailand.
C. Charoentum, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University,
Chiang Mai, Thailand, Chiang Mai, TH
17:50 - 17:50 155P - Efficacy and its impact on overall survival of transarterial chemoembolization
(TACE) combined with Lenvatinib in hepatocellular carcinoma patients belonging to BCLC
stage C
A. Rahman, AIIMS - All India Institute of Medical Sciences - Bhubaneswar, Bhubaneswar, IN
17:50 - 17:50 156P - Efficacy of ipilimumab plus nivolumab therapy in patients having hepatocellular
carcinoma with main portal vein invasion (Vp4): Multicenter real-world study
J.S. Kim, CHA Bundang Medical Center, Seongnam, KR
17:50 - 17:50 157P - Single-cell Characterization of Differentiation Trajectories and Drug Resistance
Features in Gastric Cancer with Peritoneal Metastasis
H. Peng, Peking University Cancer Hospital & Institute, Beijing, CN
17:50 - 17:50 158P - Updated Efficacy and Safety of SOX regimen combined with inetetamab as first-line
treatment for HER2-positive advanced gastric cancer
Y. Kong, The Second Affiliated Hospital of Shandong First Medical University, Taian, CN
17:50 - 17:50 159P - Spatial Organization of B Cells in the Prediction and Prognosis of Gastric Cancer
R. Tay, NUS - National University of Singapore, Singapore, SG
17:50 - 17:50 160P - Peritoneal niche evolution and micro-environmental remodeling in gastric cancer
peritoneal metastasis
J.J. Zhao, National University Cancer Institute, Singapore, SG
17:50 - 17:50 161P - Phase II study of multi-center randomized controlled trial to evaluate oral vitamin
B12 treatment for vitamin B12 deficiency after total gastrectomy in gastric cancer patients
T. Aoyama, Yokohama City University Hospital, Yokohama, JP
17:50 - 17:50 162P - Efficacy of Perioperative FLOT in Gastric Carcinoma and Gastro-Oesophageal
Junction Carcinoma in achieving PCR: Retrospective Analysis in a Single Institution
Experience
X.R. Ting, Penang General Hospital, George Town, MY
17:50 - 17:50 163P - A comparison of the dietary intake after surgery in gastric cancer patients between
laparoscopic-assisted and conventional gastrectomy
J. Morita, Kanagawa Cancer Center, Yokohama, JP

17:50 - 17:50 164P - Efficacy and safety of Anlotinib plus Toripalimab as first-line regimen in advanced
gastric cancer patients with performance status 2 (PS 2): an open-label, single arm, phase
II trial
K. Liu, Shanghai Changzheng Hospital, Shanghai, CN
17:50 - 17:50 165P - Prognostic Analysis of Pathological Complete Response after Neoadjuvant Therapy
for Locally Advanced Gastric Cancer: A National, Multicenter, Retrospective Study
J. Chen, Fudan University Shanghai Cancer Center, Shanghai, CN
17:50 - 17:50 166P - Interaction between CHOP, GRP94, and stemness state in gastric cancer samples
with Helicobacter pylori Infection
F. Alizadeh, OMID Hospital Mashhad University of Medical Sciences, Mashhad, IR
17:50 - 17:50 167P - The Factors Associated with Early Recurrence in Older Patients with Stage II/III
Gastric Cancer: A Retrospective Cohort Study
Y.-H. Shih, Taichung Veterans General Hospital, Taichung City, TW
17:50 - 17:50 168P - Sarcopenia as a Prognostic Indicator in Stage 2-3 Gastric Cancer Patients. who
underwent surgery and adjuvant chemotherapy
J.E. Kim, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, KR
17:50 - 17:50 169P - Efficacy and prognosis of PD-1 inhibitors, trastuzumab, and first line chemotherapy
for HER-2-positive advanced gastric cancer in real-world study
B. Liu, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, CN
17:50 - 17:50 170P - Differentiation Between Malignant and Benign Gastric Lesions By Multimodal
Plasma Cell-free DNA analysis
H. Vo, Medical Genetics Institute, Thu Duc city, VN
17:50 - 17:50 171P - A multicenter survey on the administration of adjuvant S-1 chemotherapy for
patients with pStage II/III gastric cancer aged 80 years and older.
A. Horinouchi, South Miyagi Medical Center, Ogawara, JP
17:50 - 17:50 172P - Circular RNA profile identifies circATXN1 is unregulated and as a proliferative factor
and prognostic marker in gastric cancer
J. Chen, Fudan University Shanghai Cancer Center, Shanghai, CN
17:50 - 17:50 173P - Gastric adenocarcinoma; Does the location matter? A Retrospective Study from a
single oncology center
A. Shablak, Hamad Medical Corporation (HMC) - National Center for Cancer Care and Research
(Al Amal Hospital), Doha, QA
17:50 - 17:50 174P - Improved Tumour Penetration and Efficacy of anti-GPC3 CAR-T Cells in
Hepatocellular Carcinoma via Locoregional Delivery
P. Wang, CUHK - Chinese University of Hong Kong, Sha Tin, HK

17:50 - 17:50 175P - Lactobacillus paracasei ZJUZ2-3 Inhibits the Gastric Tumorigenesis by inhibit NF-κB
pathway via 3-IAA
R. Yang, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN
17:50 - 17:50 176P - The Functions and Mechanisms of DHX9 and Its Target Gene AURKA in Gastric
Cancer via PI3K/AKT and TNF Signaling Pathways
Z. Chen, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,
Wuhan, CN
17:50 - 17:50 177P - The significant role of HGF mediated MAP17 including cell proliferation and
metastasis in gastric cancer
B.I. Jang, Yeungnam Univeristy Medical Center, Daegu, KR
17:50 - 17:50 178P - KEYNOTE-859 update: Pembrolizumab + chemotherapy for advanced HER2-negative
gastric or gastroesophageal junction (G/GEJ) cancer
L. Yin, Merck & Co., Inc., Rahway, US
17:50 - 17:50 179P - Personalized Minimal Residual Disease Profiling Predicts Prognosis in Esophageal
Carcinoma Undergoing Definitive Radiotherapy
L.-R. Gao, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN
17:50 - 17:50 180P - Evaluation of a minimally invasive sponge cytology sampling for screening of
esophageal squamous cell carcinoma and gastric cardia adenocarcinoma
Z. Fan, Chinese Academy of Medical Sciences and Peking Union Medical College - National
17:50 - 17:50 181P - The Efficacy, Safety and cell-free DNA of Perioperative Leucovorin, Oxaliplatin,
Docetaxel and S-1 (LOTS) for Locally Advanced Gastric or Gastroesophageal Junction
Adenocarcinoma: a prospective phase II trial
C.C. Yen, NCKUH - National Cheng Kung University Hospital, Tainan, TW
17:50 - 17:50 182P - Real-World Treatment (Tx) Patterns in Patients (pts) with HER2-Positive Locally
Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (HER2+
aGC/GEJC) in East Asia (HER2+ GASTA)
17:50 - 17:50 183P - Response of Gastric Adenocarcinoma to Neoadjuvant Chemotherapy with respect to
the presence or absence of HER2 Overexpression: A Prospective Observational Study.
P. Deb, Saroj Gupta Cancer Centre & Research Institute, KOLKATA, IN
17:50 - 17:50 186P - Efficacy and Safety Between Weekly and Monthly Neoadjuvant Cisplatin and
Fluorouracil Chemoradiotherapy Regimens in Locoregional Esophageal Squamous Cell
Carcinoma
C.-L. Lai, Taichung Veterans General Hospital, Taichung City, TW

17:50 - 17:50 187P - Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal
cancer: An individual patient data (IPD) pooled analysis of 987 patients from three
prospective observational cohort studies
Z. Lu, Peking University Cancer Hospital and Institute, Beijing, CN
17:50 - 17:50 188P - The impact of pathological regression of primary tumor and lymph node on
recurrence and survival in patients with locally advanced esophageal squamous cell
carcinoma following neoadjuvant chemo-immunotherapy
Y. Li, Jiangsu Cancer Hospital, Nanjing, CN
17:50 - 17:50 189P - Superior Anti-tumor Activity of NC18, a Novel HER2-Targeting ADC, Against Enhertu
-Resistant CDX model
L. Zhi, Novacyte Therapeutics Company., Ltd, beijing, CN
17:50 - 17:50 190P - Tislelizumab as a treatment for Esophageal carcinoma: A systematic review and
meta analysis
H.T. Hashim, University of Warith Al-Anbiyaa, College of Medicine, Karbala, IQ
17:50 - 17:50 191P - Real world data of Non Metastatic Carcinoma Esophagus patients treated with
multimodality treatment in a resource constrained setting from South India.
R.T. Matta, GSL Medical College & General Hospital, Rajahmundry, IN
17:50 - 17:50 192P - Exploring EHMT2 Modulation by Niclosamide in Esophageal Squamous Cell
Carcinoma
I.-C. Wu, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City,
TW
17:50 - 17:50 193P - DCLK1’s kinase activity drives its pro-stemness effect in esophageal squamous cell
carcinoma
Y. Yang, Fujian University of Traditional Chinese Medicine, Fuzhou, CN
17:50 - 17:50 194P - Fruquintinib in combination with S-1 for ESCC patients after first-line
immunotherapy failure: Update of dose-finding results
N. Li, PUMCH - Peking Union Medical College Hospital/Beijing Xiehe Hospital - Xidan Campus,
Beijing, CN
17:50 - 17:50 195P - miR-10a-5p targets TFAP2C to promote cisplatin-resistance in esophageal cancer
K. Pasbola, Guru Gobind Singh Indraprastha University, New Delhi, IN
17:50 - 17:50 196P - Perioperative FLOT + immunotherapy for resectable gastric and gastroesophageal
junction cancer: a systematic review and meta-analysis
L.F. Revillas, St Lukes Medical Center, Quezon City, PH
17:50 - 17:50 197P - Efficacy and safety of lenvatinib plus adebrelimab combined with hepatic arterial
infusion chemotherapy (HAIC) for unresectable biliary tract cancer
W. Guo, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN

17:50 - 17:50 198P - The Efficacy and safety of adjuvant nivolumab therapy after neoadjuvant docetaxel
plus cisplatin, 5-FU therapy for resectable locally advanced esophageal squamous cell
carcinoma
N. Ogura, NCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP
17:50 - 17:50 199P - Impact of baseline tumour burden on outcomes in EMERALD-1: a Phase 3 study of
durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in
embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
M. Kudo, Kindai University Faculty of Medicine, Osaka, JP
17:50 - 17:50 200P - Final Analysis of the ELIXIR Study: A Prospective, Multicenter, Observational Study
to Evaluate the Efficacy and Safety of Atezolizumab + Bevacizumab (Atezo+Bev) in
Japanese Patients with Unresectable Hepatocellular Carcinoma (uHCC) in a Real-World
Clinical Setting
T. Takehara, Osaka University Graduate School of Medicine, Osaka, JP
17:50 - 17:50 201P - Perioperative pembrolizumab and lenvatinib for resectable hepatocellular
carcinoma: updated efficacy and safety results from the phase 2 NeoLEAP-HCC study
H. Sun, Affiliated Zhongshan Hospital of Fudan University, Shanghai, CN
17:50 - 17:50 202P - Hepatic Arterial Infusion Tislelizumab and Chemotherapy plus DEB-TACE in
Combination with Lenvatinib for First-line Treatment of unresectable HCC: A Prospective,
Single arm, Phase 2 Study (HAITC Study)
H. Yu, Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN
17:50 - 17:50 203P - Epigenetic Promoter Signatures and Ectopic Gain of Distal Intergenic Gene
Regulators Contribute To Hepatocarcinogenesis – The Planet Study
H.-Y. Lin, NUS-National University of Singapore-Yong Loo Lin School of Medicine (YLLSoM),
Singapore, SG
17:50 - 17:50 205P - Transarterial Chemoembolization with Immune Checkpoint Inhibitors and Anti-
VEGF Antibody/Tyrosine Kinase Inhibitors as First-Line Treatment for Intermediate-Stage
Hepatocellular Carcinoma (CHANCE2202): A Target Trial Emulation Study
J.-J. Chen, Zhongda Hospital Affiliated to Southeast University, Nanjing, CN
17:50 - 17:50 206P - Avatrombopag for the treatment of immune checkpoint inhibitor/targeted
therapyrelated thrombocytopenia in patients with hepatocellular carcinoma: A
prospective, multicenter, single-arm trial
Y.-S. Wang, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine,
University of Science and Technology of China, Hefei, CN
17:50 - 17:50 207P - FOLFOX-HAIC combined with sintilimab and bevacizumab for advanced
hepatocellular carcinoma: a single-arm, phase II study
Z. Wang, Union Hospital, Tongji Medical College, Huazhong University of Science and
Technology, Wuhan, CN

17:50 - 17:50 208P - Final analysis of the REPLACEMENT study: a phase II study of atezolizumab plus
bevacizumab (atezo+bev) for patients (pts) with Transcatheter arterial chemoembolization
(TACE)–unsuitable intermediate-stage hepatocellular carcinoma (HCC) beyond the up-to-
seven criteria
T. Yamashita, Kanazawa University Hospital, Kanazawa, JP
17:50 - 17:50 209P - Hepatic arterial infusion chemotherapy sequential transarterial embolization
combined with lenvatinib and tislelizumab in patients with high-risk unresectable
hepatocellular carcinoma: a phase 2 trial
J.-H. Zhong, Guangxi Medical University Cancer Hospital, Nanning, CN
17:50 - 17:50 210P - Atezolizumab plus bevacizumab versus Lenvatinib for BCLC-B stage of patients
with hepatocellular carcinoma: a large real-life worldwide population
F. Vitiello, IRCCS Ospedale San Raffaele, Milan, IT
17:50 - 17:50 211P - Multi-center, retrospective GUIDANCE001 trial comparing TACE with or without
tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat
unresectable hepatocellular carcinoma: survival benefit in intermediate or advanced, but
not early, stages
D. Yang, Guangxi Medical University Cancer Hospital, Nanning, CN
17:50 - 17:50 212P - FOLFOX-Based Hepatic Arterial Infusion Chemotherapy Combined with Sequential
Drug-Eluting Bead Transarterial Chemoembolization for unresectable Large
Hepatocellular Carcinoma
R. Zhao, Sun Yat-sen University Cancer Center, Guangzhou, CN
17:50 - 17:50 213P - Duration of adjuvant immune checkpoint inhibitors in hepatocellular carcinoma
with high-risk recurrence factors: a prospective, multicentric cohort study
J.-Y. Su, Guangxi Medical University Cancer Hospital, Nanning, CN
17:50 - 17:50 214P - Updated results from phase II study of HAIC plus sintilimab and bevacizumab
biosimilar in patients with advanced hepatocellular carcinoma (HCC)
H. Zhang, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, CN
17:50 - 17:50 215P - Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients
(pts) with portal vein tumor thrombosis (PVTT) treated with Camrelizumab, Apatinib plus
FOLFOX Chemotherapy
L. Peng, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN
17:50 - 17:50 216P - Long-term outcomes of a multicenter phase 2 trial evaluating the efficacy of
preoperative lenvatinib therapy for patients with advanced hepatocellular carcinoma
A. Ichida, The University of Tokyo Graduate School of Medicine, Bunkyo-ku, JP
17:50 - 17:50 217P - The efficacy and safety of tislelizumab as adjuvant therapy in hepatocellular
carcinoma with high-risk of recurrence after radical reaction
N. Peng, The First Affiliated Hospital of Guangxi Medical University, Nanning, CN

17:50 - 17:50 218P - Clinical significance of tumor-associated high endothelial venules in hepatocellular
carcinoma
S. Aoyama, Graduate School of Medicine / Faculty of Medicine, Osaka University, Suita, JP
17:50 - 17:50 219P - Can the blood coagulation factor, von Willebrand factor, be a predictor of response
to atezolizumab plus bevacizumab combination therapy for advanced hepatocellular
carcinoma?
H. Takaya, Nara Medical University Hospital, Kashihara, JP
17:50 - 17:50 220P - Outcomes with First-Line Therapy and Impact of ALBI Grade in Advanced
Hepatocellular Carcinoma: Insights from a Lower-Middle-Income Country
M. Naviwala, AKUH - Aga Khan University Hospitals - Karachi, Karachi, PK
17:50 - 17:50 221P - Survival Analysis of TACE Monotherapy vs. Combination Therapy in BCLC B and C
Stage Hepatocellular Carcinoma: A Retrospective Cohort Study
C. Guo, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN
17:50 - 17:50 222P - The activity and safety of icaritin for patients with unresectable hepatocellular
carcinoma：A real world, retrospective study
Z. Hui, Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of
Sciences, Hangzhou, CN
17:50 - 17:50 223P - Hepatic artery infusion chemotherapy (HAIC) combined with camrelizumab and
apatinib as conversion therapy for initial unresectable hepatocellular carcinoma (HCC): A
prospective, single-arm phase II trial.
X. Zhou, Shandong First Medical University Affiliated Provincial Hospital, Jinan, CN
17:50 - 17:50 224P - Neoadjuvant therapy versus initial hepatectomy for resectable intermediate or
advanced hepatocellular carcinoma (GUIDANCE002): a multicenter, retrospective cohort
study
J.-H. Zhong, Guangxi Medical University Cancer Hospital, Nanning, CN
17:50 - 17:50 225P - Real adjuvant transarterial chemoembolization is not associated with good survival
in most patients with hepatocellular carcinoma: a multicenter retrospective study
J.-R. Li, Guangxi Medical University Cancer Hospital, Nanning, CN
17:50 - 17:50 226P - Immune checkpoint inhibitor rechallenge in advanced hepatocellular carcinoma: a
retrospective cohort study
J.-K. Chen, Guangxi Medical University Cancer Hospital, Nanning, CN
17:50 - 17:50 227P - Adjuvant tislelizumab plus TACE in resected high-risk hepatocellular carcinoma
(ATTACK): preliminary analysisof a prospective cohort study
J. Liu, Shanghai Public Health Clinical Center, Shanghai, CN

17:50 - 17:50 228P - Arsenic sulfide enhances the therapeutic effect of hepatocellular carcinoma
immunotherapy through STAT3-THBS1/CD47 pathway
T. Kang, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai,
CN
17:50 - 17:50 229P - The Efficacy and Safety of Avatrombopag in the treatment of Thrombocytopenia
Secondary to Targeted and Immunotherapy in Hepatocellular Carcinoma
X. Peng, The Second Affiliated Hospital of Army Medical University, Chongqing, CN
17:50 - 17:50 230P - Individual-specific Edge-network of Gene Interactions Identified a Robust

Prognostic Score in Hepatocellular Carcinoma Patients
K. Xu, Anhui Medical University, Hefei, CN
17:50 - 17:50 231P - CT Image-Based Artificial Intelligence Quantification of Intratumoral Heterogeneity

for Predicting Treatment Response to Immunotherapy Combined with Anti-Angiogenic
Drugs in Hepatocellular Carcinoma
Z.-C. Jin, Zhongda Hospital Affiliated to Southeast University, Nanjing, CN
17:50 - 17:50 232P - Selective internal radiation therapy with Yttrium-90 (Y-90) resin microspheres for
unresectable hepatocellular carcinoma: Experience of a single center in China
X. Feng, Beijing Tsinghua Chang Gung Hospital, Beijing, CN
17:50 - 17:50 233P - Association of circulating inflammatory marker ISG15 with clinical factors and
survival in patients with liver cancer
W. Yeo, The Chinese University of Hong Kong, Hong Kong, HK
17:50 - 17:50 234P - Mechanism of Acinetobacter baumannii promoting gastric cancer metastasis by
enhancing NAD metabolism
Y. Yang, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN
17:50 - 17:50 235P - Combined Atezolizumab and Bevacizumab versus Sorafenib as First-Line Treatment
for Advanced Hepatocellular Carcinoma: A Single Center Experience
A. Khalil, Sphinx Cure Oncology Center, Giza, EG
17:50 - 17:50 236P - Characteristics and Prognosis of Primary and Acquired Resistance to Immune
Checkpoint Inhibitors Combination Treatment in Unresectable Hepatocellular Carcinoma
X. Chen, CAMS-PUMC - Chinese Academy of Medical Sciences and Peking Union Medical College
- Dongdan Campus, Beijing, CN
17:50 - 17:50 237P - Radiotherapy with or without Immune checkpoint inhibitors and tyrosine kinase
inhibitors in Hepatocellular Carcinoma with severe macrovascular invasion: a
retrospective cohort study
Q.-Q. Tang, Guangxi Medical University Cancer Hospital, Nanning, CN

17:50 - 17:50 238P - Intestinal microbiota in locally advanced skin melanoma, gastric cancer and
esophageal squamous cell carcinoma patients
A. Kuzmenko, National Medical Research Center of Oncology named after N.N. Blokhin, Moscow,
RU
17:50 - 17:50 239P - Adjuvant TACE Combined with Tislelizumab in Patients with Resected
Hepatocellular Carcinoma at High Risk of Recurrence: An Open-label, Multicenter, Phase 2
Trial
T. Ma, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN
17:50 - 17:50 240P - Efficacy and Safety of Transarterial Chemoembolization (TACE) in Combination with
Tislelizumab and TKIs Versus TACE for the Treatment of Intermediate and Advanced HCC:
a retrospective cohort study
Y. Han, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
College, Beijing, CN
17:50 - 17:50 241P - Biliary Tract Cancers from Western India- A Study Depicting Demographic Trends,
presentation of molecular landscape and survival outcomes
U. Maheshwari, MOC Cancer Care & Research Centre, Mumbai, IN
17:50 - 17:50 242P - Selective internal radiation therapy with Yttrium-90 (Y-90) resin microspheres for
unresectable hepatocellular carcinoma: Experience of a single center in China
X. Feng, Beijing Tsinghua Chang Gung Hospital, Beijing, CN
17:50 - 17:50 243P - Tumor response at the time of discontinuation of atezolizumab plus bevacizumab
(Ate+Beva) predict progression free survival of patients who stop Ate+Beva therapy.
S.-Y. Hwang, Dongnam Institute of Radological and Medical Sciences-DIRAMS, Busan, KR
17:50 - 17:50 244P - Impact of genomic profiling testing on treatment outcomes in gastrointestinal
neuroendocrine carcinoma
T. Ozato, Okayama University Hospital, Okayama, JP
17:50 - 17:50 245P - Molecular landscape of neuroendocrine neoplasms using tissue and blood-based
genotyping in MONSTAR-SCREEN-2
S. Ushiyama, National Cancer Center Hospital East, Kashiwa, JP
17:50 - 17:50 246P - Efficacy of Atezolizumab Combined with Platinum and Etoposide in the Treatment
of Extrapulmonary Neuroendocrine Carcinoma
I. Ho, Taipei Veterans General Hospital, Taipei City, TW
17:50 - 17:50 247P - Gastroenteropancreatic Neuroendocrine Tumours: A 10-year Experience at the

National Cancer Institute, Malaysia
R. Mohd Zaid, National Cancer Institute, Putrajaya, MY

17:50 - 17:50 248P - Clinicopathological Profile and Outcomes of Neuroendocrine Tumors: Data from a
Multicenter Collaborative Registry in India
S.S. Panda, IMS & SUM Hospital SOA University, Bhubaneswar, IN
17:50 - 17:50 249P - The intratumoral metabolic characterization and potential mechanisms in
pancreatic ductal adenocarcinoma
D. Luo, Xiangya Hospital of Central South University, Changsha, CN
17:50 - 17:50 250P - Evaluating the Impact of Liquid Biopsy-Derived Circulating Tumor DNA (ctDNA) as
Predictive Biomarkers in Early-Stage Pancreatic Cancer Therapy Response
17:50 - 17:50 252P - Safety and Efficacy of XELOXIRI Regimen in Patients with Unresectable Pancreatic
Ductal Adenocarcinoma
B. Cao, Chinese Academy of Medical Sciences and Peking Union Medical College - National
17:50 - 17:50 253P - Prognostic nutritional index is an independent risk factor for continuing S-1
adjuvant chemotherapy in patients with pancreatic cancer who received neoadjuvant
chemotherapy and surgical resection
S. Kawahara, Kanagawa Cancer Center, Yokohama, JP
17:50 - 17:50 255P - Real-world outcomes of long-term survivors of metastatic pancreatic ductal
adenocarcinoma (mPDAC) previously treated with liposomal irinotecan (nal-IRI) for the
Asian cohort of NALLONG study
C. Yoo, Asan Medical Center - University of Ulsan, Seoul, KR
17:50 - 17:50 256P - PIK3CA mutations in pancreatic ductal adenocarcinoma (PDAC)

O. Pitiyarachchi, UNSW Sydney, Sydney, AU
17:50 - 17:50 257P - “H” to “H” precision neoadjuvant chemotherapy can improve the resectable rate in
pancreatic cancer
Y. He, The Second Affiliated Hospital of Army Medical University, Chongqing, CN
17:50 - 17:50 258P - Current trends in treatment regimens and overall survival for patients with
advanced pancreatic cancer in a real-world setting
H. Imaoka, National Cancer Center Hospital East, Kashiwa, JP
17:50 - 17:50 259P - Irinotecan liposome-based regimen in Chinese patients with advanced pancreatic
cancer: a prospective, multi-center, observational real-world study
J. Xu, Fudan University Shanghai Cancer Center, Shanghai, CN
17:50 - 17:50 260P - NALIRIFOX as subsequent therapy for metastatic pancreatic cancer after
Gemcitabine-based chemotherapy: a real-world experience in single center
H.-C. Lin, Taichung Veterans General Hospital, Taichung City, TW

17:50 - 17:50 261TiP - Randomized, open-label, multicenter, Phase 3 study of trastuzumab deruxtecan
(T-DXd) with rilvegostomig vs standard of care (SOC) in first-line, human epidermal growth
factor receptor 2 (HER2)-expressing, locally advanced or metastatic (LA/m) biliary tract
cancer (BTC): DESTINY-BTC01
M. Ikeda, National Cancer Center Hospital East, Kashiwa, JP
17:50 - 17:50 262TiP - Comparison of Adjuvant Chemoradiotherapy versus Adjuvant Chemotherapy in

carcinoma gall bladder- A randomized controlled study
D. Das, AIIMS - All India Institute of Medical Sciences - Bhubaneswar, Bhubaneswar, IN
17:50 - 17:50 263TiP - TroFuse-015: a phase 3 study of trophoblast antigen 2 (TROP2)–directed antibody-
drug conjugate sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice
(TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)
K. Shitara, Research Center for Innovative Oncology, National Cancer Center Hospital East,
Kashiwa, JP
17:50 - 17:50 264TiP - A Phase 1b/2 open-label study evaluating trastuzumab deruxtecan (T-DXd) in
combination with rilvegostomig and chemotherapy in patients with HER2-positive (HER2+)
and HER2-low gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-
Gastric03 Part 4
Y. Janjigian, Memorial Sloan Kettering Cancer Center, New York, US
17:50 - 17:50 265TiP - Phase 1/2 open-label, umbrella platform designed study of investigational agents
with or without pembrolizumab and/or chemotherapy in patients with advanced
esophageal cancer previously treated with a PD-(L)1 inhibitor: KEYMAKER-U06 substudy
06B
K. Kato, National Cancer Center Hospital, Tokyo, JP
17:50 - 17:50 266TiP - The Efficacy of Tislelizumab Combined with S-1 in Patients with Residual Primary
Lesions and Node-Negative Esophageal Squamous Cell Carcinoma After Neoadjuvant
Immunochemotherapy followed by Curative Resection: A Phase II, multicenter Trial (PPIO-
008)
Y. Wang, Daping Hospital, Army Medical University, Chongqing, CN
17:50 - 17:50 267TiP - CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in
patients with imatinib-refractory gastrointestinal stromal tumor
W.P. Yong, National University Cancer Institute, Singapore, Singapore, SG
17:50 - 17:50 Genitourinary tumours, non-prostate
17:50 - 17:50 277P - Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone for previously
untreated unresectable or metastatic urothelial carcinoma (u/mUC): Chinese population
analysis results from the phase 3 CheckMate 901 trial
D. Ye, Fudan University Shanghai Cancer Center, Shanghai, CN

17:50 - 17:50 278P - Efficacy and safety of cadonilimab plus lenvatinib in previously immunotherapy
treated advanced/metastatic clear cell renal cell carcinoma (ccRCC): a multicenter, single-
arm, phase II trial
J. Huang, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai,
CN
17:50 - 17:50 279P - Avelumab maintenance therapy in older patients with advanced urothelial
carcinoma in Japan: subgroup analyses of data from post-marketing surveillance by age
group
M. Nagata, Juntendo University Graduate School of Medicine, Tokyo, JP
17:50 - 17:50 280P - Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by number of IMDC risk
factors in patients (pts) with advanced renal cell carcinoma (aRCC): subgroup analyses
from the final analysis of the phase 3 JAVELIN Renal 101 trial
J. Haanen, Netherlands Cancer Institute, Amsterdam, NL
17:50 - 17:50 281P - Intrinsic molecular difference between bladder and upper tract urothelial
carcinomas and its impacts in treatment response
J. Kim, Korea University, Seoul, KR
17:50 - 17:50 282P - Prognostic outcome of neoadjuvant chemotherapy for non-metastatic muscle-
invasive bladder cancer (MIBC) patients: Real-world data from clinical practice at Siriraj
Hospital
P. Angsuwarangsee, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, TH
17:50 - 17:50 283P - Diagnostic Efficacy of Urine DNA Methylation based Screening Tests for Surveillance
in NMIBC: A Qualitative Analysis
G. Goel, AIIMS - All India Institute of Medical Sciences, Bathinda, Bathinda, IN
17:50 - 17:50 284P - Real-world efficacy of lenvatinib and pembrolizumab as first-line therapy in
patients with metastatic renal cell carcinoma with high burden disease.
O. Stativko, Oncology center No.1 City Clinical Hospital n.a. S.S.Yudin, Moscow, RU
17:50 - 17:50 285P - Genetic variation of the inflammatory cytokine Interleukin 17 in non-muscle
invasive bladder cancer
M. Singh, KGMU - King George's Medical University, Lucknow, IN
17:50 - 17:50 286P - Radiotherapy Outcomes of Patients with Bladder Cancer Who Are Unfit for
Cystectomy: A Retrospective Cohort Study
K. Kikuchi, Iwate Medical University, Shiwa-gun, JP
17:50 - 17:50 287P - RC48-ADC alone or in combination with immunotherapy for Locally Advanced or
Metastatic Urothelial Carcinoma with HER2 Low/null Expression: A multicenter, Real-
world, Retrospective Study
D. Wang, Sun Yat-Sen University Cancer Center, Guangzhou, CN

17:50 - 17:50 288P - The role of organ-specific response to enfortumab vedotin on survival in advanced
urothelial carcinoma patients: A Japanese multicenter retrospective study.
N. Hayakawa, St. Marianna University School of Medicine, Kanagawa, JP
17:50 - 17:50 289P - Difference in oncological efficacy between subsequent anti-PD-L1 and anti-PD-1
inhibitors following first-line platinum-based chemotherapy for patients with advanced
urothelial carcinoma
R. Kawashima, Gokeikai Osaka Kaisei Hospital, Osaka, JP
17:50 - 17:50 290P - Impact of SBRT in Oligometastatic Renal Cell Carcinoma - A Spotlight on the
Unexplored
A. Radha P, APOLLO CANCER CENTRE, BANGALORE, IN
17:50 - 17:50 291P - Cardiotoxicity profile of renal carcinoma treated with immune checkpoint
inhibitors: a meta-analysis of phase II/III randomized clinical trials
A. Nugrahani, UNAIR - University Airlangga - Campus A, Surabaya, ID
17:50 - 17:50 292P - Avelumab + axitinib (A + Ax) vs sunitinib (S) in patients (pts) with advanced renal
cell carcinoma (aRCC): subgroup analyses by age from the final analysis of the phase 3
JAVELIN Renal 101 trial
J. Haanen, Netherlands Cancer Institute, Amsterdam, NL
17:50 - 17:50 293P - Unveiling the Impact of Tertiary Lymphoid Structures on Immunotherapeutic
Responses of Renal Cell Carcinoma
17:50 - 17:50 294P - Tolerability and outcomes of definitive chemoradiotherapy for elderly patients with
muscle invasive bladder cancer
W. Jung, Ewha Womans University Mokdong Hospital, Seoul, KR
17:50 - 17:50 295P - Real-World Efficacy and Safety of Lenvatinib Plus Pembrolizumab in Metastatic
Renal Cell Carcinoma Patients with Intermediate and Poor Risk
I. Tsimafeyeu, Bureau for Cancer Research - BUCARE, Moscow, RU
17:50 - 17:50 297P - Comparative Genomic and Clinical Features between Malignant Renal Epithelioid
Angiomyolipoma and Benign Angiomyolipoma
A. Aihetaimujiang, Fudan University Shanghai Cancer Center, Shanghai, CN
17:50 - 17:50 298P - Radiotherapy Combined with Low-dose Paclitaxel plus Cisplatin for Very High Risk
Non-muscular Invasive Bladder Cancer: A Single-arm, Single-center, Prospective Trial
F. Yuan, Affiliated Cancer Hospital of Chongqing University, Chongqing, CN
17:50 - 17:50 299P - Molecular characterization of TFE3-rearranged renal cell carcinoma in pediatric
patients and adolescents
L. Haoyang, West China Hospital, Sichuan University, Chengdu, China, Chengdu, CN

17:50 - 17:50 300P - Characteristics and Outcomes of 3099 Patients Undergoing Robot-Assisted
Laparoscopic Surgery for Renal Tumors: A 10-Year Single-Center Retrospective Study
H. Guo, Nanjing Drum Tower Hospital, The Affliated Hospital of Nanjing University Medical
School,, Nanjing, CN
17:50 - 17:50 301P - Effectiveness and safety of adjuvant nivolumab after radical surgery for high-risk
urothelial carcinoma: A preliminary report of real-world data from a single institution in
Japan
Y. Yasuda, The Cancer Institute Hospital of JFCR, Koto-ku, JP
17:50 - 17:50 302P - Increased eosinophil may be predictor for efficacy and safety in patient with renal
cell carcinoma treated with ipilimumab plus nivolumab: A retrospective multicenter
study
Y. Tasaki, Nagoya City University Hospital, Nagoya, JP
17:50 - 17:50 303P - Cabozantinib Versus Cabozantinib Plus Nivolumab In First-Line Treatment Of
Advanced Renal Cell Carcinoma: A Chang Gung Medical Foundation Multicentric Cohort,
Real-World Study
C.-H. Ku, Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City,
TW
17:50 - 17:50 304P - Clinical profile and survival outcomes in Wilms tumor patient treated by SIOP
protocol at a Regional cancer center
P. Kushala, MNJ Institute of Oncology & Regional Cancer Center, Hyderabad, IN
17:50 - 17:50 305P - Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are predictors of
immune-related adverse events during nivolumab monotherapy for metastatic renal cell
carcinoma
Y. Iemura, Yamato Takada Municipal Hospital, Yamatotakada, JP
17:50 - 17:50 306P - Safety and efficacy of immune checkpoint inhibitor rechallenge in metastatic
fumarate hydratase-deficient renal cell carcinoma: A retrospective study
Y. Tang, West China Hospital, Chengdu, CN
17:50 - 17:50 307P - PSMA-positive tumor vessels around renal cancer have high tumor angiogenic
potential and predict tumor recurrence
R. Watanabe, Ehime University Graduate School of Medicine, Toon, JP
17:50 - 17:50 308P - Predictive factors and the role of conventionally fractionated radiation therapy for
bone metastasis from renal cell carcinoma in the era of targeted therapy
H. Kang, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul
, Korea, Incheon, KR
17:50 - 17:50 309P - Risk stratification of advanced urothelial carcinoma in the era of cancer
immunotherapy
G. Kaneko, Saitama Medical University International Medical Center, Saitama, JP

17:50 - 17:50 310P - Real-world observation of treatment patterns and long-term clinical outcome in
non-muscle invasive bladder cancer (NMIBC)
M. Miyake, Nara Medical University, Nara, JP
17:50 - 17:50 311P - The value of blood oxygenation level-dependent (BOLD) MR in differentiation of
fumarate hydratase‑deficient renal cell carcinoma and high-grade clear cell renal cell
carcinoma
F. Zhao, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN
17:50 - 17:50 312P - Efficacy and Safety of Tislelizumab plus Axitinib in the Treatment of Locally
Advanced Clear Cell Renal Cell Carcinoma：A single center clinical study
C. Ji, Nanjing Drum Tower Hospital, The Affliated Hospital of Nanjing University Medical School,,
Nanjing, CN
17:50 - 17:50 313P - Surveillance of Patients with Complete Response Following First-Line
Chemotherapy for Germ Cell Tumors (GCTs)
S. Arunothai, Mahidol University - Faculty of Medicine Ramathibodi Hospital, Bangkok, TH
17:50 - 17:50 314P - Effectiveness of tislelizumab combined with chemotherapy for high recurrence risk
patients with upper tract urothelial carcinoma after radical nephroureterectomy
J. Zhang, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, CN
17:50 - 17:50 315P - Clinical Characterization and Outcomes of Patients with PAX8 Positive Cancer of
Unknown Primary: a Distinct Immunophenotypic Subset
J. Allam, The University of Texas MD Anderson Cancer Center, Houston, US
17:50 - 17:50 316P - Deciphering the Poor Prognostic Signature of SLC7A5 in Clear Cell Renal Cell
Carcinoma and its Impact on Tumor Immune Microenvironment
R. Jadallah, King Abdullah University Hospital (KAUH), Irbid, JO
17:50 - 17:50 317P - Upper tract urothelial carcinoma with TP53 mutation treated by platinum-based
neoadjuvant chemotherapy may induce tumor infiltrating lymphocytes in the tumor
microenvironment
D. Ikarashi, Iwate Medical University School of Medicine, Morioka, JP
17:50 - 17:50 318P - RA-VEIL、VEIL or O-ILND which should be used for inguinal lymphadenectomy
H. Yin, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine,
Nanjing, CN
17:50 - 17:50 319P - Enfortumab vedotin with or without pembrolizumab in Asian patients with
metastatic urothelial carcinoma: The preliminary territory-wide real-world experience in
Hong Kong
D. Poon, Hong Kong Sanatorium & Hospital, Hong Kong, HK

17:50 - 17:50 320P - Patient and clinician priorities and expectations of systemic therapy in metastatic
urothelial cancer (mUC)
C.-F. Chan, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK
17:50 - 17:50 321P - The garden of forking paths: Differences in genitourinary cancer epidemiological
patterns between GLOBOCAN and GBD
T.-Q. Du, First Clinical Medical School - Lanzhou University, Lanzhou, CN
17:50 - 17:50 322P - The utility of tumour markers in detecting relapses in testicular seminoma: largest
experience from a comprehensive cancer centre in India
D. Samaddar, ACTREC, Tata Memorial Centre, Homi Bhaba National Institute, Mumbai, IN
17:50 - 17:50 323P - Clinicopathological features and transcriptomic profiles of MED15-TFE3-rearranged

renal cell carcinoma: A retrospective study of 14 cases.
S. He, West China Hospital of Sichuan University, Chengdu, CN
17:50 - 17:50 324P - Pattern of care and long-term outcomes of stage 1 seminoma: real world data from
the Indian subcontinent.
A. Dhanawat, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata
Memorial Centre, Homi Bhabha National Institute, Kharghar, IN
17:50 - 17:50 325P - Application of extended immunotherapy in advanced clear cell renal cell carcinoma
treated with first-line combination of immune-checkpoint inhibitor and tyrosine kinase
inhibitor
Q. Wang, West China Hospital of Sichuan University, Chengdu, CN
17:50 - 17:50 326P - GCLC inhibits lung metastasis of renal cell carcinoma by regulating glutathione
metabolic pathway
W. Yang, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese
Medicine, Nanjing, CN
17:50 - 17:50 327P - The Critical Role of ADCYAP1 Gene Methylation in Prognosis and Immune
Microenvironment Modulation of Bladder Cancer
W. Liu, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, CN
17:50 - 17:50 328P - Long-term Follow-up Outcomes of 142 Patients with Papillary Renal Cell Carcinoma
Undergoing Robot-Assisted Partial Nephrectomy or Radical Nephrectomy
Z. Chen, Nanjing Drum Tower Hospital, The Affliated Hospital of Nanjing University Medical
17:50 - 17:50 329P - SORL1 regulates ATAD3A to modulate cholesterol homeostasis and drive clear cell
renal cell carcinoma progression
Y. Chen, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine,
Nanjing, CN

17:50 - 17:50 330P - The effect of age on the outcome of robot assisted renal clear cell carcinoma
resection surgery：A single center retrospective study
Z. Chen, Nanjing Drum Tower Hospital, The Affliated Hospital of Nanjing University Medical
17:50 - 17:50 332P - Multi-Omics Data Reveal Potential Therapeutic Targets for Translational Renal Cell
Carcinoma: Results from the Largest Retrospective Integrated Cohort
H. Zhang, Fudan University Shanghai Cancer Center, Shanghai, CN
17:50 - 17:50 333P - Identification of Translational Renal Cell Carcinomas Based on Transformer Model
and Pathogenomic Data: A Multicenter Study
17:50 - 17:50 334TiP - A prospective, single-arm clinical study of Disitamab Vedotin (DV) combined with
Toripalimab for kidney sparing in solitary kidney or renal insufficiency or bilateral
multiple upper urinary tract urothelial carcinoma (UTUC)
X. Tian, Fudan University Shanghai Cancer Center, Shanghai, CN
17:50 - 17:50 Genitourinary tumours, prostate
17:50 - 17:50 339P - Comparison of Stereotactic Body Radiation Therapy(SBRT) and Radical
Prostatectomy (RP) in High-Risk/Very High-Risk Prostate Cancer: A Large Multi-Center
Comparative Analysis Using Propensity Score Matching (PSM)
B. Xu, Shanghai Changhai Hospital, Yangpu District, CN
17:50 - 17:50 340P - Rezvilutamide plus androgen deprivation therapy in patients with low-volume,
metastatic hormone-sensitive prostate cancer: a national, real-world cohort study
B. Wang, Chinese PLA General Hospital (301 Military Hospital), Beijing, CN
17:50 - 17:50 341P - Genomic landscape of prostate cancer patients with and without ductal
adenocarcinoma (DA) based on liquid biopsy
Q. Zhu, West China Hospital of Sichuan University, Chengdu, CN
17:50 - 17:50 342P - Utility of Prostate-specific antigen derivatives to Minimize Unnecessary Magnetic
Resonance Imaging in Patients with prior negative prostate biopsy
S.H. Song, Seoul National University Bundang Hospital, Seongnam, KR
17:50 - 17:50 343P - Pilot study evaluating the role of PSMA ligand 18 F-Florastamin PET/CT in men with
clinical suspicion of prostate cancer
W. Suh, The Catholic University of Korea - Daejeon St. Mary's Hospital, Daejeon, KR
17:50 - 17:50 344P - Treatment intensification patterns in Asian patients with metastatic hormone
sensitive prostate cancer (mHSPC)

17:50 - 17:50 345P - Patient-reported outcomes in metastatic hormone-sensitive prostate cancer
(mHSPC): Results from the China ARCHES trial
X. Lu, Fudan University Shanghai Cancer Center, Shanghai, CN
17:50 - 17:50 346P - High Genomic Risk is Associated with Clinically Significant Prostate Cancer (csPCa)
Recurrences following Focal Therapy (FT)
B.H. Hong, NCCS - National Cancer Centre Singapore, Singapore, SG
17:50 - 17:50 347P - Utilizing urine protein enrichment mass spectrometry to establish a model for
accurate early screening of prostate cancer
Y. Wang, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN
17:50 - 17:50 348P - Enzalutamide vs abiraterone plus prednisolone for elderly CRPC patients: From the
ENABLE phase 3 trial
K. Izumi, Kanazawa University Hospital, Kanazawa, JP
17:50 - 17:50 349P - Predictive Gene Signature In Primary Prostate Cancer Associated With Regional
Lymph-Node Metastasis Using Both mRNA And miRNA Profiling
D. Hoon, Providence Saint John's Cancer Institute, Santa Monica, US
17:50 - 17:50 350P - Development and Validation of a Machine Learning-Based Early Warning Model for
Initial Diagnosis of Prostate Cancer Bone Metastasis
L. Wang, Beijing Jishuitan Hospital Guizhou Hospital（Guizhou Orthopaedic Hospital）, Guiyang,
CN
17:50 - 17:50 351P - Nadir testosterone levels following androgen deprivation therapy (ADT) and
outcomes in Chinese patients with metastatic prostate cancer (mPC): The PROTECH study
S. Zhang, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, CN
17:50 - 17:50 352P - Unveiling the Potential of [-2]pro PSA-Related Index in TZ Prostate Cancer Diagnosis
Y. Toyama, Nippon Medical School Main Hospital, Tokyo, JP
17:50 - 17:50 353P - Heterogeneity of tertiary lymphoid structures predicts distinct malignancy and
immune microenvironment in prostate cancer
W. Xu, Fudan University Shanghai Cancer Center, Shanghai, CN
17:50 - 17:50 354P - Survival Outcome and Clinicopathological features of Mixed Subtype
Adenocarcinoma of the Prostate: A SEER Database Analysis 2000–2021
S. Zreigh, Ankara Yildirim Beyazit Universty, Ankara, TR
17:50 - 17:50 355P - The role of deep learning image reconstruction algorithm with small field of view in
spectral computed tomography in the diagnosis of lymph nodes in prostate cancer.
M. Chen, Sun Yat-sen University Cancer Center, Guangzhou, CN

17:50 - 17:50 356P - Cross-correlative method for in-situ analysis of multiple generic abiraterone acetate
samples.
A. Patel, Command Hospital CC Lucknow, Lucknow, IN
17:50 - 17:50 357P - Comprehensive Genomic Profiling and Treatment Outcomes in mCRPC: Focusing on
Homologous Recombination Repair Mutations
S. Hata, Oita University Faculty of Medicine, Yufu, JP
17:50 - 17:50 358P - Predictive Value of Homologous Recombination Deficiency (HRD) Scores for
Abiraterone Efficacy in Metastatic Prostate Cancer
J. Zhao, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN
17:50 - 17:50 359P - CD13 as a Potential Membrane Marker in PSMA-Negative Prostate Cancer and First-
in-Human Study of [18F]AlF-CD13-L1 PET/CT Imaging
W. Tang, Xiangya Hospital of Central South University, Changsha, CN
17:50 - 17:50 360P - Real-World Treatment and Clinical Outcomes in Metastatic Castration-Resistant
Prostate Cancer (mCRPC): REMPRO-Middle East and Africa (MEA)
G. El Husseiny, Alexandria University, Alexandria, EG
17:50 - 17:50 361P - Evaluation of the predictive ability of TP53 gene mutation by
immunohistochemistry in Japanese patients with ductal adenocarcinoma of the prostate
H. Kobayashi, National Defense Medical College, Tokorozawa, JP
17:50 - 17:50 362P - Sex Hormones and Blood Metabolites Mediating the Causal Associations between
Gut Microbiota and Prostate Cancer: Evidences from Mendelian Randomization Study
T. Liu, Anhui Medical University, Hefei, CN
17:50 - 17:50 363P - Neoadjuvant hormone therapy for PCa: a systematic review and meta-analysis of
clinical trials
L. Meng, West China Hospital of Sichuan University, Chengdu, CN
17:50 - 17:50 364P - Interpretable machine learning for prostate biopsy: cohort study
J. Dai, West China Hospital of Sichuan University, Chengdu, CN
17:50 - 17:50 365P - Radical vs Palliative RT in metastatic hormone-sensitive prostate cancer

K. Yan, The Chinese University of Hong Kong, Department of Clinical Oncology, Hong Kong, HK
17:50 - 17:50 366P - Clinicopathological predictors of favourable response to docetaxel in patients with
metastatic castration-resistant prostate cancer
B. Tran, Peter MacCallum Cancer Centre, Melbourne, AU
17:50 - 17:50 367P - Patients Health-related Quality of Life in Men with Prostate Cancer Treated by
Enzalutamide: A Systematic Review
A. Kurniawan, Faculty of Medicine, Pelita Harapan University, Tangerang, ID

17:50 - 17:50 368P - Causal relationships between dietary habits and prostate cancer: A two-sample
Mendelian randomization study
H. Zeng, West China Hospital, Sichuan University, Chengdu, CN
17:50 - 17:50 369P - Experience with Triplet Therapy in Denovo Metastatic Hormone Sensitive Prostate
Cancer- Single Center from India
V. Panicker, TMC - Tata Medical Center, Kolkata, IN
17:50 - 17:50 370P - Glucagon-like peptide-1 receptor agonists and risk of common cancers: a
transcriptomic and proteomic‐wide Mendelian randomization analysis
K. Wang, The First Affiliated Hospital of Anhui Medical University, Hefei, CN
17:50 - 17:50 371P - Multi-omics investigation of the association and underlying mechanisms between
antihypertensive drugs and urologic tumors: A Mendelian randomization study
F. Yang, The First Affiliated Hospital of Anhui Medical University, Hefei, CN
17:50 - 17:50 778TiP - Adjuvant rezvilutamide in combination with androgen-deprivation therapy, with
or without radiotherapy, in high-risk patients following radical prostatectomy: a multi-
center, open-label, two-cohort exploratory study
Y. Fan, Peking University First Hospital, Beijing, CN
17:50 - 17:50 Gynaecological cancers
17:50 - 17:50 382P - Landscape of genomic alterations in chemoradiation resistant cervical cancer
patients using whole-genome sequencing
P. Kumar, Karkinos Healthcare Pvt. Ltd., Navi Mumbai, IN
17:50 - 17:50 383P - Next-Generation Sequencing-based Assay for Detection of Human Papillomavirus
in Clinical Samples
E. Yeom, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College
of Medicine,, Seoul, KR
17:50 - 17:50 384P - Delays and Disruptions in Cervical Cancer Care during the COVID-19 Pandemic – A
retrospective single institution study.
V.K.V. Gade, PGIMER - Post Graduate Institute of Medical Education and Research, CHANDIGARH,
IN
17:50 - 17:50 385P - Establishment of a Prognostic Model for Endometrial Cancer Using CRISPR and
Machine Learning, and Identification of the Key Gene PLK1
N. Zhang, The First Affiliated Hospital of Anhui Medical University, Hefei, CN
17:50 - 17:50 386P - Impact of the Molecular Classification on Adjuvant Radiotherapy for Stage I
Endometrial Cancer： A Cohort Study in China
Y. Jiang, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,
Wuhan, CN

17:50 - 17:50 387P - COL4A6 promotes tumor progression and chemoresistance in ovarian cancer by
activation DDR1 pathway
Y.-H. Wu, Chi Mei Medical Center, Liouying, Tainan City, TW
17:50 - 17:50 388P - RENI-1: Efficacy and Safety of Niraparib as First-Line Maintenance Therapy in Newly
Diagnosed Ovarian Cancer: A Prospective, Multicenter Real-World Study，Updated in 24-
month follow-up
Z. Zheng, Fudan University Affiliated Cancer Hospital, Shanghai, CN
17:50 - 17:50 389P - Monocyte Reprogramming in High-Grade Serous Ovarian Cancer and Chemotherapy
Impact: A Single-Cell RNA Sequencing Study
K. Enikeeva, Bashkir State Medical University, Ufa, RU
17:50 - 17:50 391P - Potential association analysis and prognostic model of mitochondrial genes for
ovarian cancer based on Mendelian randomization and machine learning
N. Zhang, The First Affiliated Hospital of Anhui Medical University, Hefei, CN
17:50 - 17:50 392P - A single arm phase II study of single agent Pemetrexed in Platinum
Resistant/Refractory Epithelial Ovarian or Primary Peritoneal Cancer
S. Khurana, AIIMS - All India Institute of Medical Sciences, New Delhi, IN
17:50 - 17:50 393P - Evaluation of AU8-18, a potent CDK 2 inhibitor for the treatment of ovarian cancer
S. Kasirzadeh, University of South Australia - City East Campus, Adelaide, AU
17:50 - 17:50 394P - Post-marketing Study to Evaluate the Safety and Efficacy of Bevacizumab Biosimilar
in Patients with Advanced Ovarian Cancer
P. Mohapatra, Apollo Multi-Speciality Hospital, Kolkata, IN
17:50 - 17:50 395P - Real-world safety of olaparib in ovarian cancer (OC): A retrospective, observational,
database study in China
N. Li, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
17:50 - 17:50 396P - Real-world survival analysis of platinum-resistant recurrent ovarian cancer: A multi-
center retrospective study from China
Q. Wang, Xuzhou Central Hospital/The Fourth People's Hospital of Xuzhou, Xuzhou, CN
17:50 - 17:50 397P - Real-world outcome of dostarlimab in dMMR/MSI-H advanced/recurrent

endometrial cancer: Updated results from Korean expanded access program
M.K. Kim, Samsung Changwon Hospital - Sungkyunkwan University School of Medicine,
Changwon, KR
17:50 - 17:50 398P - Real-world data of PARP inhibitors in first-line maintenance for BRCA mutated or
HRD positive advanced ovarian cancer: A multicenter retrospective study from India
Y.S. Kumar, Institute of Medical Sciences and Sum Hospital, Siksha 'O' Anusandhan University,
Bhubaneswar, IN

17:50 - 17:50 399P - Real world experience of immunotherapy in metastatic dMMR endometrial cancer
at a tertiary cancer center
B.M. Soumya, Manipal hospitals, Bangalore, IN
17:50 - 17:50 400TiP - An open-label, multicenter, Phase 2 study of trastuzumab deruxtecan (T-DXd) in
patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 2
J.-Y. Lee, Yonsei Cancer Center and Severance Hospital, Yonsei University College of Medicine,
Seoul, KR
17:50 - 17:50 401TiP - Adebrelimab Plus Chemotherapy and Bevacizumab Induction Therapy Followed
by Maintenance Therapy with Adebrelimab Plus Fluzoparib and Bevacizumab in
Platinum-Sensitive Relapsed Ovarian Cancer (CHANGCHUN): A Single-Arm, Exploratory
Study
Z. Liu, The First Hospital of Jilin University, Changchun, CN
17:50 - 17:50 Head and neck cancer, excluding thyroid
17:50 - 17:50 414P - Prognostic factors of locally advanced hypopharyngeal cancer in Taiwan
T.-P. Lu, National Taiwan University, Taipei City, TW
17:50 - 17:50 415P - Preliminary safety and efficacy results from phase II study pulsed radiotherapy
with tislelizumab in patients with recurrent Head & Neck Cancer
X. Zhang, TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN
17:50 - 17:50 416P - A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with
chemotherapy for the treatment of anti-PD-1 resistant, recurrent, or metastatic
nasopharyngeal carcinoma (R/M NPC)
L. Wen, Union Hospital Tongji Medical College Huazhong University of Science and Technology,
Wuhan, CN
17:50 - 17:50 417P - Final and Exploratory Results of a Phase I Trial Evaluating Novel Radioenhancer
NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible LA HNSCC Patients
17:50 - 17:50 418P - Updated results of toripalimab combined with cetuximab in PD-L1 positive
untreated recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A
phase Ib/II study
Y. Guo, Shanghai East Hospital, Tongji University, Shanghai, CN
17:50 - 17:50 419P - Escalated Dose PAINTing IntEnsity Modulated Radiotherapy (PAINTER) for
Inoperable Locally Advanced Head and Neck Squamous cell carcinoma (LAHNSCC)
U. Velu, KMC - Kasturba Medical College, Manipal, Manipal, IN

17:50 - 17:50 420P - Pretreatment 18F-FDG PET-CT parameters can predict survival in patients with de
novo metastatic nasopharyngeal carcinoma receiving chemotherapy combination anti-
programmed death-1 immunotherapy
L. Gu, Sun Yat-Sen University Cancer Center, Guangzhou, CN
17:50 - 17:50 421P - Induction chemotherapy and concurrent chemoradiotherapy with cisplatin for T4
nasoethmoidal squamous cell carcinoma: the value of paclitaxel, carboplatin and
cetuximab (PCE)
N. Tanaka, National Cancer Center Hospital East, Kashiwa, JP
17:50 - 17:50 422P - Claudin-1 (CLDN1) expression in nasopharyngeal carcinoma (NPC): Association with
immune exclusion and implications for immune checkpoint inhibitor (ICI) therapy
E. Yeo, NCCS - National Cancer Centre Singapore, Singapore, SG
17:50 - 17:50 423P - NF-κB signaling pathway activity leads to identification of novel molecular
biomarkers in HPV-associated head and neck cancer
A. Kothari, UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill,
US
17:50 - 17:50 424P - Prognostic Implications of Histological Bone Involvement in Oral Squamous Cell
Carcinoma: A Comparative Analysis
A. Thaduri, Basavatarakam Indo American Cancer hospital, hyderabad, IN
17:50 - 17:50 425P - 18F-FAPI PET/CT imaging to explore the evaluation of immunotherapy efficacy in
HNSCC.
N. Li, The second hospital of Dalian Medical University, Dalian, CN
17:50 - 17:50 426P - Trop-2 and Nectin-4 expression and their relationship with tumor immune
microenvironment in salivary gland cancer
Y. Nagatani, Kobe University Hospital, Kobe, JP
17:50 - 17:50 427P - Direct Medical Costs of Nasopharyngeal Carcinoma in Indonesia: A Healthcare Payer
Perspective
C. Irawan, RSUPN Dr. Cipto Mangunkusumo, Central Jakarta, ID
17:50 - 17:50 428P - Has the cradle of anti-neoplastic immunotherapy improved the survival outcome
for nasopharyngeal malignant melanoma?
N. Mubarak, Suez Canal University Hospital, Ismailia, EG
17:50 - 17:50 429P - Head and neck primary lymphoepithelial carcinoma and the risk of multiple
primary malignancies
A. Ramadan, Suez Canal University Hospital, Ismailia, EG

17:50 - 17:50 430P - Aurora Kinase A (AURKA) Expression in Patients with Nasopharyngeal Cancers: Its
Association with Clinical Characteristics and Treatment Responses
K. Taroeno-Hariadi, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada /
Dr. Sardjito General Hospital, Yogyakarta, ID
17:50 - 17:50 432P - N6-methyladenine demethylase ALKBH1 functions as a prognostic biomarker links
immunotherapy response in metastatic head and neck cancer
C. Pandi, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical
Sciences (SIMATS), Saveetha University, Chennai, IN
17:50 - 17:50 433P - Investigating the Effectiveness and Safety of the Economically Viable and Well-
Tolerated Capecitabine and Cyclophosphamide Drug Combination in advanced head and
neck cancer: A Prospective Study in India
K. Baruah, Kidwai Memorial Institute of Oncology, Bangalore, IN
17:50 - 17:50 434P - Brachytherapy as a Modality in Head and Neck Cancer Treatment: Long-Term
Efficacy and Survival Outcomes
S. Mahajan, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN
17:50 - 17:50 435P - Efficacy and Toxicity of Different Adjuvant Chemotherapy Administration Methods
and Regimens in Locoregionally Advanced Nasopharyngeal Carcinoma
J. Chen, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for
Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, CN
17:50 - 17:50 436P - High expression of methyltransferase-like protein 11A promotes metastasis in
HNSCC and is associated with immune infiltrates and poor prognosis
B. Kannan, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical
17:50 - 17:50 437P - Real-world efficacy of induction chemotherapy followed by chemoradiotherapy

compared to concurrent chemoradiation therapy in patients with very advanced head and
neck squamous cell cancer.
O. Stativko, Oncology center No.1 City Clinical Hospital n.a. S.S.Yudin, Moscow, RU
17:50 - 17:50 438P - Promoting cell growth to prevent the spread of head and neck cancer
Y. Bai, Peter MacCallum Cancer Centre, Melbourne, AU
17:50 - 17:50 439P - Comparison of the Efficacy and Safety of Neoadjuvant PD-1 inhibitors plus
Chemotherapy vs Targeted therapy plus Chemotherapy in Locally Advanced
Hypopharyngeal Squamous Cell Carcinoma (LA HPSCC)
Y. Zhang, Bejing Tongren Hospital, Capital Medical University, Beijing, CN
17:50 - 17:50 440P - Low-Dose Nivolumab six weekly plus Triple Metronomic Chemotherapy in
Advanced Head and Neck Cancer-A prospective, Open Label Single Centre Study from
Eastern India
S. Swain, IMS & SUM Hospital, Bhubaneswar, IN

17:50 - 17:50 441P - Real-world data of nivolumab efficacy for treatment of recurrent or metastatic head
and neck squamous cell carcinoma.
M. Nosova, Oncology center No.1 City Clinical Hospital n.a. S.S.Yudin, Moscow, RU
17:50 - 17:50 442P - Comparative Outcomes of Docetaxel Plus Cisplatin Versus Paclitaxel Plus
Carboplatin in Unresectable Head and Neck Cancers: A Retrospective Study
R. Yadav, Gujarat Cancer Research Institute, AHMEDABAD, IN
17:50 - 17:50 443P - Relevance of LATS1 Gene in Head-Neck Squamous Cell Carcinoma (HNSCC)
H. Goel, AIIMS - All India Institute of Medical Sciences, New Delhi, IN
17:50 - 17:50 444P - Comparative Analysis of Induction Chemotherapy Regimens for Nasopharyngeal
Carcinoma: A Retrospective Single-Center Study
A. Alfagih, KFMC - King Fahad Medical City, Riyadh, SA
17:50 - 17:50 445P - Individualized neoadjuvant PD-1 inhibitors combined with chemotherapy for
resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) : A single-
center, retrospective trial
X. Chen, Bejing Tongren Hospital, Capital Medical University, Beijing, CN
17:50 - 17:50 446P - Prevalence and correlation of P16INK4A expression and HPV DNA positivity in
carcinoma oropharynx and their correlation with survival outcomes - report from a tertiary
cancer centre in south India.
A. Sherief P, RCC - Regional Cancer Centre, Trivandrum, IN
17:50 - 17:50 447P - Evaluating the efficacy and safety of pembrolizumab in recurrent or metastatic
head and neck squamous cell carcinoma: A multicenter, retrospective study analysis
M. Hu, Shandong Cancer Hospital and Institute, Jinan, CN
17:50 - 17:50 448P - Linking VEGF-A Expression and Genetic Alterations to Survival in Oral Squamous
Cell Carcinoma.
B. Aleem, Khyber Medical University, Lahore, PK
17:50 - 17:50 449P - Identification and validation of a novel m6A modulator LRPPRC signature
associated with oral squamous cell carcinoma
K.V. Gopalakrishnan, Saveetha Medical College and Hospital, Saveetha Institute of Medical and
Technical Sciences (SIMATS), Saveetha University,, Chennai, IN
17:50 - 17:50 450P - Dysregulated expression of Replication Factor C subunit 5 (RFC5) serves as a
potential biomarker for head and neck squamous cell carcinoma
A. Pandi, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical

17:50 - 17:50 451P - Identification of a Biomarker Compendium for different clinical stages of oral
submucous fibrosis by 2D Gel Electrophoresis and Mass Spectrometry along with
validations – A First Indian Experience
Y. Madhavan, Cancer Institute (WIA), Chennai, IN
17:50 - 17:50 452P - Characteristics and treatment patterns of Patients Diagnosed with Nasopharyngeal
Carcinoma in Indonesia: A Descriptive Study Using the National Health Insurance
Database
S. Hutajulu, Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, ID
17:50 - 17:50 453P - Cross-Resistance of Head and Neck Squamous Cell Cancer Cells to Cetuximab and
Radiation
J.A. Bonner, University of Alabama at Birmingham Hospital, Birmingham, US
17:50 - 17:50 454P - Institutional experience of concurrent Doce-aquilip in Head and Neck Cancer
patients who are Cisplatin ineligible
V. Arora, Dharamshila Narayana Superspeciality Hospital, New Delhi, IN
17:50 - 17:50 455P - A Real-World Study: Induction Chemoimmunotherapy versus Induction

Chemotherapy Followed by Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma
Patients with Stage IVa
K. Wu, Heyuan Hospital of Guangdong Provincial People's Hospital, Heyuan People's Hospital,
Heyuan, CN
17:50 - 17:50 456P - Real world analysis of usage and efficacy of immune check point inhibitors in
recurrent/metastatic head and neck cancers.
K. Domadia, HCG Cancer Centre Ahmedabad, Ahmedabad, IN
17:50 - 17:50 457P - Induction Chemotherapy: Hope or Hype in Head & Neck Cancer – Real World
Evidence from Institute of National Importance in Western Rajasthan (India).
A. Gupta, AIIMS - All India Institute of Medical Sciences, Jodhpur, Jodhpur, IN
17:50 - 17:50 458P - Nomogram for predicting lung metastases in patients with papillary thyroid cancer
under 55 years old
H. Yang, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine,
Central South University, Changsha, CN
17:50 - 17:50 459TiP - A single-arm, phase II study of envafolimab combined with chemoradiotherapy
and recombinant human endostatin in high-risk locally advanced nasopharyngeal
carcinoma
H. Zhang, Chongqing University, Chongqing, CN
17:50 - 17:50 460TiP - Neoadjuvant Immunotherapy in Combination with Chemotherapy in resectable

Locally Advanced Head and Neck Squamous Cell Carcinoma: A randomized, controlled,
open label, phase II clinical trial
L. Liu, West China Hospital, Sichuan University, Chengdu, CN

17:50 - 17:50 461TiP - TRENT-001: A phase 2 study of PD-1 inhibitors plus chemotherapy as induction
therapy in patients with poorly differentiated locally advanced head and neck squamous
cell carcinoma
Y. Ding, Bejing Tongren Hospital, Capital Medical University, Beijing, CN
17:50 - 17:50 462TiP - GRASSROOT- Global Real-world data in patients with Advanced thyroid cancer on
Standard of care and Specialized Interventions- Registry of Oncologic Outcomes with
Testing and treatment
P. Iyer, The University of Texas MD Anderson Cancer Center - Main Building, Houston, US
17:50 - 17:50 Palliative care
17:50 - 17:50 467P - Examining the Experience and Preferences of Patients with Advanced Cancer at a
Tertiary Care Center
C.W. Kwak, Duke-NUS Graduate Medical School, Singapore, SG
17:50 - 17:50 468P - Effectiveness of different clinician-prescribed antiemetics for nausea vomiting
related to oral strong opioids- prospective observational study
D. Kudal, Tata Memorial Hospital - Parel, Mumbai, IN
17:50 - 17:50 469P - Hawthorn Standardized Extract (HSE) Plus Standard Opioid Analgesia to Treat
Refractory Cancer Pain: A Single-Arm Phase I Trial (SYLT-024)
L. Su, Fujian Cancer Hospital, Fuzhou, CN
17:50 - 17:50 470P - Collusion, coping and concerns between advanced cancer patients and their family
caregivers: a single-centre study in a specialist palliative care setting
P. Jha, Homi Bhabha National Institute, Tata Memorial Hospital, Mumbai, IN
17:50 - 17:50 471P - “A lot happens after Best Supportive Care”- Unbottling the counter transference of
health-related suffering in a community cancer palliative care setting – a case study
method
V. Viswanath, Homi Bhabha Cancer Hospital and Research Center, Visakhapatnam, IN
17:50 - 17:50 472P - Exploring the Efficacy of Low-Dose Nivolumab in Metastatic Settings
K. Melemadathil, Kasturba Medical College, Manipal University, Manipal, IN
17:50 - 17:50 473P - Multiple Cohort, Open-Label, Exploratory Clinical Study of Trilaciclibe for CIM in
Combination with Chemotherapy in First-line Treatment of Advanced Solid Tumors-
Interim Data Analysis
H. Feng, Shanxi Bethune Hospital, Taiyuan，Shanxi，China, CN
17:50 - 17:50 474P - A survey conducted in Bangladesh with cancer patients to understand Palliative
and Supportive Care, Quality of Life and Care the care currently receiving using
APPROACH Questionnaire
L. Mariam, AMCGH - Ahsania Mission Cancer and General Hospital, Dhaka, BD

17:50 - 17:50 475P - Impact of Palliative Care On The Quality Of Life In Advanced Non-Small Cell Lung
Cancer Patients - A Longitudinal Study
A. Sha, educare institute of medical science, Malappuram, IN
17:50 - 17:50 476P - Quality of Life in Elderly Cancer Patients on systemic anti-cancer therapy:
Experience from a Tertiary Care Centre in Eastern India
P. Panda, AIIMS - All India Institute of Medical Sciences - Bhubaneswar, Bhubaneswar, IN
17:50 - 17:50 477P - palliative care in Hemophilia patients : Dark reality in resource poor settings
P. Shankpal, Health Alert Organisation of India, Dhule, IN
17:50 - 17:50 Precision medicine
17:50 - 17:50 484P - Molecular-genetic concordance of the primary tumor and brain metastases of
colorectal cancer (GENCONCOR-1): second interim analysis
D. Halafyan, National Medical Research Center of Oncology named after N.N. Blokhin, Moscow,
RU
17:50 - 17:50 485P - High-sensitive multi-cancers early detection for 8 cancer types by cell-free DNA
targeted methylation sequencing
H.Y. Luo, Sun Yat-Sen University Cancer Center, Guangzhou, CN
17:50 - 17:50 486P - Fusion-Derived Neoantigens: Broadening the Horizons of Personalized Cancer
Immunotherapy
T. Nguyen, Medical Genetics Institute, Ho Chi Minh city, VN
17:50 - 17:50 487P - Effect of epithelial-mesenchymal transition status on the efficacy of RAF/MEK
clamp and FAK inhibitor combination therapy for KRAS-mutated lung cancer
A. Yoshimura, Kyoto Prefectural University of Medicine, Kyoto, JP
17:50 - 17:50 488P - Audit of toxicity and tolerance of DPYD variant patients receiving fluoropyrimidines
on effectiveness of recommended dose reductions in reducing toxicity
H. Brice, University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB
17:50 - 17:50 489P - Intranodal injection of neoantigen-bearing engineered Lactococcus lactis enhances
anti-tumor immunity in multiple metastatic tumors
M. Zhu, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University,
Nanjing, CN
17:50 - 17:50 490P - ADAM15 as a potential biomarker for pan-cancer prognosis and immunotherapy:
validation in HCC
W. Guo, Shanghai East/Oriental Hospital Affiliated to Tongji University - Headquarters/Northern
Division, Shanghai, CN

17:50 - 17:50 491P - IRAK1 regulated signal from the cancer cells modulates tumor microenvironment
and promote progression and recurrence of cancer by therapeutic resistance
P. Yadav, SGRR Institute of Medical and Health Sciences, Dehradun, IN
17:50 - 17:50 492P - Efficacy and safety of larotrectinib in neurotrophic tyrosine receptor kinase fusion-
positive solid tumors: a multicenter retrospective cohort study in Korea
S. Lee, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR
17:50 - 17:50 494P - Landscape of MET activating alterations (METa) in advanced cancers (AC) using
circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and the Middle
East (AME)
B.-C. Ahn, NCC - National Cancer Center, Goyang, KR
17:50 - 17:50 495P - DPyD screening – “Opening the Pandora’s box in Indian population”: A pilot study
S.V. Saju, Meenakshi Mission Hospital and Research Centre, Madurai, IN
17:50 - 17:50 496P - Prognostic value of systemic inflammation response index (SIRI) in cancer patients
treated with PD-1/PD-L1 immune checkpoint inhibitors: a meta-analysis
X. Gu, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN
17:50 - 17:50 497P - Tumor-Naïve Approach For Circulating Tumor DNA Analysis in Multiple Types of
Cancer
N. Tu, Medical Genetics Institute, Ho Chi Minh City, VN
17:50 - 17:50 498P - Predictive Modeling of Oncogenic RNA Expression Using DNA Alterations: Insights
from Asian Rare Cancer Patients
K. De Almeida, NCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP
17:50 - 17:50 499P - Prevalence estimation of the PALB2 germline variant in East Asians and Koreans
through population database analysis
J.E. Park, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri-si, KR
17:50 - 17:50 500P - Tumor comprehensive genomic profiling: clinical implications and utilization in
VietNam
P. Nguyen, Medical Genetics Institute, Ho Chi Minh City, VN
17:50 - 17:50 501P - Comparison between tissue and ctDNA for detecting Tumor Mutation Burden (TMB)
across solid tumors – A single centre study from India
S. Karanth, Fortis Memorial Research Institute,, Gurugram, IN
17:50 - 17:50 502P - A novel miRNA pair biomarker of miR-1180-3p|miR-505-3p for predicting
neoadjuvant chemoradiotherapy survival in esophageal squamous cell carcinoma: a
multicenter study in China
S. Xin, Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing,
CN

17:50 - 17:50 503P - Retrospective Evaluation of Real-World Experience and Usefulness of Implementing
Next-Generation Sequencing in Clinical Oncology: Insights from A Developing Asian
Country
H. Johnson, Columbia Asia Hospital - Bukit Rimau, Shah Alam, MY
17:50 - 17:50 504P - Real-world prevalence of homologous recombination repair (HRR) gene mutations
in advanced breast (ABC) and selected gastrointestinal cancers (GIC) using comprehensive
next-generation sequencing (NGS) assays in Asia and the Middle East (AME)
V. Lavingia, HCG, Cancer Hospital Ahmedabad, Ahmedabad, IN
17:50 - 17:50 505P - Early experience in using tissue-free minimal residual disease (MRD) testing in
early-stage solid tumor patients from Asia and the Middle East
17:50 - 17:50 506P - Development of a sensitive urinary cfDNA profiling assay for detection and therapy
efficacy monitoring in bladder cancer
J. Su, Burning Rock Dx, Shanghai, CN
17:50 - 17:50 507P - Analysis of cancer multigene panel testing for osteosarcoma using the Center for
Cancer Genomics and Advanced Therapeutics database in Japan
Y. Suehara, National Cancer Center Research Institute, Tokyo, JP
17:50 - 17:50 508P - Survival outcomes of patients with tropomyosin receptor kinase fusion-positive
cancer receiving larotrectinib versus standard of care: a matching-adjusted indirect
comparison using real world data
C. Bokemeyer, University Medical Center Hamburg-Eppendorf, Hamburg, DE
17:50 - 17:50 509P - Real-world utilization and performance of circulating tumor DNA monitoring to
predict cancer recurrence early in Southeast Asia
V.-A. Nguyen, Medical Genetics Institute, Ho Chi Minh City, VN
17:50 - 17:50 510P - TP53 and specific co-mutations contributes to increased metastatic potential for
advanced NSCLC
H. Wang, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN
17:50 - 17:50 511P - Hierarchical clustering of immune checkpoint inhibitor-related pneumonitis in an

Asian cohort of patients
Y. Huang, National University Cancer Institute Singapore, Singapore, SG
17:50 - 17:50 512P - Genomic alterations associated with high Tumor Mutation Burden (TMB-H) status in
advanced solid tumors – a single tertiary care oncology center experience from India
A. Aggarwal, Fortis Memorial Research Institute,, Gurugram, IN
17:50 - 17:50 513P - Identification of genetic profile using ctDNA in multiple myeloma
J.J. Kim, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, KR

17:50 - 17:50 514P - Genomic Profiling of Lung Adenocarcinoma: Age and Ethnicity as Determinants of
Molecular Landscape
V. Batra, AIIMS - All India Institute of Medical Sciences, New Delhi, IN
17:50 - 17:50 515P - Implementation of HRD testing in Vietnam: Lesson learnt from Vinmec Hitech
Center.
H. Tran, Vinmec Healthcare System, Hanoi, VN
17:50 - 17:50 516P - Unveiling the Distinctive Molecular, Clinical, and Prognostic Features of Infant
Acute Myeloid Leukemia: an analysis study of pediatric AML datasets from the Children's
Oncology Group
Y. Tao, Children's Hospital Affiliated to Chongqing Medical University, Chongqing, CN
17:50 - 17:50 517P - Circulating tumor DNA dynamics to predict response to tyrosine kinase inhibitors in
patients with advanced non-small cell lung cancer: an interim report
G. Vu, Medical Genetics Institute, Ho Chi Minh City, VN
17:50 - 17:50 518P - Identification and Characterization of Neuroblastoma Prognostic Subtypes Based
on Programmed Cell Death Signatures
Y. Hong, Affiliated Cancer Hospital of Chongqing University, Chongqing, CN
17:50 - 17:50 519P - Decoding the unknowns: Tier III alterations in Solid tumors from tertiary cancer
centre in India
M. Gurav, Homi Bhabha National Institute, Tata Memorial Hospital, Mumbai, IN
17:50 - 17:50 520P - Application of updated clinical recommendations for the use of NGS (2024) in
Russian reality.
I. Myslevtsev, Autonomous Nonprofit Organization Central Clinical Hospital of St. Alexis, Moscow,
RU
17:50 - 17:50 521P - Real-World Performance of a Comprehensive Next-Generation Sequencing (NGS)

Assay for Solid Tumor Patients in Asia and the Middle East (AME)
C.-M. Tsai, Taipei Veterans General Hospital, Taipei City, TW
17:50 - 17:50 522P - CMBAST study: A real-world database of clinical and molecular characteristics in
patients (pts) harboring BRAF mutation in solid tumor profiled with NGS
X. Wang, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN
17:50 - 17:50 523P - Multimodal Analysis Of Circulating Tumor DNA (ctDNA) Combining Genetic And
Epigenetic Alterations Enhances Assay Sensitivity For Multi-Cancer Early Detection (MCED)
H. Nguyen, Medical Genetics Institute, Ho Chi Minh City, VN
17:50 - 17:50 524P - A Blood CtDNA Multimodal-Based Assay for Early Detection of Aggressive Cancer
Types Lacking Standard Screening Tests
C. Nguyen, Medical Genetics Institute, Ho Chi Minh City, VN

17:50 - 17:50 525P - Different Gene Profiles and characteristics of KRAS Mutations and KRAS
Amplification patients
X.F. Lei, The Second Affiliated Hospital of Kunming Medical University, Kunming, CN
17:50 - 17:50 Supportive care
17:50 - 17:50 530P - Comparison of hyperbaric oxygen therapy and long intestinal tube therapy for
postoperative adhesive small bowel obstruction in gastrointestinal cancer patients.
S. Goto, Tokyo Women's Medical University, Adachi Medical Center, Adachi-ku, JP
17:50 - 17:50 531P - Efficacy of Vitamin C and Zinc Injections in the Management of Mucositis: A
Comparative Observational Study
C. Patil, Kolhapur Cancer Centre, Kolhapur, IN
17:50 - 17:50 532P - Feasibility of hydromorphone PCA 10-day simple mode home management of
patients in severe pain or pain crisis: a prospective multicenter study
P. Lu, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, CN
17:50 - 17:50 533P - Discussing Fertility Preservation in Young Breast Cancer Patients In North Africa
N. Kooli, CHU Farhat Hached Sousse, Sousse, TN
17:50 - 17:50 534P - Pain reduction, feasibility, and quality of life of 2% lidocaine spray versus 2%
lidocaine oral viscous solution for head and neck cancer patients with chemoradiation-
induced mucositis: A randomized pilot study
K. Upalananda, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, TH
17:50 - 17:50 535P - A mobile application-based support on the quality of life for breast cancer survivors
M. Kaur, PGIMER - Post Graduate Institute of Medical Education and Research, Chandigarh, IN
17:50 - 17:50 536P - The Impact of Social Factors on the Success of Home-based end-of-life care for
Cancer Patients and Primary Caregivers
S. Hiramoto, Peace Homecare Clinic, Otsu City, JP
17:50 - 17:50 537P - Home blood pressure monitoring as instrument for preventing of TKI-dose
reduction in metastatic solid tumors treatment.
E. Shavarova, Peoples' Friendship University of Russia (RUDN University), Moscow, RU
17:50 - 17:50 538P - Prolonged usage of NEPA for prevention of long-delayed CINV in patients receiving
highly emetogenic chemotherapy
L. Zhang, Tianjin Medical University General Hospital, Tianjin, CN
17:50 - 17:50 539P - An Advanced Practice Nurse-Led Teleconsultation Service for rectal cancer patients
undergoing concurrent chemoradiation
C. Ho, NCIS - National University Cancer Institute Singapore, Singapore, SG

17:50 - 17:50 540P - Topical steroids for the prevention of radiation dermatitis in breast cancer - a
systematic review and network meta-analyses of randomised controlled trials
S.W. Tse, United Christian Hospital, Kowloon, HK
17:50 - 17:50 541P - Validity and Reliability of the Mongolian Version of Functional Assessment of
Cancer Therapy-General (FACT-G)
D. Gelegjamts, MNU - Mongolian National University of Medical Sciences, Ulaanbaatar, MN
17:50 - 17:50 542P - Evaluation of Psycho-Educational Therapy for Cancer-Related Fatigue (CRF) in
Breast Cancer Survivors: An IL-6 Research
M. Muamar, Medical Faculty of Sebelas Maret University, Surakarta, ID
17:50 - 17:50 543P - Clinical practice of anamorelin therapy for cachexia in pancreatic cancer
M. Okada, NCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP
17:50 - 17:50 546P - Multifaceted challenges in patient-centred oral cavity cancer care: an Asia-Pacific
cross-sectional study with patients, caregivers, and healthcare professionals
E. Hui, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK
17:50 - 17:50 547P - Association between acetaminophen exposure and 28-day mortality in critical
patients with primary lung cancer: a retrospective cohort study
X. He, The Second Xiangya Hospital of Central South University, Changsha, CN
17:50 - 17:50 548P - Patients’ Perspectives of Teleconsultations amidst the COVID 19 Pandemic and
Beyond: Experience of Cancer Patients in a Tertiary Hospital in Manila, Philippines
R. Lim, The Medical City - Augusto P. Sarmeinto Cancer Institute, City*, PH
17:50 - 17:50 549P - Analyses of risk factors for adverse events with palbociclib and the association
between adverse events occurrence and survival
H. Ishikawa, Shizuoka Cancer Center, Shizuoka, JP
17:50 - 17:50 550P - Predicting factors for psychological distress of breast cancer survivors using
machine learning techniques
J.-H. Park, Ajou University, Suwon, KR
17:50 - 17:50 551P - Clinical features, procalcitonin concentration, and bacterial infection in febrile
while hospitalized cancer patients: a descriptive study and association analysis
P. Patipatdontri, Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, TH
17:50 - 17:50 552P - The Correlation Between Types of Cancer Therapy and Quality Of Life (Qol) In
Breast Cancer Patients At Dr. Moewardi Hospital: A Retrospective Study On Global Health
Status, Functional, and Symptom Scales
W. Soewoto, Medical Faculty of Sebelas Maret University, Surakarta, ID

17:50 - 17:50 553P - Risk of Newly Incident Diabetes Mellitus and its Treatment Risk Factor in Breast
Cancer Survivors: Landmark Analyses of Nationwide Data
H. Shim, Samsung Medical Center (SMC), Seoul, KR
17:50 - 17:50 554P - Clinical outcomes of treating patients in prone compared to supine position for
breast radiotherapy: a systematic review and meta-analysis
S.W. Tse, United Christian Hospital, Kowloon, HK
17:50 - 17:50 555P - Cancer Knowledge Acquisition and Challenges in Patients and Caregivers in Hong
Kong
W. Chan, The University of Hong Kong - Li Ka Shing Faculty of Medicine, Hong Kong, HK
17:50 - 17:50 556P - A prospective observational study to compare the antiemetic efficacy of
fosnetupitant + palonosetron vs oral aprepitant + palonosetron
V. Simha, Sri Shankara Cancer Hospital and Research Centre - SSCF, BENGALURU, IN
17:50 - 17:50 557P - The Effect of Interleukin-6 Levels (IL-6) in Psycho-Educational Therapy for Cancer-
Related Fatigue (CRF) in Cancer Survivors at Dr. Moewardi General Hospital, Indonesia
W. Soewoto, Medical Faculty of Sebelas Maret University, Surakarta, ID
17:50 - 17:50 558P - Efficacy of NEPA for prevention of chemotherapy-induced nausea and vomiting in
cancer patients receiving highly emetogenic chemotherapy and usefulness of adding
olanzapine for prior grade 2 or higher emesis
J. Na, Hanyang University College of Medicine, Seoul, KR
17:50 - 17:50 559P - Effect of Oral Nutritional Supplement Formula and Dietary Counselling on
Improving Nutritional Status of Gynaecology Cancer patients
O. Khonsa, Persahabatan Central General Hospital, Jakarta, ID
17:50 - 17:50 560P - Financial Toxicity in Cancer Patients Receiving Systemic Therapies in a Rural Area
of Taiwan: Work Change and the type of Cancer Mattered
C.-L. Lai, Buddhist Tzu Chi Medical Foundation - Dalin Tzu Chi General Hospital, Dalin Township,
TW
17:50 - 17:50 561P - Patient perspectives and unmet needs on treatment and supportive care in non-
small cell lung cancer: A mixed-methods study in China
D. Zheng, Sun Yat-sen University Cancer Center, Guangzhou, CN
17:50 - 17:50 562P - Mapping Emotional Distress: Anxiety and Depression Symptoms Among Cancer
Patients and the General Population in Indonesia
U. Khairatun Hisan, National Cancer Center Graduate School of Cancer Science and Policy Korea,
Goyang-si, KR

17:50 - 17:50 563P - Screening and Early Detection of Young Breast Cancer: The Relationship Between
Education Level, Knowledge, Breast Self-Examination, Breast Complaints, and Family
History Among Female Students In Surakarta
R.H. Saputra, Medical Faculty of Sebelas Maret University, Surakarta, ID
17:50 - 17:50 565P - Prevalence of multi-drug resistant bacteria among neutropenic cancer patients and
its association with 30-day mortality – a single centre study from a Regional Cancer Centre
H. Parupalli, MNJ Institute of Oncology & Regional Cancer Center, Hyderabad, IN
17:50 - 17:50 566P - Shorter duration of primary prophylaxis filgrastim for 4AC-4T dose dense in early
breast cancer in resource-limited settings
G. Pham, Vinmec Times City International Hospital, Ha Noi, VN
17:50 - 17:50 567P - Content and effectiveness of decision aids for families with hereditary cancer: A
scoping review
M.J. An, NCC - National Cancer Center, Goyang, KR
17:50 - 17:50 568P - Baseline Burden of Comorbidity in Women Living with Advanced Breast Cancer in
Malaysia
Y.-Y. Hoo, Faculty of Medicine, University Malaya, Kuala Lumpur, MY
17:50 - 17:50 569P - Use of Teleconsultations in Adolescent and Young Adult Oncology(AYAO) patients- A
scoping review
A. Gupta, NCCS - National Cancer Centre Singapore, Singapore, SG
17:50 - 17:50 570P - NANO-LM: An updated scorecard for the clinical assessment of patients with
leptomeningeal metastases
E. Le Rhun, University Hospital Zürich, Zurich, CH
17:50 - 17:50 571P - The Economic Sequelae of Immune Related Adverse Events Secondary to Immune
Checkpoints Inhibitors in Qatar: A Hospital-Perspective Analysis.
N. Omar, Hamad Medical Corporation (HMC) - National Center for Cancer Care and Research
(NCCCR), Doha, QA
17:50 - 17:50 572P - Estimating rates of immune-related adverse events in an Australian state-wide
hospital population.
B. Jayathilaka, Peter MacCallum Cancer Center, Melbourne, AU
17:50 - 17:50 573P - Prospective assessment of the role of preoperative modified Glasgow Prognostic
Score in predicting Short-Term Quality of Life in patients with peritoneal surface
malignancies undergoing cytoreductive surgery
P. Das, JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research,
Puducherry, IN

17:50 - 17:50 574P - Adherence to Guidelines for Febrile Neutropenia Risk Assessment and G-CSF
Utilization in Chinese Oncology Practice: A Retrospective Analysis of Real-World Data
S. Luo, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital,
Zhengzhou, CN
17:50 - 17:50 575P - Real-World Clinical Study Landscape in Asia

M. Matsuo, Syneos Health, Tokyo, JP
17:50 - 17:50 576P - Spirituality: The Sixth Sense: Examining the Effect of Spirituality on the Quality of
Life, Symptom Severity, Anxiety and Depression amongst Patients with Cancer: A Cross-
Sectional Study
N. Charbel, AUBMC - American University of Beirut Medical Center, Beirut, LB
17:50 - 17:50 577P - A Real-World Analysis of Immune Checkpoint Inhibitors Outcomes in Patients with
Baseline Auto-Immune Diseases.
N. Omar, Hamad Medical Corporation (HMC) - National Center for Cancer Care and Research
(NCCCR), Doha, QA
17:50 - 17:50 578P - Tertiary cancer prevention – a national evaluation of the practices and perceptions
of hospital-based health care professionals (HHCPs) in charge of the follow-up (FU) care of
cancer
S. Delaloge, Institut Gustave Roussy, Villejuif, Cedex, FR
17:50 - 17:50 579P - Multi-cycle prophylaxis of long-acting granulocyte colony-stimulating factor in

tumor patients at risk of neutropenia due to myelosuppressive chemotherapy: A
retrospective real-world study
Q. Song, Qilu Hospital of Shandong University, Jinan, CN
17:50 - 17:50 580P - PCS-QC ACT NOW PLUS: BC & CC Screening/ Stage Shifting utilizing Integrated
Mobile Clinics & Patient Online Self-Education & Evaluation
H.G. Luna, National Kidney and Transplant Institute, Quezon City, PH
17:50 - 17:50 581P - Informal Caregiver Mental Health and Time Cost for Stomach and Pancreatic Cancer
Care
M. Pandey, IIPS - International Institute for Population Science, Mumbai, IN
17:50 - 17:50 582P - Knowledge, Attitude and Practices of physicians in Pakistan towards Onco-
hypertension.
S. Yaqub, King Edward Medical University, Lahore, PK
17:50 - 17:50 583P - Patient reported outcomes with use of orally administered Aprepitant in Highly and
Moderately emetogenic (HEC and MEC) regimens
P. D V M, Sri Shankara Cancer Hospital and Research Centre - SSCF, Bangalore, IN

17:50 - 17:50 584P - Comparison of efficacy of single agent Netupitant plus palonosetron ( NEPA ) vs
Fosaprepitant in prevention of Chemotherapy induced nausea and vomiting (CINV) in
patients receiving high dose chemotherapy for Auto-SCT In a tertiary care center from
south India
S. Chillalshetti, Kidwai Memorial Institute of Oncology, Bangalore, IN
17:50 - 17:50 585P - Representing the patterns of second primary cancers observed in Hospital Based
Cancer Registry (HBCR) at Tata Memorial Centre, Mumbai.
S. Cheulkar, ACTREC Tata Memorial Centre, Mumbai, IN
17:50 - 17:50 586P - Understanding the Impact of Physical Comorbidities on Treatment Commencement
and Completion, and Quality of Life, Among Older Cancer Patients in a Rural Australian
Setting
M. George, Calvary Mater Hospital, Waratah, AU
17:50 - 17:50 587P - A multicenter, open-label, single-arm, Phase 4 study evaluating the safety of
biosimilar bevacizumab in patients with solid tumors
S. Deodhar, Biocon Biologics Ltd, Bangalore, IN
17:50 - 17:50 588P - A retrospective analysis of cancer stage, comorbidity, performance status, and
treatment modality in leading cancer sites among geriatric patients from a hospital-based
cancer registry
K. Sivaranjini, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata
Memorial Centre, Homi Bhabha National Institute, Kharghar, IN
17:50 - 17:50 589P - Patient Centricity in Cancer: Overview Past and Current Applications of Patient
Reported Outcomes
Y. Lee, IQVIA Asia Pacific, Singapore, SG
17:50 - 17:50 591P - Fertility surveillance in girls diagnosed with pediatric cancer
S. Nilsson, University of Gothenburg, GÖTEBORG, SE
17:50 - 17:50 592TiP - The safety and efficacy of Acupuncture in Breast Cancer survivors with Post-
Mastectomy Pain Syndrome, a single-arm exploratory study (ABC-1 study).
N. Kawasaki, National Cancer Center Hospital, Tokyo, JP
17:50 - 17:50 593TiP - The Efficacy And Safety Of Mirtazapine Vs Olanzapine In Preventing
Chemotherapy Induced Nausea And Vomiting In Combination With The Triplet Regimen
In Patients Receiving Highly Emetogenic Chemotherapy- An Open Label, Prospective,
Randomized Control Study
A. Mruthyunjaya Swamy, AIIMS - All India Institute of Medical Science Rishikesh, Rishikesh, IN
17:50 - 17:50 Thoracic tumours, early stage

17:50 - 17:50 594P - Perioperative nivolumab (NIVO) in patients (pts) with resectable stage II–IIIB
NSCLC: CheckMate 77T Chinese population analysis
L. Wu, Hunan Cancer Hospital, Changsha, CN
17:50 - 17:50 595P - Thoracoscopic Intercostal Nerve Block With Cocktail Analgesics for Pain Control
After Video-assisted Thoracoscopic Surgery： A prospective, randomized, controlled,
observer-blinded study.
Y. Dong, West China Hospital, Sichuan University, chengdu, CN
17:50 - 17:50 596P - Innovative Multimodal Deep-Learning Model for Real-Time Prediction of Recurrence
in Early-Stage NSCLC
H.A. Jung, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul,
KR
17:50 - 17:50 597P - Adjuvant Osimertinib in patients with completely resected, stage IB-IIIB NSCLC
with uncommon EGFR mutations (ADMIN): Clinical characteristics, genomic profile and
molecular residual disease
C. Liu, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN
17:50 - 17:50 598P - Genomic profiling for perioperative targeted therapy in patients with early-stage
non-small cell lung cancer: LC-SCRUM-Advantage/MRD
Y. Zenke, National Cancer Center Hospital East, Kashiwa, JP
17:50 - 17:50 599P - Anlotinib Combined with Sintilimab Versus Chemotherapy Combined with
Immunotherapy in Perioperative NSCLC: A Phase II Study
T. Chu, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN
17:50 - 17:50 600P - Real-world Treatment Patterns and Survival in Resectable Stage I-III NSCLC:
THASSOS INTL Middle East and Africa (MEA) Cohort
A. Abdelaziz, Ain Shams University Hospital - Faculty of Clinical Medicine and Radiation Oncology,
Cairo, EG
17:50 - 17:50 602P - Application of Low-Power Intermittent Microwave Ablation in Treating Early-Stage
Lung Cancer Lesions
W. Liu, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, CN
17:50 - 17:50 603P - Real-World Treatment Patterns and Survival in Stage I-III NSCLC: THASSOS-INTL
Hong Kong Results
S.F. Nyaw, Tuen Mun Hospital, Tuen Mun, HK
17:50 - 17:50 604P - Comparing Uniportal and Multiportal Video-Assisted Thoracoscopic Lobectomy for
Early-Stage Lung Cancer: A Retrospective Study at a Single Center in Vietnam
L. Le, National Lung Hospital, Ha Noi, VN

17:50 - 17:50 605P - Performance of AI-based software for Pulmonary Nodule detection and
characterization on chest X-ray and correlation with CT findings: A retrospective study
R. Ravind, Renai Medicity Hospital and Research Center,Palarivattom,Ernakulam, Kochi/Cochin, IN
17:50 - 17:50 606P - Molecular characterization of non-tobacco related lung adenocarcinoma: a multi-
omics study in South-East China
J. Zhuang, Fujian Medical University - Qishan Campus, Fuzhou, CN
17:50 - 17:50 607P - Results from a feasibility pilot for integrated TB & lung cancer screening in Vietnam
A. Codlin, Friends for International TB Relief (FIT), Ho Chi Minh City, VN
17:50 - 17:50 608P - Timing of Surgery after Neoadjuvant Immunochemotherapy in Non-small Cell Lung
Cancer is Crucial for Outcome
J. Wang, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, CN
17:50 - 17:50 609P - Camrelizumab plus platinum doublet chemotherapy as adjuvant treatment of
stage IIA-IIIA non-small cell lung cancer：a phase II, single-arm research
H. Xu, Cancer Hospital Affiliated to Harbin Medical University, Harbin, CN
17:50 - 17:50 610P - Relapse pattern of NSCLC after neoadjuvant immunotherapy

X. Tan, Shanghai Chest Hospital, Shanghai, CN
17:50 - 17:50 611P - Cost-effectiveness of perioperative ICI therapy with NSCLC in Japan, USA, Brazil
T. Aranishi, Juntendo University Graduate School of Medicine, Bunkyo-ku, JP
17:50 - 17:50 612P - Adjuvant Targeted Therapy vs. Continued Immunochemotherapy in NSCLC with
Actionable Driver Mutations Detected after Neoadjuvant Immunochemotherapy
H. Deng, State Key Laboratory of Respiratory Diseases - The First Affiliated Hospital Of
Guangzhou Medical University, Guangzhou, CN
17:50 - 17:50 613TiP - “Evaluation of low dose Nivolumab with Neoadjuvant chemotherapy in non small
cell lung cancer : a phase II open label randomised clinical trial (ELON)”
N. Biswal, AIIMS - All India Institute of Medical Sciences, New Delhi, IN
17:50 - 17:50 Thoracic tumours, locally advanced
17:50 - 17:50 615P - Treatment (Tx) patterns and clinical outcomes in unresectable (UR) stg III EGFR-
mutation positive (EGFRm) NSCLC treated with chemoradiotherapy (CRT): Final analysis of
a global real-world (rw) study
J.B. Lee, Yonsei Cancer Center, Yonsei University, Seoul, KR
17:50 - 17:50 616P - Osimertinib after definitive chemoradiotherapy (CRT) in patients (pts) with
unresectable (UR) stage III epidermal growth factor receptor-mutated (EGFRm) non-small
cell lung cancer (NSCLC): Post-progression outcomes from the Phase III LAURA study
J.C.-H. Yang, National Taiwan University Hospital and National Taiwan University Cancer Center,
Taipei, TW

17:50 - 17:50 617P - Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR
mutation: A real-world study (HOT2101)
H. Kikuchi, Obihiro Kosei General Hospital, Obihiro, JP
17:50 - 17:50 618P - Impact of Neoadjuvant Radiotherapy on Cancer-Specific and Overall Survival in
Locally Advanced Malignant Thymoma: A SEER Database Analysis
X. Li, Beijing Tiantan Hospital, Capital Medical University, Beijing, CN
17:50 - 17:50 619P - Pathologic complete response is the essential element for surgical modification
after neoadjuvant chemo-immunotherapy for non-small cell lung cancer invading lobar
bronchial orifice: A multicenter retrospective cohort study
H. Zhang, Affiliated Hospital of Xuzhou Medical University,, Xuzhou, CN
17:50 - 17:50 620P - Pembrolizumab with Radiotherapy versus Pembrolizumab Alone in Non-Small Cell
Lung Cancer: A Systematic Review and Meta-Analysis
K. Wibowo, Pelita Harapan University, Tangerang, ID
17:50 - 17:50 621P - Comparison of biweekly carboplatin plus nab-paclitaxel with concurrent
radiotherapy followed by durvalumab consolidation in elderly and younger patients.
Y. Nunomura, Hirosaki University Graduate School of Medicine, Hirosaki, JP
17:50 - 17:50 622P - Our experience comparing outcomes between pleurectomy and decortication and
extended pleurectomy and decortication in a mixed Asian population of malignant
mesothelioma patients
K.J. Eng, Yong Loo Lin School of Medicine, National University Singapore, Singapore, SG
17:50 - 17:50 623P - Thoracic Oncology MDTC: A survey study on the perceptions and opinions of
healthcare teams
A.P. Mina, The Medical City - Augusto P. Sarmiento Cancer Institute, Pasig City, PH
17:50 - 17:50 624P - Multi-Omics Reveals Branched Chain Amino Acid Signatures as Prognostic Factors
for Immunotherapy Efficacy in Non-Small Cell Lung Cancer
L. Dai, Chinese Academy of Medical Sciences and Peking Union Medical College - National
17:50 - 17:50 Thoracic tumours, metastatic
17:50 - 17:50 631P - Exploratory Biomarker Analysis in EGFR mutated NSCLC Patients who treated with
Atezolizumab plus Bevacizumab and Chemotherapy from Phase III ATTLAS trial
H. Kim, Samsung Medical Center (SMC), Seoul, KR
17:50 - 17:50 632P - RATIONALE-304 Long-term Outcomes: First-line Tislelizumab (TIS) + Chemotherapy
(chemo) vs Chemo for Locally Advanced or Metastatic Nonsquamous (NSQ) NSCLC
Z. Ma, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital,
Zhengzhou, CN

17:50 - 17:50 633P - Phase Ia/Ib trial of the HER2 tyrosine kinase inhibitor zongertinib (BI 1810631) in
patients with HER2-driven solid tumors: focus on Asian patients
K. Yoh, National Cancer Center Hospital East, Kashiwa, JP
17:50 - 17:50 634P - Whole exome sequencing (WES) analyses from IMpower133 and 6-year (y) overall
survival (OS) from IMbrella A in patients (pts) with extensive-stage small cell lung cancer
(ES-SCLC) treated with atezolizumab (atezo)
S. Kao, Chris O'Brien Lifehouse, Camperdown, AU
17:50 - 17:50 635P - Cross-over Adjusted Overall Survival for Amivantamab Plus Chemotherapy Vs
Chemotherapy in First-line EGFR Exon-20 Insertion NSCLC
B.C. Cho, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR
17:50 - 17:50 636P - SKYSCRAPER-02C: phase 3 study of atezolizumab (atezo) + carboplatin + etoposide
(CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage
small cell lung cancer (ES-SCLC) in China
17:50 - 17:50 637P - Taletrectinib vs repotrectinib in ROS1-positive (ROS1+) non–small cell lung cancer
(NSCLC): A matching-adjusted indirect comparison (MAIC)
M. Nagasaka, University of California Irvine School of Medicine and Chao Family Comprehensive
Cancer Center, Orange, US
17:50 - 17:50 638P - Dacomitinib with or without dose titration in treatment naïve advanced EGFR
mutated NSCLC – primary analysis of the ATORG-003 phase 2 trial
A. Tan, National Cancer Centre Singapore, Singapore, SG
17:50 - 17:50 639P - A phase II study of irinotecan-cisplatin plus durvalumab for untreated extensive-
stage small cell lung cancer (WJOG13520L, REBORN trial)
M. Tachihara, Kobe University Graduate School of Medicine, Kobe, JP
17:50 - 17:50 640P - Exploratory ctDNA Analyses from First-in-human Phase I Trial of D3S-001 in Patients
with Advanced Solid Tumor Harboring a KRAS G12C Mutation.
B.C. Cho, Yonsei University, Seoul, KR
17:50 - 17:50 641P - METRIX: International Real-World Study of c-Met Protein Overexpression in Patients
With Non-Small Cell Lung Cancer
H. Horinouchi, National Cancer Center Hospital, Tokyo, JP
17:50 - 17:50 642P - Phase II Trial of Lazertinib Plus Pemetrexed/Carboplatin in Patients with EGFR-
Mutant Recurrent or Metastatic Non-Small Cell Lung Cancer Who Failed Prior Lazertinib
(LUCAS): Interim Analysis
M.H. Hong, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine,
Seoul, KR

17:50 - 17:50 643P - Resistance mechanisms and efficacy of first-line (1L) alectinib in patients (pts) with
ALK-rearranged non-small cell lung cancer (ALK+ NSCLC): second interim analysis of
ALCURE
A. Mouri, International Medical Centre, Saitama Medical University, Hidaka, JP
17:50 - 17:50 644P - Tifcemalimab combined with toripalimab and docetaxel as 2nd line treatment for
immunotherapy-treated squamous cell non-small cell lung cancer (Sq-NSCLC) patients: A
phase Ib/II study
D. Lv, Taizhou Hospital of Zhejiang Province, Taizhou, CN
17:50 - 17:50 645P - The Impact of Driver Gene Alteration Type on the Efficacy of Immune Checkpoint
Inhibitors
H. Tsuruoka, St. Marianna University Hospital, Kawasaki, JP
17:50 - 17:50 646P - Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for
epidermal growth factor receptor inhibitor (EGFRi)-resistant, EGFR-mutant, advanced non-
small cell lung cancer (NSCLC): Updated results from Cohort 5 in the DUBHE-L-201 study
W.F. Fang, Sun Yat-sen University Cancer Center, Guangzhou, CN
17:50 - 17:50 647P - A phase Ib/II study of second-line cadonilimab, anlotinib and docetaxel in patients
with checkpoint inhibitor (CPI)-experienced advanced non-small cell lung cancer
Y. Zhang, Shanghai Chest Hospital, Shanghai, CN
17:50 - 17:50 648P - The efficacy of ICIs plus platinum-based chemotherapy for patients with advanced
NSCLC and ECOG PS 2 (WJOG18424L): A propensity score-matched study.
S. Kataoka, Juntendo University Hospital, Bunkyo-ku, JP
17:50 - 17:50 649P - An oral, chemo-free regimen (osimertinib plus anlotinib) as first-line treatment for
EGFR-mutated advanced NSCLC (AUTOMAN): safety and survival outcome
B. Han, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN
17:50 - 17:50 650P - Impact of different lymph node status on prognosis in patients with non-small cell
lung cancer after neoadjuvant chemoimmunotherapy: A multicenter retrospective cohort
study
R. Ma, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, CN
17:50 - 17:50 651P - Efficacy and safety outcomes of Phase II study of SCC244 in NSCLC patients
harboring MET exon 14 skipping (METex14) mutations (GLORY study): long-term follow-up
analysis
Y. Yu, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CN
17:50 - 17:50 652P - 3-year follow-up of a phase III study to compare efficacy and safety of a
bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for
metastatic or recurrent non-squamous non-small cell lung cancer
C. Verschraegen, OSUCCC - The Ohio State University Comprehensive Cancer Center - James,
Columbus, US

17:50 - 17:50 653P - Baseline and 3 weeks on-treatment plasma EGFR mutation (EGFRm) dynamics in
patients with EGFR mutant advanced NSCLC treated with first line osimertinib: A
prospective, multi-center, real-world analysis
J. Wang, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN
17:50 - 17:50 654P - Efficacy and safety of first-line ipilimumab and nivolumab treatment in elderly
patients with non-small cell lung cancer
H. Imai, Saitama Medical University, Saitama, JP
17:50 - 17:50 655P - De novo MET amplification in EGFR-mutant non-small cell lung cancer
D. Lee, Faculty of Medicine, University of Malaya, Kuala Lumpur, MY
17:50 - 17:50 656P - Real-World (RW) Frontline (1L) Treatments (Txs) in Patients (Pts) With Advanced
Non-Small-Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EFGR)
Exon 20 Insertions (exon20ins) and Adjusted Comparisons Versus PAPILLON Study
Z. Li, Shanghai Jiao Tong University School of Medicine, Shanghai, CN
17:50 - 17:50 657P - Landscape of KRAS Mutations in Non-Small Cell Lung Cancer (NSCLC) patients from
Asia and Middle East (AME) using circulating tumor DNA (ctDNA)
A. Rauthan, Manipal Comprehensive Cancer Center Manipal Hospital, Bangalore, IN
17:50 - 17:50 658P - Furmonertinib 160mg as first-line treatment for advanced non-small cell lung
cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 21 L858R
mutation
M. Shi, Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital &
Jiangsu Institute of Cancer Research, Nanjing, CN
17:50 - 17:50 659P - EGFR p.E709X Point Mutation in Advanced NSCLC: Molecular Characteristics and
Precise Therapeutic Strategy Exploration
L. Pang, Sun Yat-sen University Cancer Center, Guangzhou, CN
17:50 - 17:50 660P - Proteogenomic Analysis of CSF Reveals Molecular Patterns and Potential Drug
Targets of Leptomeningeal Metastases in EGFR+ NSCLC
M. Zheng, Guangdong Lung Cancer Institute, Guangzhou, CN
17:50 - 17:50 661P - Prospective multi-institutional observational study of anti-PD-1/PD-L1 antibody

(anti-PD-1/anti-PD-L1) re-treatment in patients with non-small cell lung cancer (NSCLC)
previously treated with anti-PD-1/PD-L1 plus chemotherapy: NJLCG1901
H. Tanaka, Hirosaki University, Hirosaki, JP
17:50 - 17:50 662P - Comparison of atezolizumab/etoposide/platinum and

durvalumab/etoposide/platinum for extensive-stage small cell lung cancer in Japan: A
multicenter retrospective observational study.
H. Sakashita, Yokosuka Kyosai Hospital, Yokosuka, JP

17:50 - 17:50 663P - Cisplatin (CDDP)+Etoposide (ETP)+Durvalumab (DUR) vs. Carboplatin
(CBDCA)+ETP+Atezolizumab (ATZ): propensity score matching (PSM) real-world data (RWD)
on CDDP-fit extensive disease (ED)-small cell lung cancer (SCLC)
K. Hamai, Ja Onomichi General Hospital, Onomichi, JP
17:50 - 17:50 664P - Chemotherapy combination regimens for EGFR-TKI resistant metastatic EGFR-
mutated NSCLC: a systematic review and network meta-analysis
B. Qin, Shanghai Changzheng Hospital, Shanghai, CN
17:50 - 17:50 665P - Real-World Effectiveness and Safety of First-Line (1L) Osimertinib for EGFR-Mutated
(EGFRm) Advanced NSCLC: A prospective, multi-center, real-world study in China
(FLOURISH Study)
J. Zheng, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN
17:50 - 17:50 666P - First-Line Camrelizumab Plus Chemotherapy for Brain Metastases in NSCLC: The
CTONG 2003 Randomized Controlled Trial
J.-J. Yang, Guangdong Provincial People's Hospital, Guangzhou, CN
17:50 - 17:50 667P - Furmonertinib 160mg as first-line treatment for metastatic EGFR mutation-positive
non-small cell lung cancer (NSCLC) patients with central nervous system (CNS) metastases
Y. Zhang, Hunan Cancer Hospital, Xiangya School of Medicine, Central South University,
Changsha, Hunan, CN
17:50 - 17:50 668P - The Impact of MTAP Loss on response to immune checkpoint inhibitors in stage IV
NSCLC: A Prospective RealWorld Analysis
A. El-Helali, HKU - The University of Hong Kong, Hong Kong, HK
17:50 - 17:50 669P - A retrospective observational study on the efficacy of local ablative therapy for
oligoprogression in non-small cell lung cancer patients who responded to immunotherapy
combined chemotherapy.
S. Kuyama, NHO Iwakuni Clinical Center, Iwakuni, JP
17:50 - 17:50 670P - Phase 3 study of zipalertinib plus first-line (1L) platinum-based chemotherapy in
patients (pts) with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion
(ex20ins) mutations (REZILIENT3): Safety Lead-in Results
T. Kurata, Kansai Medical University Hospital, Osaka, JP
17:50 - 17:50 671P - Radiomics models using machine learning algorithms to differentiate the primary
focus of brain metastasis.
Y. Xie, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, CN
17:50 - 17:50 672P - Association between the administration time and therapeutic effect of nivolumab
in patients with non-small cell lung cancer : A multicenter retrospective observational
study
Y. Iwahashi, NHO Kinki-Chuo Chest Medical Center, Sakai, JP

17:50 - 17:50 673P - Diagnosis and treatment of ROS1 fusion-positive non-small-cell lung cancer in
China: preliminary report of a nationwide survey
F. Zhou, Shanghai East/Oriental Hospital Affiliated to Tongji University - Southern Division,
Shanghai, CN
17:50 - 17:50 674P - Real-world outcomes of first-line platinum doublet chemotherapy plus Tyrosine
Kinase Inhibitors (TKI) in advanced epidermal growth factor receptor (EGFR)-mutated non-
small cell lung cancer (NSCLC)
Y.F. Low, NCCS - National Cancer Centre Singapore, Singapore, SG
17:50 - 17:50 675P - Assessing later-line treatment strategies and outcomes in EGFR oncogene-driven
stage IV non-small cell lung cancer.
M. Maddula, Crown Princess Mary Cancer Centre Westmead, Westmead, AU
17:50 - 17:50 676P - NEJ053C: A phase II study of nivolumab and ipilimumab combined with
chemotherapy after lung stereotactic body radiotherapy as first-line therapy for stage IV
non-small cell lung cancer
K. Watanabe, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,
Bunkyo-ku, JP
17:50 - 17:50 677P - Comparison of performance of MET amplification detection by FISH, NGS and
ddPCR in EGFRm advanced NSCLC patients post first-line osimertinib treatment failure:
Analysis from a prospective, multi-center study in China
P. Xing, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
17:50 - 17:50 678P - Ramucirumab plus Erlotinib (RAM+ERL) for advanced non-small cell lung cancer
(NSCLC) harboring EGFR L858R mutation (L858R mut): A multicenter retrospective
observational cohort study (REAL-SPEED)
M. Ishihara, Teikyo University School of Medicine, Tokyo, JP
17:50 - 17:50 679P - Low-dose Durvalumab in Combination with Etoposide and Platinum as First-line
Treatment of Patients with Extensive-stage Small Cell Lung Cancer - a Multi-Institutional
study from India
V. Agarwala, Narayana Superspeciality Hospital - Howrah, Howrah, IN
17:50 - 17:50 680P - Sequential afatinib (AFA) to osimertinib (OSI) in EGFR-mutant NSCLC: an
exploratory analysis of initial AFA dosage in Gio-Tag Japan, a multicenter prospective
observational study
A. Hata, Kobe Minimally Invasive Cancer Center, Kobe, JP
17:50 - 17:50 681P - Characterising the Genomic Landscape of Advanced non-squamous NSCLC of
Chinese - A Territory-Wide Study in Hong Kong
A. El-Helali, HKU - The University of Hong Kong, Hong Kong, HK

17:50 - 17:50 682P - First-Line Serplulimab for Advanced Squamous Non-Small Cell Lung Cancer: A
Multicenter, Single-Arm, Real-World ASTRUM-004R Study
B. Shen, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and, The Affiliated
Cancer Hospital of Nanjing Medical University, Nanjing, CN
17:50 - 17:50 683P - Aumolertinib Plus Anlotinib in Advanced EGFR-mutant NSCLC with Brain
Metastasis (Alot BRAIN): A Single-arm, Phase II Study (GASTO 1063) (updated data)
L.K. Chen, Sun Yat-sen University Cancer Center, Guangzhou, CN
17:50 - 17:50 684P - A phase I study of a common neoantigen srRNA vaccine (JCXH-212) with or without
toripalimab in patients with non-small cell lung cancer(NSCLC)
H. Chen, Peking University Cancer Hospital & Institute, Beijing, CN
17:50 - 17:50 685P - Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients
after first-line osimertinib treatment failure: a real-world, multi-center prospective study
in China
Y.-K. Shi, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
17:50 - 17:50 686P - The Predictive efficacy of tumor mutational burden for Immune Checkpoint
Inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of
randomized controlled trials
M. Ying, Chongqing University Cancer Hospital, Chongqing, CN
17:50 - 17:50 687P - Profile of Actionable oncogenic alterations (AGA) among patients with advanced
NSCLC in South India- A multicentric study
K. Pavithran, Amrita Institute of Medical Sciences, Kochi, IN
17:50 - 17:50 688P - The efficacy of first-line chemotherapy combined with immunotherapy or anti-
angiogenic therapy for advanced KRAS-mutant non-small cell lung cancer
H. Qiang, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN
17:50 - 17:50 689P - Patterns of disease progression and efficacy of local ablative therapy among
patients with metastatic EGFR-mutation positive non-small cell lung cancer treated with
first-line osimertinib
C.C. Chen, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK
17:50 - 17:50 690P - Clinical Outcomes of Patients with advanced EGFR mutation positive (EGFRm) non-
small cell lung cancer (NSCLC) with MET amplification (METamp) after osimertinib
resistance: a multicentre retrospective study
O.H. Chen, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK
17:50 - 17:50 691P - Mechanisms of acquired resistance to first-line (1L) osimertinib in EGFR-mutated
(EGFRm) advanced NSCLC: Results from a prospective, multi-center, real-world study in
China (FLOURISH study)
J. Zheng, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN

17:50 - 17:50 692P - Landscape of co-occurring OncoKB tier 1/2 alterations in EGFR-mutated Lung
Adenocarcinoma (LUAD) harboring common driver alterations using circulating tumor
DNA (ctDNA) Next Generation Sequencing (NGS) in Asia and the Middle East (AME).
17:50 - 17:50 693P - Treatment Comparison of Amivantamab vs. Real World Therapies Among Patients
with NSCLC Harboring EGFR Exon 20 Insertion Mutations: An External Control Analysis
(ECA) Using NTUH NSCLC Dataset in Taiwan
J.-Y. Wu, National Taiwan University Hospital Yun-Lin Branch, Douliu City, Yunlin County, TW
17:50 - 17:50 694P - Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for

Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on
the Role of Performance Status
T. Yamada, Kyoto Prefectural University of Medicine, Kyoto, JP
17:50 - 17:50 695P - Second-line envafolimab and beyond in locally advanced or metastatic non-small
cell lung cancer
M. Guan, AnHui Chest Hospital, Hefei, CN
17:50 - 17:50 696P - Impact of local therapy on survival in patients with brain metastases from non-
small cell lung cancer (NSCLC): a real-world cohort study
L. Wu, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
17:50 - 17:50 697P - Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell
Lung Cancer: A Phase Ⅱ Trial (ALWAYS)
H.L. Chen, Affiliated Hospital of Guangdong Medical University, Zhanjiang, CN
17:50 - 17:50 698P - First-line Aumolertinib in EGFR-Mutant Pulmonary Adenosquamous Carcinoma:

Updated Overall Survival of the Multicenter, Single-Arm, Prospective Study (ARISE)
L. Zhang, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN
17:50 - 17:50 699P - Osimertinib Combined with Chemotherapy as First-Line Treatment in EGFR-Mutant
Advanced NSCLC Patients: The First Real-World Analysis in China
W. Ji, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN
17:50 - 17:50 700P - Survival and Efficacy of Gefitinib Plus Chemotherapy Versus Gefitinib Monotherapy
on EGFR-mutant Advanced Non small Cell Lung Cancer: A Systematic Review and Meta-
analysis
K. Ismael, St. Luke's Medical Center, Quezon City, PH
17:50 - 17:50 701P - Concordance of different immunohistochemical assays in MET protein

overexpression detection in lung adenocarcinoma
L. Liu, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,

17:50 - 17:50 702P - Young and Vulnerable: the alarming trends of lung cancer in young adults from
India
P. Thamarai Selvan, Cancer Institute (WIA), Chennai, IN
17:50 - 17:50 703P - Efficacy and Safety of Lurbinectedin in Chinese patients with extensive-stage Small
Cell Lung Cancer(ES-SCLC): A Multicenter, Retrospective Real World Study
Y. Xiang, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CN
17:50 - 17:50 704P - Exploring the optimal tumour mutational burden (TMB) cutoff for predicting
efficacy of immune checkpoint inhibitors (ICI) in Chinese patients with advanced non-
small-cell lung cancer (NSCLC): A territory-wide study
V. Lee, The University of Hong Kong - Li Ka Shing Faculty of Medicine, Hong Kong, HK
17:50 - 17:50 705P - Exploring the Impact of DDR Pathway Gene Mutations on the Immune
Microenvironment in Non-Small Cell Lung Cancer Patients
C. Lin, Radiotherapy Department Shantou Central Hospital, Shantou, CN
17:50 - 17:50 706P - Comparison of Irinotecan/carboplatin versus Etoposide/carboplatin for extended

disease small cell lung cancer (ED-SCLC): A systematic review and meta-analysis of
randomized controlled trials.
Z. Afzal, Shanxi Provincial Cancer Hospital, Taiyuan, CN
17:50 - 17:50 707P - Investigation of prognostic factors in extensive stage small cell lung cancer with
immune checkpoint inhibitors in first-line treatment using real-world data; are immune-
related adverse events also a prognostic factor?
T. Nishimura, Mie Chuo Medical Center, Tsu, JP
17:50 - 17:50 709P - The impact of antibiotic use on ICI plus chemotherapy versus chemotherapy in
NSCLC patients with PD-L1 expression of 1% to 49%
Y. Toyota, Kurashiki Central Hospital, Kurashiki, JP
17:50 - 17:50 710P - Retrospective Study on the Tolerability of Anti-PD-L1 Antibody Plus Platinum-
Etoposide for Elderly Patients with Extensive-Stage Small-Cell Lung Cancer Based on Body
Mass Index
Y. Terashima, Graduate School of Medicine, Nippon Medical School, Tokyo, JP
17:50 - 17:50 711P - Prognostic Impact of Oligometastasis in Elderly Patients with Extensive-stage Small
Cell Lung Cancer
D. Morinaga, Hokkaido University Hospital, Sapporo, JP
17:50 - 17:50 712P - Efficacy and Safety Evaluation of First-line Immunotherapy Combing with
Chemotherapy Followed by Local Consolidation Radiotherapy for Stage IV Non-Small Cell
Lung Cancer
L.-J. Tian, Binzhou Medical University Hospital, Binzhou, CN

17:50 - 17:50 713P - Multicenter Observational Study on combination immunotherapy for Extensive-
Stage Small Cell Lung Cancer
Y. Masui, Juntendo University Hospital, Bunkyo-ku, JP
17:50 - 17:50 714P - Real-World treatment pattern and clinical outcome in Chinese NSCLC patients with
KRAS G12C mutation.
L. Shen, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN
17:50 - 17:50 715P - Impact of serum anti-p53 antibody on efficacy of immune checkpoint inhibitors in
advanced non-small cell lung cancer.
T. Shimizu, Nihon University School of Medicine, Tokyo, JP
17:50 - 17:50 716P - A new model for identification of lung cancer metastasis cells in cerebrospinal fluid
J. Feng, Tianjin Huanhu Hospital, Tianjin, CN
17:50 - 17:50 717P - Non-SqCC EGFR-mutant NSCLC patients with RAS-PI3K-AKT-RAF Alterations Have
Poorer Response to EGFR-TKIs and Overall Survival
Y.-C. Hsiao, Taichung Veterans General Hospital, Taichung City, TW
17:50 - 17:50 718P - EML4-ALK gene variants and PD-L1 expression: Their Impact on Clinical Outcomes
in ALK-Positive NSCLC
S. Meedimale, IMS & SUM Hospital SOA University, Bhubaneswar, IN
17:50 - 17:50 719P - Genomic profiling of driver gene alterations in patients with non-small cell lung
cancer, patterns of treatment and impact on survival outcomes – A single center
experience of more than 1200 patients
M. Shah, Tata Memorial Centre, Mumbai, IN
17:50 - 17:50 720P - Interleukin gene expression and their impact on prognosis in metastatic NSCLC
S. Meedimale, IMS & SUM Hospital SOA University, Bhubaneswar, IN
17:50 - 17:50 721TiP - A Phase 1/2 study of davutamig (REGN5093), a MET×MET bispecific antibody, in
patients with MET-altered, advanced non-small cell lung cancer (aNSCLC): Trial in progress
update
M.-J. Ahn, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR
17:50 - 17:50 722TiP - TiP: Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy
with Cryoablation in the First-Line Treatment of Advanced Non-Squamous Non-Small Cell
Lung Cancer (NSCLC)
B. Zhang, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai,
CN

17:50 - 17:50 723TiP - Liposomal irinotecan (Lipo-IRI) alone or in combination with famitinib or
platinum for patients with extensive-stage small cell lung cancer (ES-SCLC) after failure of
first-line immunotherapy: a multicenter, randomized, open-label, multicohort phase 2
trial
H. Xu, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College,
Beijing, CN
17:50 - 17:50 724TiP - Phase 2 Study of Aumolertinib combined with metronomic oral vinorelbine and a
platinum-based agent in patients with previously untreated EGFR-mutated advanced
non-small cell lung cancer
X. Hou, Hanzhong Central Hospital, Hanzhong, CN
17:50 - 17:50 725TiP - Osimertinib combined with bevacizumab and chemotherapy as first-line
treatment in EGFR-mutated advanced non-squamous non-small cell lung cancer with
concurrent mutations
M. Shen, Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN
17:50 - 17:50 726TiP - A Multicenter Cluster Randomized Controlled Study to Evaluate Guideline
Adoption through Lung Cancer Clinical Care Quality Improvement Project (QIP) in
Pulmonary and Critical Care Medicine (PCCM) Department in China
W. Li, Institute of Respiratory Health and multicomorbidity, West China Hospital, Sichuan
University, Chengdu, CN
17:50 - 17:50 728TiP - Osimertinib with Chemotherapy as First-line Therapy for Patients with Locally
Advanced or Metastatic Epidermal Growth Factor Receptor Mutation (EGFRm) Non-Small
Cell Lung Cancer (NSCLC): A Prospective, Multi-centre, Real-World Study (FOREFRONT)
B. Han, Shanghai Jiao Tong University School of Medicine, Shanghai, CN
17:50 - 17:50 729TiP - A real-world study to explore therapeutic changing mode of locally therapy during
1L lorlatinib treatment in unresectable ALK+ NSCLC patients
J. Zhao, Peking University Cancer Hospital & Institute, Beijing, CN
17:50 - 17:50 General interest
17:50 - 17:50 731P - Development and Implementation of an Organized Community-Approach Clinical

Screening Program for Cervical, Breast and Oral Cancers in Nawly, Jashore in Bangladesh
E.Y.T. Wong, NCCS - National Cancer Centre Singapore, Singapore, SG
17:50 - 17:50 732P - “Study on breast cancer and cervical cancer screening using mammography and
pap smear test”.
T. Selvaraju, Assam Cancer Care Foundation, Guwahati, IN
17:50 - 17:50 733P - Real-world experience with a multi-cancer early detection test in Southeast Asia
D. Nguyen, Medical Genetics Institute, Ho Chi Minh City, VN

17:50 - 17:50 734P - Generalizable Artificial Intelligence Model for Thyroid Cancer Diagnosis with
Inexperienced Sonographer
W. Zhang, Shanghai Jiao Tong University School of Medicine, Shanghai, CN
17:50 - 17:50 735P - Integrating a data curation artificial intelligence system to identify cancer registry
data elements from unstructured electronic health records
Y.-H. Yang, National Health Research Institutes - National Institute of Cancer Research, Tainan,
TW
17:50 - 17:50 736P - Lost of interest in academic careers among young oncology residents: a French
longitudinal survey
N. Taranto, Hopital René Huguenin - Institut Curie, Saint-Cloud, FR
17:50 - 17:50 737P - The Perspectives of Healthcare Professionals on Biospecimen Donation for
Research: A Cross-sectional Survey in Pakistan
Z. Jamil, King Edward medical university Lahore Pakistan, Lahore, PK
17:50 - 17:50 738P - Utilizing pre-existing immunity against well-known bacterial and viral pathogens
as a strategy to combat immune resistance within the tumor microenvironment
L. Carmon, BIM-consulting, Ramat Hasharon, IL
17:50 - 17:50 739P - SHMT2 regulates metabolic reprogramming hallmark of cancer and promotes
cancer progression
N. Kumar, SGRR Institute of Medical and Health Sciences, Dehradun, IN
17:50 - 17:50 740P - Pulmonary Resectable Mets of Osteosarcoma With Anti-angiogenic and
CHemotherapy (PROACH), An open-label, single-arm phase 2 clinical trial: The pathological
study of the post-surgical specimens
Q. Bao, Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN
17:50 - 17:50 741P - Osteosarcoma in Japan: Report from the Bone and Soft Tissue Tumor Registry 2006-
2022
K. Ogura, NCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP
17:50 - 17:50 742P - 18F-FDG PET/CT can stratify the prognosis of standard responders after
neoadjuvant chemotherapy in osteosarcoma.
T. Takemori, NCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP
17:50 - 17:50 744P - SBRT combined with PD-1 blockade for relapsed/ refractory osteosarcoma: a
preliminary report
Q. Bao, Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN
17:50 - 17:50 745P - Chemotherapy without methotrexate in untreated localised osteosarcoma : a 10-
year single center retrospective analysis.
K.Y. Ooi, Hospital Sultan Ismail, Johor Bahru, MY

17:50 - 17:50 746P - Impact of adjuvant (AC)and neoadjuvant (NAC) chemotherapy in patients (pts) with
soft tissue sarcoma (STS): a real-life exhaustive nationwide study (DEEPSARC).
J.-Y. Blay, Centre Léon Bérard, Lyon, FR
17:50 - 17:50 748P - Multimodal integration of radiology, pathology and transcriptomics for prediction
of response to neoadjuvant therapy in patients with retroperitoneal liposarcoma
L. Ma, Zhongshan Hospital, Fudan University, Shanghai, CN
17:50 - 17:50 750P - Clinicopathological features and treatment outcomes of adolescents and adults
Rhabdomyosarcoma: A single institutional experience.
R. Joarder, Tata Memorial Hospital, Mumbai, IN
17:50 - 17:50 751P - Infantile versus adult-type fibrosarcoma and the risk of multiple primary
malignancies
H. Sherif, Menoufeya University Faculty of Medicine, Cairo, EG
17:50 - 17:50 752P - Epithelioid sarcoma: A retrospective study of efficacy and safety of first-line
treatment
C. Zhang, Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN
17:50 - 17:50 754P - Posterior mediastinal Neuroblastoma: clinicopathological features and the role of
chemotherapy
A. Hatata, Tanta University - Faculty Of Medicine, Tanta, EG
17:50 - 17:50 755P - A Retrospective Study on Epidemiological and Disease Characteristics of Chinese
NF1 patients in Real World：Promise study
Z. Wang, Shanghai Ninth People's Hospital - Shanghai Jiao Tong University School of Medicine,
Shanghai, CN
17:50 - 17:50 756P - Differential expression of clinical biomarkers in intraocular retinoblastoma patients
S. Sharma, AIIMS - All India Institute of Medical Sciences, New Delhi, IN
17:50 - 17:50 757P - Molecular Insights into Oxygen-Sensing Signaling in Primary and Chemoreduced
Retinoblastoma Patients
M. Supriya, AIIMS - All India Institute of Medical Sciences, New Delhi, IN
17:50 - 17:50 758P - Single Institutional Experience with Weekly Paclitaxel for Advanced Extramammary
Paget’s Disease
Y. Kurokami, OICI - Osaka International Cancer Institute, Osaka, JP
17:50 - 17:50 759P - Efficacy and Safety of HLX07 Monotherapy in Advanced Cutaneous Squamous Cell
Carcinoma: an Open-label, Multicentre Phase 2 Study
C. Li, Southern Medical University Nanfang Hospital, Guangzhou, CN

17:50 - 17:50 760P - Immunological and Molecular Profiling of Cutaneous Squamous Cell Carcinoma: A
Comparison of Organ Transplant Recipients vs Non-Transplant Recipients in an Asian
Cohort in Singapore
C.C. Oh, Singapore General Hospital, Singapore, SG
17:50 - 17:50 761P - Bowen’s Disease and the risk of multiple primary skin malignancies
E. Hasanin, University of Tripoli, Tripoli, LY
17:50 - 17:50 762P - Systemic treatment for patients with advanced Merkel cell carcinoma in Japan; A
multicenter retrospective study
E. Nakano, NCCH - National Cancer Center Hospital, Chuo-ku, JP
17:50 - 17:50 763P - The Role of Immunotherapy in Adjuvant Treatment of Stage III Melanoma - A Meta-
Analysis of Current Trials
17:50 - 17:50 764P - Neutrophil to Lymphocyte Ratio (NLR) as a Prognostic Biomarker in Melanoma
Patients Treated with Immune Checkpoint Inhibitors
O. Oey, University of Western Australia, Perth, AU
17:50 - 17:50 765P - Impact of Breslow scale and mitotic rate on the survival outcome of pediatric
cutaneous malignant melanoma
N. Ali, Alexandria Faculty of Medicine, Alexandria City, EG
17:50 - 17:50 766P - Efficacy and safety of concurrent bevacizumab in combination with standard
radiotherapy and temozolomide followed by bevacizumab in combination with
temozolomide and surufatinib in glioblastoma: A phase 2 clinical trial
H. Zhang, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN
17:50 - 17:50 767P - A prospective study for assessment of neurocognitive function in patients with
grade 2 and 3 gliomas
A. Mehta, PGIMER - Post Graduate Institute of Medical Education and Research, Chandigarh, IN
17:50 - 17:50 768P - Does Dose to Subventricular Zone act as a Predictor of Overall Survival and
Progression Free Survival in Glioblastoma multiforme (GBM) ?
N. Lall, Institute of Medical Sciences, Banaras Hindu University, Varanasi, IN
17:50 - 17:50 769P - The prognostic impact of CDKN2A/B heterozygous deletions in meningioma-
insights of a multicenter analysis
F. Ippen, Heidelberg University Hospital, Heidelberg, DE
17:50 - 17:50 770P - Real World implication on survival of the 2021 WHO CNS5 classification of central
nervous system tumours
K. Nair, AIIMS - All India Institute of Medical Sciences, JODHPUR, IN

17:50 - 17:50 771P - Systematic Review of Chemotherapy followed by reduced dose radiotherapy
Regimens for Primary Central Nervous system Germ cell tumor
F. Dharmaraja, UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID
17:50 - 17:50 772P - Comparative Analysis of Myelodysplastic Syndrome (MDS) and Clonal Cytopenia of
Undetermined Significance (CCUS) Using a Genetic Approach
Y. Kang, Yonsei University College of Medicine, Seoul, KR
17:50 - 17:50 773P - Utility of the Kyoto Prognostic Index in lower-risk DLBCL: A supplementary analysis
of JCOG0601
T. Kobayashi, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, JP
17:50 - 17:50 774P - High MTV and low CD4/CD8 ratio before apheresis are poor prognostic factors in
patients with r/r LBCL treated with CAR T-cell therapy
M. Mino, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,
Bunkyo-ku, JP
17:50 - 17:50 775P - CD58 alterations govern antitumor immune responses by inducing PD-L1 and IDO
in diffuse large B-cell lymphoma
Y. Zhang, TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN
17:50 - 17:50 776P - Prognostic significance of baseline Vitamin D level on the outcome of Diffuse Large
B cell Lymphoma
A. Sherief P, RCC - Regional Cancer Centre, Trivandrum, IN
17:50 - 17:50 777P - Glasgow prognostic score in Diffuse large B cell lymphoma: single institutional
observational study
B. Krishnan, RCC - Regional Cancer Centre, Thiruvananthapuram, Thiruvananthapuram, IN
17:50 - 17:50 779P - Prognostic Value of Micro-vessel Density in Classical Hodgkin Lymphoma: A
Systematic Review
D. Amelia, Trainee of Hematology and Medical Oncology Faculty of Medicine Universitas
Indonesia, Central Jakarta, ID
17:50 - 17:50 780P - Comparative assessment of machine learning model performance in clinical
classification of acute lymphoblastic leukemia subtypes
S. Lim, Yonsei University College of Medicine, Seoul, KR
17:50 - 17:50 782P - The prognostic significance of CD25 & CD123 expression in Acute myeloid leukemia
F. Thasneem, RCC - Regional Cancer Centre, Thiruvananthapuram, Thiruvananthapuram, IN
17:50 - 17:50 783P - Retrospective Comparison of Venetoclax +Azacytadine and Mini Conditioning (5+2)
regimen in elderly AML patients - Efficacy and Safety analysis
B. Teja, Continental Hospitals, Hyderabad, IN

17:50 - 17:50 784P - The Risk of Second Primary Malignancies of Infectious Etiologies Among Leukemia
Survivors.
S. Elshatoury, Suez Canal University Teaching Hospitals, Ismailia, EG
17:50 - 17:50 785P - Cytogenetic and clinical profile of CML patients presenting in blast crisis:
Prospective study from a regional cancer centre in South India
K. Asutkar, Kidwai Memorial Institute of Oncology, Bangalore, IN
17:50 - 17:50 786P - Effects of Induction Regimens on Stem Cell Mobilization Yields in Newly Diagnosed
Multiple Myeloma
H. Park, SNUH - Seoul National University Hospital, Seoul, KR
17:50 - 17:50 788P - Analyses of Long-term safety and blood levels of daratumumab in patients with
multiple myeloma after switching from intravenous to subcutaneous administration
K. Yamaoka, Kobe City Medical Center General Hospital, Kobe, JP
17:50 - 17:50 789P - The outcome of multiple myeloma patients presenting with renal impairment - A
real world data
K. V A, Regional Cancer Centre, Thiruvananthapuram, IN
17:50 - 17:50 790P - Treatment outcomes of All -Trans-Retinoic acid(ATRA),Arsenic trioxide(ATO) and
Daunorubicin(DNR) in High risk Pediatric Acute Promyelocytic leukemia(APL) a single
center study at a quaternary care center in South India.
P.C. Thotakura, Manipal Hospitals - Vijayawada, Vijayawada, IN
17:50 - 17:50 791P - Clinical characteristics and survival nomogram for malignant solid tumors in
infants: A population-based study
W. Chen, Fujian Children's Hospital, Fuzhou, CN
17:50 - 17:50 792P - Prevalence of Depression among Children diagnosed with Cancer at Regional
Cancer Center in India
V. Niveditha, MNJ Institute of Oncology & Regional Cancer Center, Hyderabad, IN
17:50 - 17:50 793TiP - Efficacy and Safety of Combined Radioactive Iodine-125 Seeds and PARP Inhibitor
(Fluzoparib) in Advanced Unresectable Soft Tissue Sarcoma: A Phase II Trial (NCT05894018)
D. Liu, Sun Yat-Sen University Cancer Center, Guangzhou, CN
17:50 - 17:50 YO3 - Remarkable response to Fam-trastuzumab deruxtecan-nxki (T-DXd) in metastatic

Her2neu positive carcinoma breast with active brain disease- a case experience
B.M. Soumya, Manipal Comprehensive Cancer Center Manipal Hospital, Bangalore, IN
17:50 - 17:50 YO4 - Breast Carcinoma disguised as Systemic Sclerosis: A case report of unusual
Paraneoplastic Syndrome
A.P. Mina, The Medical City - Augusto P. Sarmeinto Cancer Institute, Pasig City, PH

17:50 - 17:50 YO5 - Thyroid Metastasis in a 65-year-old Filipino Female with Breast Cancer: A Case
Report
A.V. Alipio, The Medical City - Augusto P. Sarmeinto Cancer Institute, Pasig City, PH
17:50 - 17:50 YO6 - BRAF mutation in HR positive HER2 negative advanced breast cancer
C. Hing, NUH- National University Hospital, Singapore, SG
17:50 - 17:50 YO7 - Sacituzumab Govitecan in the Treatment of Recurrent Triple-Negative Breast Cancer
in a Patient with HRD-Positive and BRCA1/2 Wild-Type Germline: A Case Report
J. Zhang, Tianjin Cancer Hospital Airport Hospital, Tianjin, CN
17:50 - 17:50 YO8 - Potential role of 68Ga- and 177Lu-cyclic pentapeptides for targeting in-vivo CXCR4
receptor expression in a non-invasive manner
T. Lakhanpal, PGIMER - Postgraduate Institute of Medical Education and Research, Chandigarh,
Chandigarh, IN
17:50 - 17:50 YO9 - Case Report: Successful Continuation of Treatment with BRAF Inhibitors After
Treatment Modification for Serous Retinal Detachment in BRAF V600E-Mutated Metastatic
Colorectal Cancer
Y. Amano, OICI - Osaka International Cancer Institute, Osaka, JP
17:50 - 17:50 YO10 - Confronting Dual Fronts: Management of Lupus Nephritis, Advanced Colon Cancer,
and Nephrotoxicity in the Emergence of Nephro-Oncology
W.S. Choo, Canselor Tuanku Muhriz Hospital, National University of Malaysia, Kuala Lumpur, MY
17:50 - 17:50 YO11 - The short-term outcomes of treatment and regional lymph node analysis in
laparoscopic complete mesocolic excision for colon cancer
T. Nguyen, Hue University of Medicine and Pharmacy, Hue City, VN
17:50 - 17:50 YO12 - The management of shunt dysfunction caused by stent deviation during
transjugular intrahepatic portosystemic shunt surgery for esophageal and gastric varices
bleeding：a case report and comprehensive literature review
J.-M. Chen, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, CN
17:50 - 17:50 YO13 - De Novo Metastatic Gastric Adenocarcinoma with Bone Marrow Metastasis: A
Challenging Case with Cardiac Tamponade and Multiple Strokes Following
Immunotherapy
W.C. Hsieh, Taipei Municipal Wanfang Hospital, Taipei City, TW
17:50 - 17:50 YO14 - Intrahepatic Cholangiocarcinoma with rare esophageal metastasis presenting as
left shoulder pain
A. Cruz, The Medical City, Pasig City, PH
17:50 - 17:50 YO15 - Immediate results of transarterial chemoembolization of hepatocellular carcinoma

on the background of liver cirrhosis
K. Qodirov, Ixlos DOCTOR MT, Tashkent, UZ

17:50 - 17:50 YO17 - A case of adult-onset malignant rhabdoid tumor of kidney responded to VAC
therapy
I. Kita, Kagawa University Faculty of Medicine/Graduate School of Medicine, Miki, JP
17:50 - 17:50 YO19 - Vulvar Squamous Cell Carcinoma: A Case Report

D.J. Bacomo, SPMC - Southern Philippines Medical Center, Davao City, PH
17:50 - 17:50 YO20 - A Case Series of Second-line Trastuzumab Deruxtecan for the Treatment of
Metastatic HER2-Expressing Gastric-Type Mucinous Carcinoma of Cervix in Singapore
D. Ang, NCCS - National Cancer Centre Singapore, Singapore, SG
17:50 - 17:50 YO21 - Intra-Pericardial Chemotherapy for Pericardial Effusion in Soft Tissue Sarcoma of
Lung: A Case Report
K. Mg, Sri Ramachandra Higher Education and Research Center, Chennai, IN
17:50 - 17:50 YO22 - Case series of advanced cancer patients harboring FGFR3-TACC3 fusions detected
by comprehensive genomic profiling
S.-C. Chen, Taipei Veterans General Hospital, Taipei City, TW
17:50 - 17:50 YO23 - Case report: Management of Early-Stage Colorectal Cancer (CRC) Patients with
tissue free Minimal Residual Disease (MRD)
Y.-Y. Hsieh, Taipei Medical University - Shuang-Ho Hospital, New Taipei City, TW
17:50 - 17:50 YO24 - SCLC presented with Paraneoplastic Necrotizing Myopathy

V. Ratanatharathorn, Mahidol University - Faculty of Medicine Ramathibodi Hospital, Bangkok, TH
17:50 - 17:50 YO25 - Is it lung or mediastinal? An unusual case of a TTF-1 positive neuroendocrine tumor
in the mediastinum and lung presenting as superior vena cava syndrome
F.A. Co, St. Luke's Medical Center - Global City, Taguig City, PH
17:50 - 17:50 YO26 - Misdiagnosis of Lung Adenocarcinoma Mimicking Manifestations of Pulmonary

Tuberculosis: A Case Report
T. Meirissa, Lampung University, Bandar Lampung, ID
17:50 - 17:50 YO30 - Maximizing EGFR-TKI Therapy: Extending Initial Duration to 39 Months via Dose
Escalation and Combination Strategies from A Case Report
X. Wang, The Third Bethune Hospital of Jilin University, Changchun, CN
17:50 - 17:50 YO31 - A Long-Term Survival Case of Osimertinib-Resistant Lung Adenocarcinoma With
Pleural Metastases Responding to High-Dose Aumolertinib Plus Anlotinib
Z. Chen, Beijing Chest Hospital, Capital Medical University, Beijing, CN
17:50 - 17:50 YO32 - A Rare Presentation of a 63 year old Filipino Woman with Metastatic Non-Small Cell
Lung Cancer Driver Negative Masquerading as an Intracardiac Mass
A.G.J. Chan, St Lukes Medical Center - Quezon City, Quezon City, PH

17:50 - 17:50 YO35 - Relapsed Mantle Cell Lymphoma with Complete Metabolic Response on Rituximab
Gemcitabine-Oxaliplatin. Treatment in a Resource Limited Setting in the Philippines, A
Case Report
V. Tatoy, University of the Philippines - Philippine General Hospital, Cagayan de Oro, PH
17:50 - 17:50 YO36 - Rare case of B-lymphoblastic lymphoma: paraspinal mass presenting with
paraplegia
N. K, Tata Memorial Hospital - Parel, Mumbai, IN
17:50 - 17:50 YO37 - Combining targeted therapy with conventional approach in advanced papillary
thyroid cancer (PTC)
P. Iyer, The University of Texas MD Anderson Cancer Center - Main Building, Houston, US

08-12-2024
Title: Mini Oral session: Genitourinary tumours
Chair: Johan Chan, SG; Elena Castro, ES
09:00 - 09:05 335MO - Prevalence of Low Muscle Mass/Sarcopenia in Prostate Cancer Patients
Undergoing Androgen Deprivation Therapy and Association with Muscle Strength and
Physical Function
D. Taaffe, Edith Cowan University, Perth, AU
09:05 - 09:10 336MO - A Phase II Single-Arm, Open-Label Trial of Pamiparib in Metastatic Castration-
Resistant Prostate Cancer (mCRPC) Patients with Deleterious Germline or Somatic
BRCA1/2 Alterations or Homologous Recombination Deficiency (HRD): Interim Analysis of
Efficacy and Safety Results
D. Zhao, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for
Cancer Medicine, Sun Yat-Sen University Cancer Center, GUANGZHOU, CN
09:10 - 09:15 337MO - Efficacy and safety of rezvilutamide (Rez) plus androgen-deprivation therapy
(ADT) in patients with high-volume, metastatic, hormone-sensitive prostate cancer
(mHSPC) aged ≤64, 65–74, and ≥75 years: post-hoc analysis of randomized phase 3 CHART
trial
X. Qiu, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, CN

E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES
09:32 - 09:37 272MO - PUNCH01: Interim results from a phase II study of intra‑arterial chemotherapy
（IAC）combined withtislelizumab and Bacillus Calmette-Guerin (BCG) in high-risk non-
muscle-invasive bladder cancer (HR NMIBC)
Z. Wang, The First Affiliated Hospital, Sun Yat-sen University The Urology Department, Guang
Zhou, CN
09:37 - 09:42 273MO - DURANCE: A phase Ib/II study to assess the safety and activity of DURvalumab
(MEDI4736) in combination with S-488210/S-488211 vAccine in Non-muscle invasive
bladder CancEr
G. Leone, University College London, London, GB
09:42 - 09:47 274MO - Efficacy and safety of fruquintinib combined with serplulimab as 1st line
treatment in advanced non-clear cell renal cell carcinoma (nccRCC): A single-arm,
multicentre clinical trial
J. Huang, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai,
CN

J. Chan, SGH - Singapore General Hospital / SingHealth-Academia, Singapore, SG

10:04 - 10:09 275MO - Neoadjuvant Sacituzumab Govitecan, followed by radical cystectomy, for
Patients With Muscle-Invasive Bladder Cancer (MIBC): Updated Interim Results of SURE-01
trial
B. Maiorano, IRCCS San Raffaele Hospital, Milan, IT
10:09 - 10:14 338MO - Efficacy and safety of Tislelizumab(T) combined with Gemcitabine and
Cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after
radical local surgery: a prospective, phase II study
M. Cao, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, CN
10:14 - 10:19 276MO - Epidemiology, treatment (tx) patterns, and clinical outcomes of patients (pts)
with locally advanced or metastatic urothelial cancer (la/mUC) in Taiwan: a retrospective
cohort study
L.-N. Chien, National Yang Ming Chiao Tung University, Taipei, TW


Title: Focus on treatment of specific sarcoma types
Chair: Herbert Ho Fung Loong, HK; Christina Roland, US
09:00 - 09:15 Desmoid tumours

B. Kasper, UMM - Universitaetsklinikum Mannheim, Mannheim, DE
09:15 - 09:30 Liposarcoma

H.H.F. Loong, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK
09:30 - 09:45 Chondrosarcoma

E. Connolly, Chris O'Brien Lifehouse, Sydney, AU
09:45 - 10:00 Alveolar soft part sarcoma (ASPS)

S. Stacchiotti, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

Title: Session in collaboration with AACR - The expanding portfolio of
targeted and cellular therapies in oncology-mechanisms of action and
proofs of principle
Chair: Camille Rolin, LU; William Sellers, US
09:00 - 09:20 Multi specific immunotherapeutic engagers

C. Rolin, Luxembourg Institute of Health, Luxembourg, LU
09:20 - 09:40 Biparatopic antibodies targeting FGFR2 for the treatment of cholangiocarcinoma and
gastric cancer
W. Sellers, Broad Institute, Cambridge, US
09:40 - 10:00 CLAUDIN-6 CAR-T + mRNA vaccine

J. Haanen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam,
NL
10:00 - 10:20 Gene and cell-based therapies beyond CAR-T

B. Choi, Harvard Medical School, Boston, US

Title: Cancer survivorship: The end is the start
Chair: Michael Jefford, AU; Ivana Bozovic Spasojevic, RS
09:00 - 09:25 Late effects from cancer treatments

Y.T. Cheung, Chinese CHUK - University of Hong Kong, Sha Tin, HK
09:25 - 09:50 Safety of pregnancy in young patients with breast cancer (POSITIVE trial)
H.J. Kim, Asan Medical Center - University of Ulsan, Seoul, KR
09:50 - 10:15 Improving the model of care for cancer survivors

M. Jefford, Peter MacCallum Cancer Center, Melbourne, AU

Title: Role of intraperitoneal chemotherapy in ovarian area)
cancer
Chair: Jung-Yun Lee, KR; asima mukhopadhyay, IN
09:00 - 09:45 Expert

S. Sampige Prasannakumar, Manipal Comprehensive Cancer Center Manipal Hospital,
Bangalore, IN

Title: Nasopharyngeal cancer (NPC): Treatment strategies for locally
advanced disease
Chair: Brigette Ma, HK; Sjoukje Oosting, NL
10:45 - 11:10 Making sense of sequencing: Optimising (neo)adjuvant strategies around concurrent
chemoradiation
H. Mai, Sun Yat-Sen University Cancer Center, Guangzhou, CN
11:10 - 11:35 New guidelines for NPC staging: Do they impact practice?
B. Ma, The Chinese University of Hong Kong, Sha Tin, HK
11:35 - 12:00 Is there a role for radiotherapy de-intensification?

P. Blanchard, Institut Gustave Roussy, Villejuif, Cedex, FR

Title: Have we seen everything from checkpoints inhibitors?
Chair: Han Chong Toh, SG; Elena Garralda, ES
10:45 - 11:05 Immune checkpoint inhibitor toxicities: What we know about mechanisms of action and
current trends in management
J. Lee, NCCS - National Cancer Centre Singapore, Singapore, SG
11:05 - 11:25 New checkpoint inhibitors and combinations beyond PD1/PDL1

E. Garralda, Vall d'Hebron University Hospital, Barcelona, ES
11:25 - 11:45 What do translational analytics teach us about IO therapy in solid tumours
K.-K. Shiu, University College London Hospitals NHS Foundation Trust, London, GB
11:45 - 12:15 Interactive discussion: Everything you wanted to know about IO but never dared to ask

Title: Practicing oncology across the globe: ESMO Clinical Practice
Guidelines and Pan Asian adaptations (in collaboration with TOS, ISMPO,
KSMO)
Chair: Elizabeth Smyth, GB; David Tai, SG
10:45 - 10:55 A clinical case and analysis of its management according to the recent PAGA: Biliary cancer
L.-T. Chen, National Health Research Institutes - National Institute of Cancer Research, Tainan
City, TW
10:55 - 11:05 Differences between the parent guideline (CPG) and the PAGA: Genetics, biology and
practice differences between West and Asia
E. Smyth, Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, GB

11:15 - 11:25 A clinical case and analysis of its management according to the recent PAGA: Lung cancer
S.-H. Lee, Samsung Medical Center (SMC), Seoul, KR
J. Menis, AOU Integrata di Verona - Ospedale Borgo Roma, Verona, IT
11:45 - 11:55 A clinical case and analysis of its management according to the recent PAGA: Ovarian
cancer
S. Nag, Sahyadri Hospital, Pune, IN
I. Ray-Coquard, Centre Léon Bérard, Lyon, FR

Title: Targeting DNA damage response (DDR): Next generation drugs and
the importance of biomarkers
Chair: Ruth Plummer, GB; Herbert Ho Fung Loong, HK
10:45 - 11:10 Second generation PARP inhibitors to overcome toxicity

T.A. Yap, The University of Texas MD Anderson Cancer Center - Main Building, Houston, US
11:10 - 11:35 Refining patient selection: Benefits and risks of treating unselected patient groups
S.-A. Im, SNUH - Seoul National University Hospital, Seoul, KR
11:35 - 12:00 Other synthetic lethality targets

R. Plummer, Newcastle University, Newcastle upon Tyne, GB

Title: What is new for ALK+ NSCLC? area)
Chair: Noemi Reguart, ES
10:45 - 11:30 Expert

S. Popat, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

Title: Updates on gliomas and meningiomas
Chair: Sharon Low, SG; Ho-Keung Ng, HK
10:55 - 11:15 Updates on treatment of gliomas

Z. Lwin, Royal Brisbane and Women's Hospital, Herston, AU
11:15 - 11:35 Updates on treatment of meningiomas

M. Weller, USZ - Universitätsspital Zürich - Klinik für Neurologie, Zurich, CH
11:35 - 11:55 Controversies on RT for IDH-mutant glioma and meningiomas

G. Minniti, Sapienza Università di Roma, Rome, IT

Title: Amgen - Precision oncology: innovative approaches in the
management of gastrointestinal cancers
Chair: Wei Peng Yong, SG

W.P. Yong, NUHS - National University Health System, Singapore, SG
12:35 - 12:55 RAS-guided treatment in CRC and the role of combination therapies
H. Kawakami, Kindai University - Faculty of Medicine, Osaka, JP
12:55 - 13:15 Emerging targeted therapies in G/GEJ cancer

J. Lee, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR
13:15 - 13:35 Current biomarker testing practices and future considerations for G/GEJ cancers
K.-M. Kim, Samsung Medical Center (SMC), Seoul, KR
13:55 - 14:00 Summary and closure

W.P. Yong, NUHS - National University Health System, Singapore, SG

Title: Prova Education - HER2+ advanced solid tumors: A fireside chat on
harnessing molecular profiling to improve patient outcomes
Chair: Eric Van Cutsem, BE

E. Van Cutsem, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

12:35 - 12:45 Molecular profiling in the era of tumor-agnostic approvals
12:45 - 12:55 The molecular tumor board for tumor agnostic therapeutic approaches
12:55 - 13:05 HER2 overexpression testing to guide therapy in advanced solid tumors
K. Moore, Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US
13:05 - 13:20 Clinical trial evidence in HER2+ advanced solid tumors

K. Moore, Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US
13:20 - 13:35 From podium to practice: Application and guidelines in HER2+ advanced solid tumors
J.C.-H. Yang, NTUCC - National Taiwan University Cancer Center, Taipei City, TW
13:35 - 13:50 Team-based safety monitoring, prophylaxis, and management with HER2-directed therapy
J.C.-H. Yang, NTUCC - National Taiwan University Cancer Center, Taipei City, TW
13:50 - 13:55 Our “message worth sharing” on HER2+ advanced solid tumors
13:55 - 14:00 Audience question and answer session


Title: Merck Healthcare KGaA - Shaping the future of mCRC: Expert
dialogues on research and practice
Chair: Takayuki Yoshino, JP; Peter Gibbs, AU

T. Yoshino, National Cancer Center Hospital East, Kashiwa, JP
12:35 - 12:50 Sequencing in mCRC: The latest data in RAS wt disease

T. Yoshino, National Cancer Center Hospital East, Kashiwa, JP
12:50 - 13:10 Sequencing in mCRC: Clinical insights on anti-EGFR rechallenge

C.-T. Chen, NTUH - National Taiwan University Hospital, Taipei City, TW
13:10 - 13:25 Novel strategies in mCRC: What’s being investigated?

P. Gibbs, WEHI - Walter and Eliza Hall Institute of Medical Research, Parkville, AU
13:25 - 13:45 Novel strategies in mCRC: Anti-EGFR plus BRAF inhibitor combinations in practice
S. Han, NCCS - National Cancer Centre Singapore, Singapore, SG

13:45 - 13:55 Panel discussion moderated by the Co-Chairs
13:55 - 14:00 Meeting close
T. Yoshino1, P. Gibbs2, 1National Cancer Center Hospital East, Kashiwa, JP, 2WEHI - Walter and
Eliza Hall Institute of Medical Research, Parkville, AU

Title: AstraZeneca - Exploring advances in immunotherapy for
hepatobiliary and gastric cancers
Chair: Do-Youn Oh, KR

12:35 - 12:45 Evolving strategies: Immunotherapy-based regimens for biliary tract cancer
12:45 - 13:00 Case study and discussions

13:00 - 13:10 Redefining treatment goals: Immuno-oncology approaches for hepatocellular carcinoma
S. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK
13:10 - 13:25 Case study and discussions

S. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK
13:25 - 13:35 Perioperative approaches: Exploring the potential of integrating immunotherapy and
chemotherapy in resectable gastric cancer
13:35 - 13:55 Case study and discussion

13:55 - 14:00 Close

12:30 - 14:00 Type: ESMO Colloquium Hall 407

Title: ESMO Colloquium supported by Astellas - Locally advanced and
metastatic urothelial cancer (UC): State-of-the-art management in the new
continuum of care
Chair: Ignacio Duran, ES; Thomas Powles, GB
12:30 - 12:35 Introduction and background of locally advanced and metastatic urothelial cancer
I. Duran, HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES

12:35 - 12:50 Optimal definition of patient populations: Platinum eligibility and biology-informed
science
12:50 - 13:05 ESMO Guidelines on state-of-the-art management of patients with first-line locally
advanced and metastatic urothelial cancer and applicability in Asia Pacific
X. Sheng, Peking University Cancer Hospital & Institute, Beijing, CN
13:05 - 13:20 Continuum of care after progression on first-line therapy: Testing and rationalising
13:20 - 13:30 Optimal management of ADC toxicities in patients with urothelial malignancies
A. Weickhardt, Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, AU
13:30 - 13:40 Case presentation of a patient with metastatic urothelial cancer: Criteria for choosing the
right regimens in first-line and second-line locally advanced and metastatic urothelial
cancer
E.H. Jung, Seoul National University Bundang Hospital, Seongnam, KR
13:55 - 14:00 Summary and conclusion


Title: Vesalius talk - Opportunities and challenges in area)
global oncology for young oncologists from Asia-Pacific
12:30 - 13:15 Panellists
H.H.F. Loong 1, D. Trapani2, S. Popat3, J. Lee4, 1The Chinese University of Hong Kong - Prince of
Wales Hospital, Sha Tin, HK, 2Università degli Studi di Milano, Milan, IT, 3The Royal Marsden
Hospital - NHS Foundation Trust, London, GB, 4NCCS - National Cancer Centre Singapore,
Singapore, SG

Title: New approaches to gastrointestinal cancers (GI) treatments
Chair: Chiara Cremolini, IT; Timothy Price, AU
14:15 - 14:35 Navigating ctDNA grey areas: Techniques, performance and appropriate trial designs
P. Laurent-Puig, Université Paris Cité, Paris, FR
14:35 - 14:55 Clinical application of ctDNA: From minimal residual disease MRD to the continuum of
care in the metastatic setting
C. Cremolini, AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT

14:55 - 15:15 Leveraging novel technologies to unravel the tumor microenvironment in GI cancers
J. Lee, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR
15:15 - 15:35 Novel theranostic approaches

P. Kunz, Yale University School of Medicine, New Heaven, US

Title: Debates in early stage NSCLC without oncogenic drivers
Chair: Enriqueta Felip, ES; Hong Kwan Kim, KR
14:15 - 14:20 Presentation of case 1: Bulky and multi N2 - What to do?

E. Felip, Vall d'Hebron University Hospital, Barcelona, ES
14:20 - 14:35 Perioperative chemo immunotherapy: Published evidence-based

E. Felip, Vall d'Hebron University Hospital, Barcelona, ES
14:35 - 14:50 Concurrent chemoradiotherapy followed by immunotherapy

K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG
14:50 - 14:55 Presentation of case 2: Stage II disease

H.K. Kim, Samsung Medical Center (SMC), Seoul, KR
14:55 - 15:10 Upfront surgery

H.K. Kim, Samsung Medical Center (SMC), Seoul, KR
15:10 - 15:25 Perioperative chemo immunotherapy: Challenges


Title: Managing bladder cancer in 2024: From muscle invasive to advanced
disease
Chair: Ignacio Duran, ES; Renu Eapen, AU
14:15 - 14:30 The role of cystectomy

R. Eapen, Peter MacCallum Cancer Centre, Melbourne, AU
14:30 - 14:45 Bladder preservation strategies

M. Saad, UMMC - University Malaya Medical Centre, Kuala Lumpur, MY

14:45 - 15:00 Perioperative treatment
R. Iacovelli, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT
15:00 - 15:15 Redefining first-line treatment

15:15 - 15:30 How do I choose my second-line in metastatci urothelial cancer (mUC)


Title: Optimal management of head and neck cancer in special situations
Chair: Jean-Pascal Machiels, BE; Bhumsuk Keam, KR
14:15 - 14:20 Presentation of case/condition
14:20 - 14:40 Management of older patients

S. Oosting, UMCG - University Medical Center Groningen, Groningen, NL
14:40 - 15:00 Management in the locally advanced setting (cisplatin non-eligible)

B. Keam, Seoul National University Hospital, Seoul, KR
15:00 - 15:20 Management in the R/M setting (oligometastatic and cisplatin non-eligible)

Title: Mini Oral session: Gynaecological cancers
Chair: Chee Khoon Lee, AU; asima mukhopadhyay, IN; Clare Scott, AU
14:15 - 14:20 376MO - The impact of crossover to surgery in the no-surgery group on the survival: a post-
hoc analysis of the SOC-1 trial
L. Shen, Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN
14:20 - 14:25 377MO - Lymph node dissection before initial treatment for locally advanced cervical
cancer: a systematic review and meta-analysis
H. Zhang, Chinese Academy of Medical Sciences and Peking Union Medical College - National

A. Mukhopadhyay, CNCI - Chittaranja National Cancer Institute, Kolkata, IN

14:40 - 14:45 378MO - Efficacy and Safety of Disitamab Vedotin in Treatment of HER2 Expressed
Advanced or Recurrent Gynecological Cancers
D. Wang, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN
14:45 - 14:50 379MO - Homologous recombination deficiency testing in Vietnamese patients with
ovarian cancer
N. Tran, Medical Genetics Institute, Ho Chi Minh City, VN

15:05 - 15:10 380MO - Role of Therapy in the Development of Second Primary Malignancies in Ovarian
Cancer Survivors: A SEER Database Analysis
A. Alhusban, IAU - The University of Jordan, Amman, JO
15:10 - 15:15 381MO - Progression Free Survival and Overall Survival in Platinum-Based Chemotherapy
Alone versus Immune Checkpoint Inhibitor (ICI)-Platinum-Based Chemotherapy
Combination in First Line Treatment for Advanced, Metastatic or Recurrent Endometrial
Adenocarcinoma: A Meta-Analysis
M.C. Vistal, St. Luke's Medical Center, Quezon City, PH

C.K. Lee, St George Hospital Cancer Care Centre, Kogarah, AU
14:15 - 16:00 Type: Special session Room 324

Title: Radiation oncology session 2
Chair: Francoise Mornex, FR; Melvin Lee Kiang Chua, SG
14:15 - 14:35 Treatment modalities in HPV-associated oropharynx cancer

Y.C. Ahn, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul,
KR
14:35 - 14:40 Q&A
14:40 - 15:00 Lymphocytes sparing radiotherapy

M.L.K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG
15:00 - 15:05 Q&A

15:05 - 15:25 Better imaging tools for adaptive radiotherapy
A. Berlin, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA
15:25 - 15:30 Q&A
15:30 - 15:50 Oligometastatic lung cancer: State of the art
F. Mornex1, J. Ma2, 1Université Claude Bernard Lyon1, Lyon, FR, 2SGH - Singapore General
Hospital / SingHealth-Academia, Singapore, SG
15:50 - 15:55 Q&A
15:55 - 16:00 General discussion and conclusions

Title: How to respond to a wish for hastened death area)
Chair: Stein Kaasa, NO
14:15 - 15:00 Expert

G. Yang, NCCS - National Cancer Centre Singapore, Singapore, SG

final_programme_asia2024

Uploaded by

Copyright:

Available Formats

final_programme_asia2024

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

final_programme_asia2024

Uploaded by

Copyright:

Available Formats

06-12-2024

09:00 - 10:00 Type: Special session Hall 406

H. Van Laarhoven1, G. Long 2, 1Academic Medical Center, University of Amsterdam, Amsterdam,

09:15 - 09:35 Token of Appreciation Endorsing society representatives

10:15 - 11:45 Type: Educational session Hall 405

10:15 - 10:35 Combat against pancreato-biliary tract cancer using immunotherapy

11:15 - 11:35 Future development of immunotherapy in GI cancers

11:35 - 11:45 Q&A and discussion

10:15 - 11:30 Type: Proffered Paper session Hall 404

Last update: 21-11-2024 08:38:22am Final Programme

10:35 - 10:47 Invited discussant 1O and 36O

11:07 - 11:19 Invited Discussant 27O and 2O

11:19 - 11:29 Q&A and discussion

10:15 - 11:45 Type: Educational session Hall 401

11:05 - 11:30 Embedding immunotherapy in the treatment of cervical cancer

11:30 - 11:45 Q&A and discussion

10:15 - 11:45 Type: Proffered Paper session Hall 402

Last update: 21-11-2024 08:38:22am Final Programme

10:35 - 10:47 Invited Discussant 57O and 58O

10:47 - 10:57 Q&A and discussion

11:17 - 11:29 Invited Discussant 478O and 59O

11:29 - 11:39 Q&A and discussion

10:15 - 11:45 Type: Proffered Paper session Hall 406

10:35 - 10:47 Invited Discussant LBA8 and 625O

10:47 - 10:52 Q&A and discussion

Last update: 21-11-2024 08:38:22am Final Programme

11:22 - 11:37 Invited Discussant LBA5, LBA6 and LBA7

11:37 - 11:45 Q&A and discussion

10:15 - 11:45 Type: Educational session Hall 407

10:15 - 10:35 Virotherapy for cancer: Coming into the clinic

10:15 - 11:45 Type: Educational session Room 324

10:15 - 10:40 Bispecific antibodies in diffuse large B cell lymphoma (DLBCL)

10:40 - 11:05 Bispecific antibodies in frontline treatment

Last update: 21-11-2024 08:38:22am Final Programme

11:30 - 11:45 Q&A and discussion

10:30 - 11:15 Type: Meet the expert Discussion hub (exhibition

10:30 - 11:15 Expert

12:00 - 13:30 Type: Industry Satellite Symposium Hall 405

12:00 - 12:10 Advancing therapeutic strategies in precision medicine

12:10 - 12:25 Driving improved outcomes in NSCLC: KRASG12C inhibitors

12:25 - 12:45 Innovative approaches in SCLC: DLL3 T-cell engager therapy

12:45 - 13:05 Optimizing care in DLL3 T-cell engager therapy

13:05 - 13:25 Panel discussion and Q&A

13:25 - 13:30 Summary and close

12:00 - 13:30 Type: Industry Satellite Symposium Hall 404

12:00 - 12:05 Welcome and introduction

Last update: 21-11-2024 08:38:22am Final Programme

13:25 - 13:30 Closing remarks

12:00 - 13:30 Type: Industry Satellite Symposium Hall 401

12:00 - 12:05 Welcome and introduction

13:05 - 13:20 Q&A and discussion

13:20 - 13:30 Closing remarks

Last update: 21-11-2024 08:38:22am Final Programme

12:00 - 12:10 Welcome and opening remarks: Gastric cancer in Asia

12:10 - 12:30 Precision medicine in gastric cancer: Targeted therapy approaches

13:25 - 13:30 Closing remarks

12:00 - 13:30 Type: Industry Satellite Symposium Hall 407

12:00 - 12:05 Introduction

12:05 - 12:35 Molecular subclassification and biomarker strategies in endometrial cancer

12:55 - 13:15 Future directions: Emerging trends and unanswered questions